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1 Summary	
Hypoxia,	being	the	inadequate	tissue	supply	of	oxygen,	is	a	characteristic	of	many	solid	tumors	that	
has	 negative	 implications	 for	 the	 patient’s	 prognosis.	 Cancer	 cells	 adapt	 to	 this	 hostile	
microenvironment	by	inducing	transcriptomic	and	translational	changes,	which	ultimately	can	lead	to	
their	 epithelial-to-mesenchymal-transition	 (EMT)	 and	 resistance	 to	 anti-tumor	 treatments	 like	
radiation-,	chemo-	and	immunotherapy.	Thus,	it	is	fundamental	to	investigate	the	impact	of	hypoxia	
on	novel	developing	therapies,	such	as	the	intratumoral	activation	of	the	innate	pattern	recognition	
receptor	retinoic	acid-inducible	gene	I	(RIG-I)	using	5’-triphosphate	RNA	(3pRNA)	ligands.	Stimulation	
of	RIG-I	signaling	elicits	tumor	cell	death	as	well	as	anti-tumoral	immunity	and	has	shown	promising	
results	 in	 preclinical	 studies	 against	 malignant	 melanoma.	 However,	 the	 influence	 of	 oxygen	
deprivation	 on	 the	 function	 of	 RIG-I	 has	 not	 been	 investigated.	 That	 is	 why	 this	 study	 aimed	 at	
uncovering	 the	 effects	 of	 hypoxia	 on	 the	 RIG-I	 signaling	 pathway	 and	 the	 immunostimulatory	
potential	of	3pRNA	in	murine	melanoma.			
As	presented	here,	3pRNA-induced	RIG-I	protein	upregulation	was	attenuated	upon	hypoxic	
incubation	(2%	partial	oxygen	pressure)	as	compared	to	normoxia	 (20%	partial	oxygen	pressure)	 in	
different	 melanoma	 cell	 lines,	 which	 occurred	 concomitant	 to	 the	 induction	 of	 EMT	 and	
downregulation	 of	 interferon	 alpha	 (IFNα)	 receptor	 expression.	 Interestingly,	 while	 IFNα	 lost	 its	
capacity	 to	 trigger	 an	 immune	 response	 under	 hypoxia,	 the	 RIG-I	 signaling	 outcome	 was	 largely	
unaffected	 in	B16F10	melanoma	cells,	 as	 indicated	by	unaltered	 induction	of	 IFN-stimulated	genes	
and	equal	expression	of	major	histocompatibility	complex	(MHC)	class-I	and	programmed	cell	death	
ligand	1	(PDL-1).	Besides,	cytokine	profiles	were	moderately	modulated;	exhibiting	enhanced	3pRNA-
stimulated	type-I	IFN	production.	Most	importantly,	the	ability	of	3pRNA-treated	melanoma	cells	to	
activate	melanocyte	antigen	specific	CD8+	T-cells	and	NK	cells	 in	vitro	was	not	 inhibited	by	oxygen	
deprivation.	Finally,	treatment	of	melanoma	cells	with	vitamin	C	as	ROS	scavenger	or	NFκB	inhibitors,	
to	 protect	 cells	 from	 EMT,	 reinstated	 3pRNA-induced	 RIG-I	 expression	 in	 hypoxic	 cells	 in	 vitro.	
Moreover,	 vitamin	C	 also	 increased	 intratumoral	 proinflammatory	 cytokine	 production	 and	 anti-
tumor	efficacy	in	a	subcutaneous	melanoma	model	in	vivo.	
In	 conclusion,	 this	 thesis	 provides	 evidence	 that	 the	 immunostimulatory	 potential	 of	 RIG-I	
activation	is	preserved	under	hypoxia	and	resists	attenuation	of	RIG-I	protein	upregulation	as	well	as	
tumor	 cell	 IFNα-desensitization.	 Thus,	 immunotherapy	 utilizing	 3pRNA	 proved	 superior	 to	 IFNα	 by	
being	effective	also	in	hypoxic	tumors.	Furthermore,	adjuvant	vitamin	C	treatment	has	the	potential	
to	 aggravate	 3pRNA-mediated	 tumor	 eradication.	 These	 findings	 essentially	 contribute	 to	 the	
successful	 establishment	 of	 3pRNA	 mono-	 or	 combinatorial	 therapies	 to	 the	 valuable	 benefit	 of	
melanoma	patients.	
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2 Zusammenfassung	
Eine	unzureichende	Versorgung	von	Zellen	mit	Sauerstoff	(Hypoxie)	ist	ein	häufiges	Merkmal	solider	
Tumore	 und	 wirkt	 sich	 negativ	 auf	 die	 Prognose	 betroffener	 Patienten	 aus.	 Um	 sich	 an	 die	
lebensfeindliche	Umgebung	anzupassen,	 kommt	es	bei	 hypoxischen	Krebszellen	 zu	Veränderungen	
des	 Transkriptoms	 und	 Proteoms,	 die	 letztendlich	 zur	 epithelialen-zu-mesenchymalen-Transition	
(EMT)	 der	 Zellen,	 sowie	 zur	 Resistenz	 gegen	 Bestrahlungs-,	 Chemo-	 und	 Immuntherapie	 führen	
können.	 Daher	 ist	 eine	 Untersuchung	 der	 Auswirkungen	 von	 Hypoxie	 auf	 neue	 Tumortherapien	
Voraussetzung	 für	 deren	 erfolgreiche	 Entwicklung,	 so	 auch	 für	 die	 intratumorale	 Aktivierung	 des	
Mustererkennungsrezeptors	 RIG-I	 (engl.:	 retinoic	 acid-inducible	 gene	 I)	mithilfe	 seines	 spezifischen	
Liganden	 5’-triphosphorylierter	 RNA	 (3pRNA).	 Die	 Stimulierung	 des	 RIG-I	 Signalweges	 führt	 zum	
Tumorzelltod,	 bei	 gleichzeitiger	 Induktion	 einer	 anti-tumoralen	 Immunantwort,	 und	 hat	
vielversprechende	 Ergebnisse	 in	 präklinischen	 Studien	 zur	 Behandlung	 des	 malignen	 Melanoms	
geliefert.	 Jedoch	wurde	der	 Einfluss	 von	 Sauerstoffmangel	 auf	die	 Funktion	 von	RIG-I	 bislang	nicht	
untersucht.	Daher	sollte	diese	Arbeit	die	Auswirkungen	von	Hypoxie	auf	den	RIG-I	Signalweg	und	die	
immunstimulatorischen	Fähigkeiten	von	3pRNA	in	murinen	Melanomzellen	aufklären.	
Die	 Ergebnisse	 zeigten	 eine	 Verminderung	 der	 3pRNA-induzierten	 Aufregulation	 der	 RIG-I	
Proteinmenge	 als	 Folge	 der	 Hypoxie	 (2%	 Sauerstoffpartialdruck)	 im	 Vergleich	 zu	 normoxischen	
Bedingungen	(20%	Sauerstoffpartialdruck).	Dies	ging	mit	einer	EMT	und	verringerten	Expression	des	
Interferon	alpha	(IFNα)	Rezeptors	einher.	Interessanter	Weise	blieb	die	immunaktivierende	Fähigkeit	
von	 RIG-I	 hiervon	 weitgehend	 unbeeinflusst,	 was	 sich	 durch	 eine	 unveränderte	 Expression	 IFN-
stimulierter	 Gene,	 sowie	 eine	 gleichbleibende	 Aufregulation	 des	 Haupthistokompatibilitäts-
komplexes	 Klasse-I	 (engl.:	 major	 histocompatibility	 complex	 class-I,	 MHC	 class-I)	 und	 des	
immunregulatorischen	 Oberflächenmoleküls	 PDL-1	 (engl.:	 programmed	 cell	 death	 ligand	 1)	
auszeichnete.	Daneben	wurde	eine	moderate	Änderung	der	3pRNA-induzierten	Zytokin-Produktion	
beobachtet,	die	eine	Erhöhung	der	Typ-I	IFN	Menge	beinhaltete.	Von	besonderer	Bedeutung	ist	die	
Beobachtung	dass	3pRNA-behandelte	Melanomzellen	auch	unter	Hypoxie	in	der	Lage	waren	Antigen-
spezfische	 CD8+	 T-Zellen	 und	 NK	 Zellen	 in	 vitro	 zu	 aktivieren	 –	 eine	 Grundvoraussetzung	 für	 eine	
erfolgreiche	 Immuntherapie.	 Schließlich	 konnte	 durch	 die	 Behandlung	 der	 Zellen	 mit	 dem	
Antioxidants	Vitamin	C	oder	NFκB	Inhibitoren	zum	Schutz	vor	einer	EMT,	die	3pRNA-induzierte	RIG-I	
Expression	 in	 hypoxischen	 Zellen	 wiederhergestellt	 werden.	 Darüber	 hinaus	 resultierte	 die	
zusätzliche	Vitamin	C	Behandlung	in	vivo	in	einer	verstärkten	intratumoralen	Zytokinproduktion	und	
einer	verbesserten	anti-tumoralen	Wirkung	von	3pRNA	in	einem	Model	transplantierter,	subkutaner	
Melanome.	
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Zusammengefasst	 zeigt	 diese	 Arbeit	 dass	 die	 RIG-I-vermittelte	 Immunaktivierung,	 entgegen	 einer	
verminderten	RIG-I	Aufregulation	und	einer	Desensibilisierung	gegenüber	IFNα,	auch	unter	Hypoxie	
erhalten	bleibt.	Folglich	ist	die	3pRNA-basierte	Immuntherapie	einer	Behandlung	mit	IFNα	überlegen,	
da	 sie	 ihre	 Wirksamkeit	 in	 hypoxischen	 Tumoren	 behält.	 Weiterhin	 kann	 eine	 unterstützende	
Behandlung	 mit	 Vitamin	 C	 die	 anti-tumorale	 Aktivität	 von	 3pRNA	 verstärken.	 Diese	 Erkenntnisse	
leisten	 einen	 unverzichtbaren	 Beitrag	 zur	 erfolgreichen	 Entwicklung	 von	 3pRNA-Mono-	
und	-Kombinationstherapien	und	stellen	somit	einen	kostbaren	Gewinn	für	Melanom	Patienten	dar.		
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3 Introduction	
3.1 The	innate	and	adaptive	immune	response		
To	cope	with	the	constant	infectious	threat	of	fungi,	parasites,	bacteria	or	viruses	the	human	body	is	
equipped	 with	 the	 strong	 physical	 barriers	 of	 the	 skin	 and	 inner	 epithelia	 as	 well	 as	 two	 finely	
coordinated	cellular	defence	systems:	the	innate	and	adaptive	immune	responses.	Key	elements	and	
concepts	 illustrating	 the	 establishment	 of	 complex	 protective	 immune	 responses	 are	 summarized	
concisely	in	the	following	section.		
Upon	 pathogen	 invasion	 through	 one	 of	 the	 physical	 barriers,	 the	 innate	 immune	 system	
poses	the	first	line	of	defence.	Macrophages	and	neutrophils	provide	initial	protection	by	eliminating	
extracellular	 pathogens	 through	 their	 active	 internalisation	 (phagocytosis).	 These	 cells	 can	 rapidly	
detect	a	wide	range	of	microorganisms	with	the	help	of	pathogen	recognition	receptors	 (PRR)	that	
activate	upon	detecting	evolutionarily	conserved	microbial	structures,	so-called	pathogen-associated	
molecular	 patterns	 (PAMPs).	 Consequently,	 cytokines	 released	 from	 these	 cells	 coordinate	 the	
function	 of	 other	 immune-	 and	 non-immune	 cells	 equipped	 with	 relevant	 cytokine	 receptors.	
Moreover,	 secreted	chemokines	mediate	 the	attraction	of	additional	effector	cells	 from	the	 innate	
and	adaptive	 immune	systems	1.	For	example,	natural	killer	 (NK)	cells	disrupt	pathogen-infected	or	
tumor	 cells	 by	 releasing	 the	 cytotoxic	 content	 of	 their	 lytic	 granules	 following	 complex	 signal	
integration	 of	 activating	 and	 inhibiting	 receptors	2.	 Other	 innate	 immune	 cells,	 like	 dendritic	 cells	
(DCs),	 phagocytose	 microbial	 matter	 at	 the	 site	 of	 infection	 and	 subsequently	 present	 their	
processed	 foreign	 peptides	 in	 surface-expressed	 major	 histocompatibility	 complexes	 (MHC).	 MHC	
class-II	molecules	are	classically	loaded	with	peptides	derived	from	extracellular	pathogens	and	their	
expression	is	largely	restricted	to	immune	cells.	In	contrast,	MHC	class-I	is	expressed	by	all	nucleated	
cells	 and	 allows	 presentation	 of	 intracellularly-generated	 peptides,	 including	 those	 specific	 for	
viruses	 or	 characteristic	 for	 tumor	 cells	 (tumor-associated	 antigens,	 TAA).	 Following	DC	homing	 to	
the	 lymph	 node,	 antigen-receptors	 on	 CD4+	 and	 CD8+	 T-cells	 recognize	 antigens	 bound	 to	 MHC	
class-II	and	MHC	class-I	respectively,	leading	to	activation	of	adaptive	immunity.	Consequently,	CD8+	
T-cells	 (also	 called	 cytotoxic	 T	 lymphocytes,	 CTL)	 disrupt	 their	 target	 cells	 through	 the	 release	 of	
cytotoxic	 molecules	 similar	 to	 NK	 cells.	 Whereas	 CD4+	 helper	 T-cells	 can	 either	 drive	 the	 B-cell	
response,	 leading	to	specific	antibody	production,	or	assist	CD8+	T-cell	activation	1,3.	 Importantly,	 in	
DCs	 so-called	 cross-presentation	 allows	 loading	 of	 peptide	 antigens	 derived	 from	 extracellular	
sources	also	in	MHC	class-I	molecules,	enabling	cytotoxic	CD8+	T-cell	activation	against	extracellular	
pathogens.	
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In	 contrast	 to	 innate	 immune	 cells,	 which	 can	 be	 activated	 by	 the	 single	 event	 of	 PRR-binding,	
adaptive	immune	cells	require	a	second	signal	in	addition	to	antigen-recognition.	The	co-stimulatory	
molecules	(CD80	and	CD86)	providing	this	signal	for	T-cell	activation	upon	their	interaction	with	the	
DC	in	the	lymph	node	can	be	induced	by	PRR-stimulation	within	the	DC	4,5.	Whereas	innate	immune	
cells	possess	a	limited	number	of	germline-encoded	PRR,	adaptive	immune	cells	utilize	a	vast	variety	
in	their	antigen-receptors	due	to	genetic	recombination	during	their	development,	enabling	them	to	
specifically	detect	virtually	any	presented	peptide.		
Importantly,	 sophisticated	mechanisms	 ensure	 termination	of	 effector	 functions	 to	 avoid	 an	
overshooting	immune	response	and	excessive	tissue	damage.	T-cells	can	express	multiple	inhibitory	
receptors,	embodying	“immune	checkpoints”	that	enable	regulation	of	the	extent	of	their	activation.	
These	receptors	like	programmed	cell	death	protein	1	(PD-1)	and	cytotoxic	T-lymphocyte-associated	
antigen	4	(CTLA-4)	respectively	blunt	T-cell	activity	during	the	effector	phase,	or	outcompete	binding	
of	 activating	 receptors	 during	 the	 activation	 phase	 in	 the	 lymph	 node.	 Both	 pathways	 result	 in	
suppression	 of	 T-cell	 function	 and	 induction	 of	 immune	 tolerance	6,7.	 Additionally,	 regulatory	 T-	
(Treg)	 cells	 can	 attenuate	 immune	 responses	 by	 secreting	 immunomodulatory	 cytokines.	 In	
pathologic	situations	such	as	cancer,	myeloid-derived	suppressor	cells	(MDSC)	can	also	contribute	to	
immunosuppression	and	thus	prevent	efficient	clearing	of	tumor	cells	8.		
All	 in	 all,	 the	 concerted	 actions	 of	 the	 innate	 and	 adaptive	 immune	 responses,	 with	 the	
indispensable	contribution	of	PRRs	to	their	initial	activation,	provides	the	host	with	rapid	and	lasting	
protection	against	a	huge	variety	of	pathogens.	
	
3.2 The	pattern	recognition	receptor	RIG-I		
The	special	 importance	of	PRRs	was	 lately	underlined	by	awarding	the	Nobel	Prize	 in	physiology	or	
medicine	2011	 to	 the	 immunologists	 Jules	A.	Hoffmann	and	Bruce	A.	Beutler.	 Hoffmann	 identified	
the	 drosophila	 Toll-gene	 as	 being	 involved	 in	 pathogen	 sensing	 and	mediating	 efficient	 protection	
from	infection,	whereupon	Beutler	discovered	a	Toll-like	receptor	(TLR)	in	mice	that	is	responsible	for	
detection	of	bacterial	lipopolysaccharide	(LPS)	and	consequent	activation	of	innate	immunity.		
Depending	on	their	localization,	three	different	general	classes	of	PRRs	can	be	distinguished:	
soluble	 receptors	 like	 mannose-binding	 lectin	 as	 part	 of	 the	 complement	 system,	 cytoplasmic	
receptors	and	membrane-bound	receptors	(Figure	1).	The	latter	class	includes	C-type	lectin	receptors	
(CLR),	which	mainly	detect	 fungal	PAMPs	and	TLRs	that	 recognize	a	wide	variety	of	PAMPs	ranging	
from	 lipid-based	 bacterial	 cell	 wall	 components	 and	 microbial	 proteins,	 to	 distinct	 nucleic	 acid	
structures	9.	Until	today,	respectively	10	and	12	functional	TLRs	have	been	identified	in	humans	and	
mice,	 which	 are	 expressed	 either	 at	 the	 plasma	 membrane	 surface	 or	 within	 the	 endosomal	
compartment,	thus	providing	surveillance	of	bacterial	and	viral	entry	routes	10.	In	phagocytic	cells	the	
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endosomal	 localization	allows	 instant	pathogen	detection,	as	 incorporated	material	 is	 first	directed	
into	these	intracellular	vesicles.	Cytosolic	PRRs	comprise	the	recently	discovered	DNA	receptor	cyclic	
GMP-AMP	synthase	(cGAS)	as	well	as	the	nucleotide-binding	domain	(NOD)-like	receptors	(NLR)	and	
retinoic	 acid-inducible	 gene	I	 (RIG-I)-like	 receptors	 (RLR)	11.	 NLRs	 recognize	 bacterial	 peptidoglycan	
amongst	 others	12.	 Whereas	 RLRs	 detect	 viral	 nucleic	 acids	 in	 the	 cytosol,	 the	 place	 of	 viral	
replication,	thus	providing	an	important	contribution	to	the	protection	against	viral	infection	13.		
	
	
	
Figure	1:	 Pattern	 recognition	 receptors	 and	 their	 cellular	 localizations.	While	mannose-binding	 lectin	 (MBL)	 is	a	soluble	
receptor	and	part	of	the	complement	system,	the	transmembrane	C-type	lectin	receptors	(CLR)	are	situated	on	the	plasma	
membrane	 surface.	 Toll-like	 receptors	 (TLR)	 form	 homo-	 or	 heterodimers	 at	 the	 plasma-	 or	 endosomal	 membranes.	
Cytosolic	receptors	comprise	cyclic	GMP-AMP	synthase	(cGAS),	nucleotide-binding	domain	(NOD)-like	receptors	(NLR)	and	
retinoic	 acid-inducible	 gene	I	 (RIG-I)-like	 receptors	 (RLR).	 The	 latter	 family	 consists	 of	 RIG-I,	 melanoma	 differentiation	
associated	 factor	5	 (MDA5)	 and	 laboratory	 of	 genetics	 and	 physiology	2	 (LGP2).	 The	 characteristic	 N-terminal	 caspase-
activation	 and	 -recruitment	 domains	 (CARD),	 helicase	 domains	 and	 C-terminal	 domains	 (CTD)	 are	 shown	 to	 indicate	
structural	homologies	within	the	RLR.	
	
The	RLR	family	is	composed	of	the	ubiquitously	expressed	receptors	RIG-I,	melanoma	differentiation	
associated	factor	5	(MDA5)	and	laboratory	of	genetics	and	physiology	2	(LGP2),	all	of	which	belong	to	
the	 family	of	DExD/H	 (Asp-Glu-X-Asp/His)	box	RNA	helicases	and	 share	a	distinct	domain	 structure	
(Figure	1).	Although	all	RLRs	detect	virus-derived	RNA,	RIG-I	and	MDA5	discriminate	their	ligands	in	a	
length-dependent	 manner	 with	 RIG-I	 binding	 short	 and	 MDA5	 long	 dsRNA	 species	14.	 Still,	 both	
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receptors	ultimately	activate	the	same	signaling	pathway	inducing	a	cellular	antiviral	state,	whereas	
LGP2	has	rather	been	ascribed	a	regulatory	role	that	is	discussed	in	detail	in	section	6.2.	
RIG-I,	 the	 eponymous	 receptor	 of	 the	 RLR	 family,	 was	 initially	 identified	 in	 promyelocytic	
leukemia	cells	as	one	of	the	genes	induced	by	retinoic	acid	treatment	15.	Yet,	its	important	function	in	
innate	immunity	remained	elusive	until	2004	when	Yoneyama	et	al.	found	RIG-I	to	be	involved	in	the	
detection	of	viral	nucleic	acids	16.	RIG-I	has	hereafter	been	identified	as	the	receptor	for	ssRNA	virus	
genomes	 like	 newcastle	 disease	 virus,	 sendai	 virus,	 vesicular	 stomatitis	 virus,	 hepatitis	 C	 virus	 and	
influenza	A	and	B	as	well	as	 for	RNA	polymerase	 III-derived	transcripts	of	DNA	viruses	13,17,18.	Much	
effort	has	been	undertaken	to	decipher	the	structural	characteristics	of	the	minimal	RIG-I	ligand	and	
in	 2006	 two	 groups	 independently	 discovered	 5’-triphosphate	 ends	 as	 essential	 prerequisites	 for	
RIG-I-mediated	RNA	detection	19,20.	Schlee	and	colleagues	further	described	the	minimal	RIG-I	agonist	
to	be	blunt-ended	5’-triphosphate	dsRNA	of	at	least	20	base	pairs	21.	Yet,	it	was	recently	found	that	
5’-diphosphate	 ends,	 as	 found	 in	 reovirus	 genomes,	 are	 also	 sufficient	 for	 RIG-I	 activation,	 thus	
extending	 the	 number	 of	 RIG-I-detectable	 viruses	22.	 Still,	 the	 specificity	 of	 RIG-I	 for	 di-	 or	
triphosphorylated	RNA	allows	the	discrimination	between	self	and	non-self	molecules	as	eukaryotic	
5’-ends	 of	 messenger	 RNA	 (mRNA)	 are	 modified	 by	 a	 cap	 structure	 and	 2’O-methylation	 of	 the	
terminal	 nucleotide	23.	 Even	 though	 the	 chemical	 synthesis	 of	 RIG-I-activating	 RNAs	 is	 technically	
possible	24,	 laboratory	 research	on	RIG-I	 is	mostly	performed	by	 transfection	of	 in	vitro	 transcribed	
ssRNA	containing	a	5’-triphosphate	moiety	(3pRNA)	ultimately	forming	a	hairpin	structure	that	also	
potently	activates	the	receptor.		
Binding	of	the	3pRNA	ligand	to	RIG-I	is	accomplished	by	a	central,	ATPase	activity-containing	
RNA	helicase	domain	and	a	C-terminal	domain	(CTD)	that	are	characteristic	features	of	RIG-I,	MDA5	
and	LGP2.	Furthermore	MDA5	and	RIG-I	 share	 two	N-terminal	 caspase-activation	and	 -recruitment	
domains	 (CARDs),	 which	 are	 liberated	 upon	 receptor	 activation	25.	 Since	 the	 adaptor	 protein	
mitochondrial	 antiviral	 signaling	 protein	 (MAVS,	 also	 known	as	 IPS-1,	 CARDIF	 and	VISA)	 contains	 a	
CARD	 as	well,	 homotypic	 interactions	 of	 these	 domains	 lead	 to	 the	 formation	 of	 large	 oligomeric	
complexes	 of	 several	 MAVS	 and	 RIG-I	 molecules	26.	 Originally,	 localization	 of	 MAVS	 at	 the	
mitochondrial	membrane	was	thought	to	be	essential	for	proper	RIG-I	signalling	27,	but	according	to	
Dixit	 et	 al.	 also	 peroxisomal	 MAVS	 is	 responsible	 for	 the	 establishment	 of	 an	 early	 antiviral	
response	28.	 The	 oligomerization	 of	MAVS	 provides	 a	 scaffold	 for	 the	 recruitment	 of	 downstream	
signaling	molecules	that	ultimately	activate	members	of	the	inhibitor	of	nuclear	factor-κB	(IκB)	kinase	
(IKK)	 family	 (Figure	 2).	 Signaling	 through	 the	 canonical	 IKK	 complex	 consisting	 of	 IKKα,	 IKKβ	 and	
nuclear	 factor-κB	 essential	 modulator	 (NEMO)	 results	 in	 the	 phosphorylation	 and	 proteasomal	
degradation	 of	 IκB,	 thus	 liberating	 the	 transcription	 factor	 nuclear	 factor-κB	 (NFκB).	 Additionally,	
RIG-I	activation	signals	via	the	non-canonical	IKK	complex	containing	IKKε	and	TANK-binding	kinase	1	
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(TBK1).	 These	 protein	 kinases	 phosphorylate	 interferon-regulatory	 factor	3	 (IRF3)	 and	 IRF7	 that	
subsequently	 form	 homo-	 or	 heterodimers.	 Finally,	 upon	 NFκB	 and	 IRF3/7	 translocation	 into	 the	
nucleus	 the	 transcription	 of	 type-I	 interferon	 (IFN)	 and	 inflammatory	 cytokines	 is	 induced,	
functionally	 kicking-off	 the	 antiviral	 immune	 response	 induced	 by	 RLR	16,29.	 Moreover,	 the	 direct	
production	of	antiviral	factors	via	peroxisomal	MAVS	is	mediated	by	IRF1	28.	This	establishment	of	an	
antiviral	 state	 is	 further	 amplified	 by	 a	 feed-forward	 loop	 initiated	by	 autocrine	 and	paracrine	 IFN	
signaling.	 Binding	 of	 RIG-I-induced	 type-I	 IFN	 to	 its	 cognate	 receptor	 activates	 the	 janus	 kinase	
(Jak)	/	signal	 transducer	 activator	 of	 transcription	 (STAT)	 pathway,	 resulting	 in	 the	 expression	 of	
hundreds	of	interferon-stimulated	genes	(ISG),	including	RIG-I	itself	30.	
	
Figure	2:	 The	RIG-I	 signaling	pathway.	Upon	binding	of	5’-triphosphorylated	RNA	(3pRNA)	RIG-I	oligomerizes	with	MAVS	
and	ubiquitin	chains	 (Ub),	 leading	to	the	activation	of	 IKK	complexes.	Subsequent	phosphorylation	events	 induce	nuclear	
translocation	of	the	transcription	factors	IRF3/7	and	NFκB.	Expression	of	proinflammatory	cytokines	and	type-I	interferons	
(IFN)	induces	an	antiviral	state,	which	is	fostered	by	IFN-induced	JAK-STAT	forward-signaling	and	subsequent	expression	of	
interferon-stimulated	 genes	 (ISG).	 RIG-I:	 retinoic	 acid-inducible	 gene	I;	 MAVS:	 mitochondrial	 antiviral	 signaling	 protein;	
TOM70:	translocase	of	outer	membrane	70;	HSP90:	heat	shock	protein	90,	TBK1:	TANK-binding	kinase	1;	 IKK:	 inhibitor	of	
nuclear	 factor-κB	kinase;	 IRF:	 interferon-regulatory	 factor;	NEMO:	nuclear	 factor-κB	essential	modulator;	 IκB:	 inhibitor	of	
nuclear	 factor-κB;	 NFκB:	 nuclear	 factor-κB;	 IFNαR:	 interferon	 alpha	 receptor;	 JAK:	 janus	 kinase;	 STAT:	 signal	 transducer	
activator	of	transcription.	
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A	functional	antiviral	immune	response	not	only	requires	a	fast	and	powerful	activation,	it	also	needs	
an	early	enough	termination	to	prevent	collateral	tissue	damage	and	florid	autoimmunity.	It	is	hence	
not	 surprising	 that	many	molecules	 have	been	 found	 to	 be	 involved	 in	 the	 regulation	of	 the	RIG-I	
signaling	 pathway.	 To	 begin	 with,	 post-translational	 modifications	 of	 RIG-I	 can	 either	 enhance	 its	
function,	 like	 the	 conjugation	 of	 small	 ubiquitin-like	 modifier-1	 (SUMO),	 or	 inhibit	 the	 antiviral	
response	 such	as	RIG-I	phosphorylation	and	conjugation	of	 ISG15	31–34.	Moreover,	ubiquitin	plays	a	
paramount	role	in	regulation	of	RIG-I	signaling.	While	lysine	48-linked	ubiquitination	through	the	E3	
ligase	 RNF125	 (ring-finger	 protein	 125)	 leads	 to	 enhanced	 proteasomal	 degradation	 of	 RIG-I,	 the	
conjugation	of	lysine	63	(K63)-linked	ubiquitin	chains	to	the	CARD	by	TRIM25	(tripartite	motif	protein	
25)	 is	 necessary	 for	 the	 interaction	 of	 RIG-I	 with	 MAVS	35,36.	 Additionally,	 RNF135-mediated	 K63-
linked	ubiquitination	at	 the	RIG-I	C-terminus	 fosters	RIG-I	signaling	37.	Finally,	unanchored	ubiquitin	
chains	activate	RIG-I	and	promote	signal	transduction	by	inducing	RIG-I	oligomerization	38,39.		
Besides	 direct	 regulatory	 modifications	 to	 the	 RIG-I	 protein,	 functioning	 of	 its	 signaling	
pathway	 is	 influenced	 by	 components	 that	 facilitate	 protein-protein	 interactions,	 like	 heat	 shock	
protein	 90	 alpha	 (HSP90α).	 This	 molecular	 chaperone	 directly	 binds	 RIG-I,	 thereby	 protecting	 the	
receptor	from	proteasomal	degradation	40.	HSP90	is	furthermore	involved	in	the	recruitment	of	TBK1	
and	 IRF3	 to	 mitochondria	 in	 collaboration	 with	 the	 mitochondrial	 import	 receptor	 translocase	 of	
outer	membrane	70	 (TOM70).	By	binding	HSP90	as	well	 as	MAVS,	TOM70	assembles	 the	different	
signaling	 proteins	 (RIG-I,	 MAVS,	 TBK1,	 IRF3),	 thereby	 crucially	 facilitating	 signal	 transduction	 and	
transcription	 factor	activation	41.	 Lastly,	Tal	and	colleagues	 found	RLR	signaling	 to	be	 influenced	by	
reactive	 oxygen	 species	 (ROS)	 as	 they	 observed	 amplified	 IFN	 secretion	 upon	 the	 accumulation	 of	
ROS	in	the	absence	of	autophagy.	Moreover,	RLR	signaling	could	be	enhanced	by	the	generation	of	
mitochondrial	 ROS	 independently	 of	 autophagy	 by	 inhibiting	 electron	 transfer	 within	 the	
mitochondrial	respiratory	chain	42.		
In	summary,	a	whole	armada	of	factors	is	involved	in	fine-tuning	the	RIG-I	pathway	to	ensure	
effective	 antiviral	 defence	 without	 the	 devastating	 effects	 of	 an	 overshooting	 immune	 response.	
Furthermore,	such	detailed	knowledge	about	RLR	signaling	and	its	function	in	 innate	immunity	sets	
the	stage	for	utilizing	these	receptors	in	cancer	immunotherapy	as	activators	of	a	cancer	cell-directed	
immune	response.	
	
3.3 Immunotherapy	of	cancer	
In	2013	cancer	 immunotherapy	was	proclaimed	breakthrough	of	the	year	by	one	of	the	most	high-
ranking	 scientific	 journals,	 Science,	 in	 recognition	 of	 the	 considerable	 improvement	 novel	
immunotherapies	 have	 achieved	 in	 the	 overall	 survival	 of	 end-stage	 cancer	 patients,	 in	 particular	
advanced	melanoma.	The	concept	of	cancer	immunotherapy	is	based	on	the	specific	activation	of	the	
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innate-	 or	 adaptive	 immune	 system	 against	 tumors	 or	 the	 blockade	 of	 immune-inhibiting	
mechanisms,	 in	 order	 to	 achieve	 eradication	of	 the	malignant	 cells	 and	 establish	 the	 formation	of	
long-lasting	 immune	 memory	 cells.	 This	 section	 provides	 an	 overview	 of	 already	 approved	
immunotherapies	and	the	most	promising	experimental	strategies,	as	summarized	in	Figure	3.		
One	of	 the	most	direct	ways	 to	boost	 the	 immune	system,	yet	 in	a	non-specific	manner,	 is	
the	 systemic	 application	 of	 cytokines.	 Recombinant	 IFNα	 and	 interleukin	2	 (IL-2)	 are	 approved	
compounds	 for	 cancer	 therapy	 and	 are	 respectively	 used	 for	 treatment	 of	 melanoma,	 kaposi	
sarcoma,	 several	 haematological	 cancers,	metastatic	 kidney	 cancer	 and	metastatic	melanoma.	 The	
functions	of	IFNα	include	maturation	and	activation	of	DCs,	enhancement	of	MHC	expression	as	well	
as	the	generation	of	CTL,	whereas	IL-2	activates	NK	cells	and	stimulates	growth	and	differentiation	of	
CD8+	T-cells.	The	latter	was	however	also	found	to	expand	Treg	cells	43–45.		
	
	
	
Figure	 3:	 Different	 cancer	 immunotherapy	 approaches.	 (A)	 Pre-existing	 immune	 responses	 can	be	boosted	by	 systemic	
application	 of	 interferons	 (IFN)	 or	 cytokines.	 (B)	 Antibody-dependent	 strategies	 involve	 the	 blockade	 of	 immune	
checkpoints	 to	 prevent	 T-cell	 exhaustion,	 antibodies	 that	 target	 tumor-associated	 antigens	 (TAA)	 and	 carry	 cytostatic,	
cytotoxic	or	radioactive	compounds	as	well	as	bi-	or	trispecific	antibodies	that	bridge	tumor	and	immune	cells.	(C)	Currently	
investigated	agonists	of	pattern	recognition	receptors	(PRR)	include	5’-triphosphorylated	RNA	(3pRNA)	activating	retinoic-
acid	 inducible	 gene	 I	 (RIG-I),	 as	 well	 as	 Toll-like	 receptor	 (TLR)	 agonists	 like	 CpG-oligodeoxynucleotides	 (ODN),	 dsRNA	
(polyI:polyC12U)	 or	 nucleoside	 analogues.	 (D)	 Vaccination	 approaches	 aim	 at	 activating	 antigen-specific	 immune	 effector	
cells	 either	 by	 administration	 of	 short	 peptides	 and	 synthetic	 long	 peptides	 (SLP)	 consisting	 of	 several	 antigens	 or	 by	
reinfusion	 of	 ex	 vivo	manipulated	 dendritic	 cells	 (DC)	 that	 present	 TAA-epitopes	 on	major	 histocompatibility	 complexes	
(MHC).	 (E)	Adoptive	cell	 transfer	comprises	the	 isolation	of	 immune	cells	 like	cytotoxic	T-lymphocytes	(CTL),	 their	ex	vivo	
expansion	and	genetic	manipulation	to	express	tumor-specific	receptors	and	their	reinfusion	into	the	patient.	
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Holding	eight	U.S.	Food	and	Drug	Administration	 (FDA)-approved	compounds	 the	most	prosperous	
group	 of	 immunotherapeutics	 are	 the	 therapeutic	 antibodies.	 This	 class	 comprises	 antibodies	 that	
target	tumor-associated	antigens	and	may	carry	a	cytostatic,	cytotoxic	or	radioactive	compound,	as	
well	as	bi-	or	trispecific	antibodies	and	checkpoint-inhibitors.	By	combining	antigen-binding	domains	
with	 tumor	 cell-	 and	 effector	 cell	 specificity	 in	 one	 molecule,	 lacking	 the	 Fc	 domain	 of	 classical	
antibodies,	 bi-	 and	 trispecific	 antibodies	 enhance	 the	 interaction	 of	 effector	 and	 target	 cells.	 This	
ultimately	results	in	effector	cell	activation	and	target	cell	killing.	This	technique	for	example	enables	
targeted	NK	 cell	 activation	by	utilizing	 a	CD16	 specific	 domain	 (bi-	 or	 trispecific	 killer	 cell	 engager,	
BiKE	 or	 TriKE)	 or	 T-cell	 activation	 through	 incorporation	 of	 a	 CD3	 specific	 domain	 (bispecific	 T-cell	
engager	 antibody,	 BiTE)	46,47.	 The	 first	 licensed	 BiTE	 antibody,	 blinatumomab,	 is	 directed	 against	
CD19-expressing	acute	lymphoblastic	 leukemia	cells	and	was	launched	in	2014.	In	contrast	to	these	
directly	activating	 therapeutic	antibodies,	checkpoint-inhibitors	enhance	T-cell-mediated	tumor	cell	
eradication	by	blocking	inhibiting	receptor	interaction	during	their	priming	or	effector	phase.	For	the	
first	 time	 overall	 survival	 of	 advanced	melanoma	 patients	 could	 be	 increased	 from	 6.4	months	 to	
10.1	 months	 and	 16.8	 months,	 using	 anti-CTLA-4-	 and	 anti-PD-1	 antibodies	 respectively	48,49.	 The	
latter	additionally	showed	promising	anti-tumor	activity	against	non-small	cell	lung	cancer	and	renal	
cell	 cancer	50,51.	 Until	 today	 three	 checkpoint-inhibiting	 antibodies,	 ipilimumab	 (anti-CTLA-4),	
nivolumab	and	pembrolizumab	(both	anti-PD-1)	have	been	approved	and	are	continuously	studied	in	
mono-	 and	 combinatorial	 therapies.	 For	 example,	 nivolumab	 plus	 ipilimumab	 achieved	 objective	
responses	 in	 53%	 of	 advanced	 melanoma	 patients,	 all	 with	 tumor	 reduction	 of	 80%	 or	 more	52.	
Unfortunately,	 the	downside	of	 releasing	the	brakes	on	the	 immune	system	 is	 the	risk	of	 immune-
related	adverse	events,	 such	as	diarrhea,	 colitis	 and	 rashes,	 that	might	have	 severe	 impact	on	 the	
patient’s	health	and	quality	of	life,	which	should	not	be	neglected.	
Active	 induction	of	 an	 antigen-specific	 immune	 response	 is	 the	 goal	 of	 different	 vaccination	
strategies,	including	peptide	and	DC	vaccines.	The	former	technique	relies	on	direct	administration	of	
TAA-epitopes	 that	either	bind	directly	 to	external	MHC	molecules	 (short	peptides)	or	are	 taken	up	
and	 processed	 by	 DCs	 beforehand	 (long	 peptides).	 As	 example,	 synthetic	 long	 peptides,	 possibly	
containing	several	antigens,	have	shown	successful	induction	of	T-cell-mediated	immunity	and	anti-
cancer	efficacy	in	patients	with	human	papilloma	virus	positive	cervical	cancer	53,54.	Alternatively,	DC-
based	vaccination	makes	use	of	autologous	DCs	that	are	loaded	ex	vivo	with	TAA	and	reinfused	into	
the	patient	together	with	immunostimulatory	intervention.	In	2010	the	first	therapeutic	autologous	
vaccine,	 sipuleucel-T,	 was	 approved	 for	 treatment	 of	 asymptomatic	 or	 minimally	 symptomatic	
castration-resistant	 metastatic	 prostate	 cancer.	 In	 the	 corresponding	 study,	 treatment	 with	
autologous	 DCs	 that	 had	 been	 exposed	 to	 a	 chimeric	 protein	 of	 human	 growth	 factor	 GM-CSF	
(granulocyte	 macrophage	 colony-stimulating	 factor)	 and	 prostatic	 acid	 phosphatase	 led	 to	 a	 4.1	
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months	 increase	 in	median	 survival	 and	a	22.5%	 reduction	of	 risk	of	death.	 In	 this	 setting	GM-CSF	
induces	 the	 maturation	 and	 expansion	 of	 DCs,	 while	 their	 presentation	 of	 prostatic	 acid	
phosphatase-derived	peptides	activates	T-cells	exclusively	against	prostate	cancer	cells	55.	
Although	 the	 above-mentioned	 compounds	 are	 the	 only	 approved	 immunotherapies	 so	 far,	
other	 strategies,	 like	 adoptive	 cell	 transfer	 (ACT),	 have	 shown	encouraging	 results	 in	 clinical	 trials.	
This	 technique	 implies	 the	 isolation	 of	 autologous	 or	 allogenic	 immune	 effector	 cells	 that	 are	
expanded,	 activated	 and	 possibly	 genetically	 manipulated	 ex	 vivo	 to	 increase	 their	 number	 and	
tumor	 specificity,	 to	 be	 subsequently	 re-infused	 into	 the	 patient.	 Suitable	 cell	 types	 for	 ACT	 are	
cytotoxic	lymphocytes	like	NK	cells	and	CTL.	To	enhance	anti-tumor	effector	functions	isolated	cells	
can	be	 equipped	with	 TAA-specific	 T-cell	 receptors	 or	 chimeric	 antigen	 receptors	 (CAR).	 The	 latter	
have	 been	 initially	 developed	 by	 Steve	 A.	 Rosenberg	 and	 Zelig	 Eshhar	 and	 consist	 of	 an	 antigen-
binding	domain	of	a	TAA-specific	antibody	fused	to	intracellular	signaling	domains	that	render	T-cell	
activation	 independent	 of	 MHC	 molecules	56.	 CAR	 T-cells	 have	 shown	 to	 be	 safe	 and	 induce	
considerable	 rates	 of	 objective,	 long-lasting	 clinical	 responses	 in	 trials	 using	 CD19-directed	 CARs	
against	 different	 types	 of	 B-cell	 malignancies	 characterized	 by	 their	 surface	 CD19	 expression	57,58.	
Likewise,	CAR	T-cells	have	demonstrated	promising	safety	and	efficacy	profiles	against	solid	tumors,	
for	 example	 by	 targeting	 the	 diasialoganglioside	GD2	on	 neuroblastoma	 cells	 or	 human	 epidermal	
growth	factor	receptor	2	(HER2)	on	sarcoma	59,60.				
Finally,	 therapeutic	 immune	 activation	 can	 be	 achieved	 by	 employing	 PRRs	 in	 different	
stimulatory	settings.	Although	PRR	agonists	have	demonstrated	anti-tumor	effects	 in	monotherapy,	
they	are	currently	predominantly	 studied	as	adjuvant	molecules	61.	 For	example	TLR3	activation	by	
polyI:polyC12U	 (polyI:polyC	 dsRNA	with	 a	U	mismatch	 every	 12th	 base	 of	 the	 C	 strand)	 is	 tested	 in	
breast	 cancer	 patients	 as	 adjuvant	 therapy	 in	 combination	with	HER2	 vaccination	 (NCT01355393).	
Furthermore,	 imiquimod,	 a	 small	 molecule	 nucleoside	 analogue	 that	 functions	 as	 TLR7/8	 agonist,	
induced	rejection	of	skin	metastases	in	breast	cancer	patients	upon	topical	administration	and	is	now	
tested	 in	combination	with	cyclophosphamide	and	radiotherapy	(NCT01421017)	62.	Lastly,	TLR9	can	
be	activated	by	synthetic	oligonucleotides	 that	mimic	bacterial	unmethylated	CpG	DNA	sequences,	
like	CpG-7909.	Yet,	this	compound	has	demonstrated	varying	effects	in	clinical	trials.	While	inclusion	
of	 CpG	 as	 adjuvant	 in	 a	 peptide	 vaccination	 strategy	 in	 metastatic	 melanoma	 patients	 elevated	
antigen-specific	 T-cells	 by	 10-fold	 and	 enhanced	 cytokine	 production	 upon	 in	 vitro	 re-stimulation,	
another	 study	 in	 melanoma	 patients	 exhibited	 no	 superior	 clinical	 outcome	 to	 standard	
therapies	63,64.	 Importantly,	 these	 diverse	 TLR	 ligands	 all	 share	 the	 disadvantage	 that	 they	 usually	
only	act	on	immune	cells	without	having	any	direct	effects	on	tumor	cells.		
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3.4 RIG-I	as	immunotherapeutic	target	
The	suitability	of	RIG-I	as	immunotherapeutic	target	is	based	on	its	ubiquitous	expression,	including	
tumor	 cells,	 as	well	 as	 a	 number	 of	 signaling	 effects	 that	 collectively	 result	 in	 stimulation	 of	 anti-
tumor	immunity	and	induction	of	tumor	cell	death.	These	qualities	have	also	been	studied	in	vivo	by	
intratumoral	injection	of	RIG-I	ligands	complexed	with	a	polymer-based	transfection	reagent	(in	vivo-
jetPEI®).	Since	this	compound	is	not	yet	approved	for	human	application,	efficient	delivery	poses	the	
current	 limitations	 to	RIG-I-targeted	 immunotherapy.	Thus,	efforts	are	ongoing	 to	 find	 the	optimal	
delivery	 tool	 that	 protects	 the	 ligand	 from	 degradation,	 is	 non-toxic	 and	 allows	 specific	 tumor	
targeting	to	reach	the	primary	tumor	and	metastases	upon	intravenous	application.	
Besch	and	colleagues	first	described	that	activation	of	RIG-I	triggers	mitochondrial	apoptosis	in	
melanoma	cells.	 Importantly,	this	apoptotic	effect	 is	restricted	to	malignant	cells,	as	non-malignant	
cells	 are	 largely	protected	by	 their	endogenous	expression	of	Bcl-xL	65.	 The	 induction	of	 tumor	cell	
death,	 which	 can	 provide	 the	 immune	 system	 with	 an	 important	 source	 of	 tumor	 antigens,	 was	
furthermore	 described	 in	 human	 ovarian	 cancer	 and	 pancreatic	 cancer	 cells	5,66.	 In	 addition,	 RIG-I-
mediated	cell	death	is	considered	to	be	immunogenic.	This	refers	to	the	release	of	danger	signals	like	
HMGB1	 (high	 mobility	 group	 protein	 B1)	 or	 the	 translocation	 of	 calreticulin	 to	 the	 outer	 cell	
membrane	 that	 may	 facilitate	 antigen	 uptake	 by	 DCs	5.	 Duewell	 et	 al.	 demonstrated	 that	 IFN	
produced	by	3pRNA-treated	 tumor	cells	activates	DCs,	which	 then	effectively	cross-present	TAA	 to	
naive	 CD8+	 T-cells.	 Moreover,	 RIG-I	 activation	 sensitizes	 tumor	 cells	 for	 CTL-mediated	 killing	 by	
enhancing	surface	expression	of	MHC	class-I	and	Fas	5.		
While	RIG-I	ligands	were	shown	to	induce	systemic	activation	of	B-cells,	CD4+	and	CD8+	T-cells	
as	well	as	NK	and	NKT	cells	 in	vivo,	anti-tumoral	effects	seem	to	be	mediated	by	different	 immune	
cell	 types	depending	on	 the	 tumor	model.	 This	 likely	 results	 from	 tumor	 type-specific	 variations	 in	
the	expression	of	MHC	class-I	and	activating	NK	cell	ligands	as	well	as	the	availability	of	TAA.	Utilizing	
a	B16	melanoma	lung	metastasis	model	Poeck	et	al.	demonstrated	that	anti-tumor	activity	relies	on	
NK	but	not	CD8+	T-cells	67.	In	contrast,	in	a	pancreatic	cancer	model	the	therapeutic	efficacy	of	RIG-I	
ligands	was	solely	dependent	on	CD8+	T-cells,	whereas	NK	cells	were	dispensable	68.	Moreover,	RIG-I	
therapy	might	benefit	from	an	IFNα-dependent	reduction	of	MDSC	frequency	and	their	suppressive	
function	as	shown	for	TLR9	activation,	as	well	as	 from	reduced	attraction	of	Treg	cells	owing	to	an	
IFN-dependent	blockade	of	intratumoral	CCL22	(C-C	motif	chemokine	22)	expression	69,70.	
Besides	these	intrinsic	anti-cancer	properties,	RIG-I	ligands	carry	the	inherent	possibility	to	be	
equipped	with	 a	 RNA-interference	 (RNAi)	 functionality,	 thus	 enabling	 simultaneous	 knockdown	 of	
oncogenes	or	anti-apoptotic	proteins	for	example.	The	effective	induction	of	anti-tumor	immunity	by	
such	 dual-functional	 3p-siRNAs	 was	 shown	 by	 Poeck	 and	 colleagues	 in	 a	 B16	 melanoma	 lung	
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metastasis	 model	 and	 meanwhile	 this	 concept	 has	 been	 adapted	 for	 TGFβ	 (transforming	 growth	
factor	β)	silencing	in	pancreatic	cancer	67,68.		
In	 summary,	 the	 ubiquitous	 expression	 of	 RIG-I	 together	 with	 the	 tumoricidal	 and	
immunostimulatory	 properties	 of	 RIG-I	 agonists	 renders	 3pRNA	 a	 promising	 candidate	 for	 future	
tumor	immunotherapy,	for	example	of	malignant	melanoma.	
	
3.5 Malignant	melanoma	
Malignant	 melanoma,	 a	 malignancy	 of	 pigmented	 cells,	 metastasizes	 quickly	 and	 overall	 patient	
survival	 rates	 are	 very	 low.	 Still,	 this	 tumor	 has	 a	 high	 intrinsic	 immunogenicity,	 mediated	 by	 a	
strongly	expressed	unique	set	of	differentiation	antigens.	Although	melanoma	makes	up	only	2%	of	
all	skin	cancers,	the	incidence	rates	rapidly	increased	over	the	past	30	years	(from	11.2	new	cases	per	
100,000	in	1982	to	22.9	per	100,000	in	2012	71)	and	it	accounts	for	the	vast	majority	of	skin	cancer	
deaths.	 Treatment	 options	 and	 survival	 chances	 are	 closely	 related	 to	 the	metastatic	 potential	 of	
melanoma,	which	 is	 demonstrated	 by	 a	 5-year	 relative	 survival	 rate	 of	 98%	 for	 local	 disease	 that	
declines	 to	 63%	 for	 regional	 and	 16%	 for	 distant	 stage	 disease	72.	 Thus,	 an	 early	 detection	 and	
surgical	resection	of	this	malignancy	is	still	most	beneficial	for	prognosis.		
In	40-60%	of	advanced	melanoma	activating	mutations	in	the	BRAF	kinase	(serine/threonine-
protein	kinase	B-raf)	can	be	found,	that	constantly	drive	the	successive	oncogenic	MAPK	(mitogen-
activated	protein	kinase)	pathway	73.	Hence,	targeted	therapy	utilizing	V600E-mutated	BRAF-	or	MEK	
(MAPK	 kinase)	 inhibitors,	 such	 as	 vemurafenib,	 dabrafenib	 and	 trametinib,	 can	 potently	 improve	
overall-	and	progression-free	survival	of	mutation-positive	melanoma	patients	74–76.	Still,	tumor	cells	
frequently	develop	resistance	and	the	group	of	therapy	responders	is	limited.		
The	 recent	 development	 of	 immune	 checkpoint-inhibitors	 has	 further	 significantly	 extended	
the	 overall	 survival	 of	 advanced	melanoma	 patients.	 In	 accumulated	 data	 of	multiple	 ipilimumab-
trials,	 three-year	 survival	 rates	 of	 advanced	 melanoma	 patients	 were	 22%	 and	 median	 overall	
survival	added	up	to	11.4	months	77.	Of	note,	immune	checkpoint-inhibition	might	come	along	with	
severe	 adverse	 effects.	 Yet,	 these	 have	 been	 shown	 to	 be	 generally	 manageable	 with	 temporary	
immunosuppression.	 Moreover,	 PD-1-directed	 antibodies	 appeared	 to	 have	 improved	 toxicity	
profiles	as	compared	to	CTLA-4	blockade	78.			
Since	a	large	proportion	of	melanoma	patients	still	does	not	benefit	long-term	from	these	new	
checkpoint-inhibiting	 and	 targeted	 therapies,	 combinatorial	 approaches	 need	 to	 be	 further	
developed	to	maximize	benefit.	This	will	most	 likely	 involve	the	combined	use	of	 immunotherapies	
from	different	classes,	or	a	combination	of	classic	interventions	with	immunotherapies	79.	In	general,	
targeted	RIG-I	 activation	by	3pRNA	 in	 the	 tumor	microenvironment	 can	 focus	 the	attention	of	 the	
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immune	 system	 to	 the	 tumor	 site,	 possibly	 maximizing	 local	 efficacy	 and	 reducing	 systemic	 side	
effects.	
 
3.6 Tumor	hypoxia	and	its	consequences	
During	 the	 development	 of	 a	 therapy	 that	 functions	 directly	 on	 tumor	 cells,	 like	 RIG-I-mediated	
immunotherapy,	 different	 stress	 factors	 found	 within	 the	 tumor	 microenvironment	 have	 to	 be	
considered	 as	 they	 may	 alter	 drug	 function	 or	 -efficacy.	 These	 include	 nutrient	 deprivation,	 pH	
variations,	 necrotic	 neighboring	 cells	 or	 tumor	 hypoxia.	 The	 latter	 is	 the	 inadequate	 tissue	 supply	
with	 oxygen	 that	 compromises	 biologic	 functions	80.	 Throughout	 the	 body	 the	 partial	 oxygen	
pressure	 (pO2)	 differs	 substantially	 from	 the	 21%	 of	 the	 inspired	 air	 and	 varies	 greatly	 between	
tissues	 reaching	13%	 in	arterial	blood,	10%	 in	kidney	and	4%	 in	muscle	 for	example	81.	Yet,	normal	
tissues	 are	 well	 adapted	 to	 the	 local	 oxygen	 conditions	 they	 reside	 in.	 In	 inflamed	 tissue	 oxygen	
availability	 is	 often	 further	 reduced	 due	 to	 increased	 oxygen	 consumption	 by	 infiltrating	 immune	
cells	 and	 blood	 vessels	 that	 are	 clogged	with	 phagocytes.	 This	 can	 induce	 suppression	 of	 immune	
functions	and	hypoxia	might	 thus	serve	as	a	physiologic	brake,	 limiting	cytotoxic	action	of	 immune	
effector	 cells	 and	 protecting	 healthy	 tissue	 against	 excessive	 damage	 and	 autoimmunity.	
Importantly,	 pO2-values	 found	 in	 tumors	 are	 often	 even	 lower	 than	 in	 the	 healthy	 tissue	 they	 are	
derived	 from	 resulting	 in	 tumor	 hypoxia	 (Figure	 4).	 As	 demonstrated	 by	 a	 study	 of	 Lartigau	 and	
colleagues	 hypoxia	 is	 also	 commonly	 found	 in	 malignant	 melanoma.	 Utilizing	 a	 needle	 probe	
technique	they	detected	a	median	pO2	of	1.6%	in	tumors	and	0.9%	in	skin	metastases	as	compared	
to	 5%	 in	 surrounding	 “normal”	 tissue	82.	 This	 can	 be	 caused	 by	 rapid	 tumor	 cell	 proliferation	
exceeding	 vascular	 growth,	 leading	 to	 increased	 diffusion	 distances,	 structural	 and	 functional	
abnormality	of	vessels	and	disturbed	microcirculation	83.		
As	 a	 reaction	 to	 oxygen	 deprivation	 cells	 can	 activate	 the	 transcription	 factors	 NFκB	 and	
hypoxia-inducible	 factor	 (HIF),	 which	 can	 induce	 the	 expression	 of	 hundreds	 of	 genes,	 including	
glycolytic	enzymes,	glucose	transporters,	angiogenic	molecules,	survival	and	growth	factors	as	well	as	
heat	 shock	 proteins	80,84,85.	 Thereby	 the	 cellular	metabolism	 is	 shifted	 towards	 anaerobic	 glycolysis	
and	neovascularization	is	induced,	the	latter	being	largely	dependent	on	vascular	endothelial	growth	
factor	 (VEGF)-mediated	 proliferation	 and	migration	 of	 endothelial	 cells	86.	 Beyond	 that,	 hypoxia	 is	
associated	 with	 resistance	 to	 radiation	 and	 chemotherapy,	 epithelial-to-mesenchymal	 transition	
(EMT)	 and	 escape	 of	 immune	 surveillance,	 all	 of	 which	 will	 be	 elucidated	 below.	 Together,	 these	
modulations	allow	cells	to	adapt	to	the	hostile	environment	or	to	facilitate	their	escape	by	enhancing	
tumor	cell	spread	and	tumor	tissue-invasion.	
Indeed,	 the	phenomenon	of	 tumor	hypoxia	was	originally	discovered	as	a	 factor	mediating	
resistance	to	radiation	therapy.	As	early	as	in	the	1950s	Gray	et	al.	observed	that	the	concentration	
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of	 oxygen	 dissolved	 in	 tissues	 at	 the	 time	 of	 irradiation	 influences	 treatment	 outcome	87.	 That	 is	
because	ionizing	radiation	causes	the	formation	of	radicals	in	the	DNA	either	by	direct	ionization	or	
by	reaction	with	hydroxyl	radicals	and	other	ROS	produced	from	radiolysis	of	water	88.	
	
	
	
Figure	4:	Correlation	of	tumor	growth	and	hypoxia.	With	increasing	tumor	size,	vascularization	becomes	more	and	more	
insufficient	 resulting	 in	 a	 decrease	 of	 the	 partial	 oxygen	 pressure	 (pO2).	 When	 pO2-values	 fall	 below	 those	 of	 the	
surrounding	healthy	tissue	and	biologic	functions	of	cells	are	compromised,	the	tumor	is	considered	hypoxic.	Adapted	from	
Brahimi-Horn	and	Pouyssegur	89.		
	
Importantly,	hypoxia	also	plays	a	role	in	resistance	to	chemotherapy.	While	the	abnormal	structure	
and	function	of	blood	vessels	can	prevent	efficient	drug	delivery	 into	the	tumor,	hypoxia-mediated	
slowing	 of	 proliferation	 limits	 the	 effectiveness	 of	 drugs	 that	 target	 highly	 proliferative	 cells	81.	
Moreover,	oxygen	deprivation	enhances	genetic	 instability,	 for	example	through	the	enrichment	of	
DNA	mismatch	 repair	deficient	 cells,	 that	might	affect	 genes	 involved	 in	drug	uptake,	 -metabolism	
and	-export,	thus	accelerating	the	development	of	therapy	resistant	clones	81,90.		
Besides	its	impediment	of	classical	therapies,	hypoxia	is	known	to	induce	EMT	in	tumor	cells	
including	murine	melanoma	cells	91.	 This	 reversible	dedifferentiation	of	 resident	epithelial-like	 cells	
into	motile	mesenchymal-like	cells	plays	an	important	physiological	role	in	embryo	formation,	organ	
development,	 wound	 healing	 and	 tissue	 regeneration	92.	 As	 example,	 keratinocytes	 in	 wounds	
undergo	 partial	 EMT	 to	 gain	 the	 ability	 to	move	 and	 attach	 to	 new	 substrates	 and	 thus	 facilitate	
wound	 re-epithelialization	93.	 During	 tumor	 development	 EMT	 is	 induced	 by	 a	 number	 of	 events,	
including	 hypoxia-mediated	 formation	 of	 ROS	 and	 NFκB	 activation	94,95.	 Transition	 into	 the	
mesenchymal	 phenotype	 provides	 cancer	 cells	 with	 an	 enhanced	 migratory	 capacity,	 increased	
invasiveness	 and	 protection	 against	 apoptosis.	 Moreover,	 this	 kind	 of	 phenotypic	 plasticity	 can	
contribute	to	cancer	cell	resistance	to	chemo-,	immuno-	and	targeted	therapies	96.	Thus,	EMT	is	not	
only	 a	 consequence	 of	 tumor	 formation	 owing	 to	 environmental	 changes	 like	 the	 occurrence	 of	
hypoxia,	but	at	the	same	time	it	 is	a	stimulant	of	tumor	spread	and	often	is	associated	with	cancer	
immune	 escape.	 Exemplarily	 for	 the	 relationship	 between	 EMT	 and	 immune	 escape	 is	 a	 study	 by	
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Landsberg	and	colleagues	who	showed	that	immune	evasion	of	melanoma	cells	can	be	mediated	by	
reversible	 loss	 of	 melanocytic	 antigens	 during	 tumor	 necrosis	 factor	 alpha	 (TNFα)-induced	 switch	
between	a	differentiated	and	dedifferentiated	phenotype.	As	a	result	T-cell	recognition	is	prevented	
and	melanoma	cells	acquire	resistance	to	adoptive	cell	transfer	therapy	97.	
However,	 EMT	 is	 only	 one	 among	 many	 different	 mechanisms	 of	 hypoxic	 tumor	 cells	 to	
evade	 immune	 attack.	 Importantly,	 hypoxia	 induces	 suppression	 of	 immune	 functions.	 This	 is	
indicated	 for	example	by	 impaired	survival	and	proliferation	of	CD4+	T-cells	as	well	as	 loss	of	 IFNγ-
production	 by	 Th1	 CD4+	 T-cells,	 an	 effect	 mediated	 by	 increased	 expression	 of	 immunoinhibitory	
IL-10	98,99.	Additionally,	differentiation	and	maturation	of	DCs	upon	TLR	stimulation	 is	 repressed,	as	
well	as	their	homing	to	lymph	nodes,	thereby	preventing	T-cell	priming	100.	Still,	what	functions	as	a	
‘friend’	 in	 the	 setting	 of	 inflammation	 may	 act	 as	 a	 ‘foe’	 in	 the	 fight	 against	 cancer.	 Moreover,	
hypoxic	tumor	cells	can	evolve	additional	 immunosuppressive	mechanisms.	Amongst	others,	tumor	
cell	 susceptibility	 to	NK-	or	CTL-mediated	 lysis	 is	 impaired	by	hypoxia-induced	autophagy	 in	breast	
cancer	 and	 lung	 cancer	 cells	 respectively,	 an	 effect	 that	 can	 be	 prevented	 by	 inhibiting	
autophagy	101,102.	As	shown	by	Barsoum	et	al.	resistance	to	CTL-mediated	lysis	 is	further	aggravated	
by	 the	 HIF-dependent	 upregulation	 of	 PDL-1	 expression	 on	 cancer	 cells,	 thus	 enforcing	 T-cell	
apoptosis	via	 the	PD-1	receptor	 in	 response	to	hypoxia	103.	Blocking	HIF	accumulation	by	activating	
nitric	oxide	signaling	instead	represses	PDL-1	upregulation	and	resistance	to	T-cell	attack.	Diminished	
nitric	oxide	signaling	upon	oxygen	deprivation	is	also	involved	in	shedding	of	cell	stress-induced	MHC	
class-I	chain-related	(MIC)	molecules	on	human	prostate	cancer	cells,	which	prevents	the	binding	of	
activating	 receptors	on	NK	and	 cytotoxic	 T-cells	104.	Nitric	oxide	mimetics	 and	autophagy	 inhibitors	
therefore	 represent	 encouraging	 tools	 to	 counteract	 hypoxia-related	 tumor	 immune	 escape.	All	 in	
all,	these	studies	clearly	demonstrate	that	without	learning	the	effect	of	hypoxia	on	RIG-I	signaling,	
we	will	never	get	3pRNA-mediated	cancer	immunotherapy	to	work	right.		
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3.7 Aim	of	the	study	
Knowing	 that	 hypoxia	 contributes	 to	 tumor	 immune	 escape	 on	 different	 levels	 and	 based	 on	 the	
observation	 that	 IFNα	 receptor	 (IFNαR)	expression	and	 IFNα	signaling	are	diminished	upon	oxygen	
deprivation	105,	 the	 starting	 hypothesis	 of	 this	 thesis	 assumed	 a	 negative	 influence	 of	 hypoxia	 on	
RIG-I	function	and	thus	on	3pRNA-mediated	tumor	immunotherapy.		
To	 test	 this	 hypothesis,	 effects	 of	 oxygen	 deprivation	 on	 the	 RIG-I	 expression	 itself	 were	
investigated	in	a	set	of	murine	melanoma	cell	lines	and	primary	tissue	cells.	Moreover,	the	influence	
of	 hypoxia	 on	 different	 regulatory	 components	 that	 play	 crucial	 roles	 in	 signal	 transduction	 from	
RIG-I	to	the	effector	transcription	factors	were	additionally	analysed.	Finally,	functional	repercussions	
of	 the	 hypoxia-mediated	 effects	 on	 RIG-I	 signaling	 outcome	 were	 investigated.	 In	 particular	 anti-
melanoma	antigen-specific	T-	and	NK	cell	responses	were	studied	in	different	settings.	
The	gained	insights	were	then	used	for	the	identification	of	measures	that	might	enhance	the	
RIG-I	 response	 under	 hypoxia	 and	 result	 in	 beneficial	 treatment	 outcome	 in	 an	 in	 vivo	 model	 of	
transplantable	murine	melanoma.	
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4 Material	and	methods	
4.1 Material	
4.1.1 Consumables	
Blotting	paper	 GE	Healthcare	 Chalfont	St	Giles,	GB	
Cell	culture	flasks	(75	cm2)	 Sarstedt	 Nümbrecht	
Cell	strainer	(70	µm,	nylon)	 Corning	 Amsterdam,	Netherlands	
Centrifuge	tubes	(15	ml,	50	ml)	 Greiner	Bio-One	 Frickenhausen	
Cluster	tubes	 Corning	 Amsterdam,	Netherlands	
Cryo	tubes	 Greiner	Bio-One	 Frickenhausen	
ELISA	plates	 Thermo	Scientific	 Rochester	
Lumitrac	200	96-well	white	immunology	
plate	 Greiner	Bio-One	 Frickenhausen	
Microlances	(30	G,	0.3	x	13	mm)	 BD	Biosciences	 Franklin	Lakes,	NJ,	USA	
Micropipette	tips		 Greiner	Bio-One	 Frickenhausen	
Micropipette	tips,	RNase	free	 Corning	 Amsterdam,	Netherlands	
Micropipette	tips,	with	filter	 Corning	 Amsterdam,	Netherlands	
Microplates		
(flat-	/	round	bottom)	 Greiner	Bio-One	 Frickenhausen	
Neubauer	chamber	 VWR	International	 Darmstadt	
Nitrocellulose	membrane	(0.2	µm,	0.45	µm)	 GE	Healthcare	 Buckinghamshire,	GB	
PCR	tubes	(0.2	ml)	 Biozym	Scientific	 Hessisch	Oldendorf	
Petri	dishes	(10	cm)	 Sarstedt	 Nümbrecht	
Pipettes	(5	ml,	10	ml,	25	ml)	 Greiner	Bio-One	 Frickenhausen	
qPCR	plates	 Sarstedt	 Nümbrecht	
Quick	spin	oligo	columns	(mini)	 Roche	 Basel,	Switzerland	
Reagent	reservoirs	 Brand	 Wertheim	
Scalpels	 Pfm	medical	 Cologne	
Spin	columns	 Centic	Biotec	 Heidelberg	
Syringes	(5	ml)	 BD	Biosciences	 Franklin	Lakes,	NJ,	USA	
Syringes	Inject-F	(1	ml)	 B.	Braun	 Melsungen	
Test	tubes	(0.5	ml,	1.5	ml,	2	ml)	 Sarstedt	 Nümbrecht	
Tissue	culture	test	plates		
(12	well,	48	well,	96	well)	 TPP	Techno	Plastic	Products	 Trasadingen,	Switzerland	
Zirconia	beads	(1	mm	diameter)	 Biospec	Products	 Bartlesville,	OK,	USA	
	
4.1.2 Equipment	
ABI	7900HT	 Applied	Biosystems	 Waltham,	MA,	USA	
Balance,	electronic	 Sartorius	 Göttingen	
Blotting	equipment	 BioRad	 Hercules,	CA,	USA	
Centrifuge	5810R	 Eppendorf	 Hamburg	
EnVision	Multilabel	plate	reader		 Perkin	Elmer	 Waltham,	MA,	USA	
Epoch	Microplate	Spectrophotometer	 BioTek	 Winooski,	VT,	USA	
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FACS	Canto	 BD	Biosciences	 Franklin	Lakes,	NJ,	USA	
FACS	LSR	II	 BD	Biosciences	 Franklin	Lakes,	NJ,	USA	
Homogenizer	 Bertin	Technologies	 Montigny	le	Bretonneux,	France	
Hypoxia	incubator		 Life	Technologies	 Carlsbad,	CA,	USA	
Immunofluorescence	microscope	 Leica	Biosystems	 Wetzlar	
Magnetic	stirrer	 Velp	Scientifica	 Usmate,	Italy	
Microcentrifuge	5415R	 Eppendorf	 Hamburg	
Micropipettes	 Eppendorf	/	Rainin	 Hamburg	
Microscope	Nicon	Eclipse	TS100	 Nikon	 Düsseldorf	
Microtome	RM2255	 Leica	Biosystems	 Wetzlar	
Multichannel	pipette	 VWR	International	 Darmstadt	
NanoDrop	 Peqlab	 Darmstadt	
Odyssey	Fc	Imaging	System	 LI-COR	Biotechnology	 Lincoln,	NE,	USA	
pH	meter	 Hanna	instruments		 Vöhringen	
Pipetting	aid	 Integra	Biosciences	 Konstanz	
Power	supply		 Labnet	International	 Edison,	NJ,	USA	
SDS-gel	electrophoresis	equipment	 BioRad	 Hercules,	CA,	USA	
Shaker	 NeoLab	 Heidelberg	
Sterile	bench	 Thermo	Scientific	 Waltham,	MA,	USA	
Thermocycler	 Analytik	Jena	 Jena	
Thermomixer	 Eppendorf	 Hamburg	
Vortex	mixer	 Velp	Scientifica	 Usmate,	Italy	
Water	jacketed	CO2	incubator	
Panasonic	Biomedical	Sales	
Europe	 Etten	Leur,	The	Netherlands	
Water	bath	 Julabo		 Seelbach	
X-ray	film	developing	machine		 CAWO	 Schrobenhausen	
	
4.1.3 Solid	chemicals		
Actinomycin	D	 AppliChem	 Darmstadt	
Albumin	fraction	V	 Roth	 Karlsruhe	
Ammonium	persulfate	 Roth	 Karlsruhe	
Bromphenolblue	(BPB)	 Roth	 Karlsruhe	
Calcium	chloride	(CaCl2)	 Roth	 Karlsruhe	
Disodium	hydrogen	phosphate	(Na2HPO4)	 Roth	 Karlsruhe	
Dithiotreitol	(DTT)	 Roth	 Karlsruhe	
Glycine	 Roth	 Karlsruhe	
L-ascorbic	acid	 Sigma-Aldrich	 St.	Louis,	MO,	USA	
Milk	powder	 Roth	 Karlsruhe	
Ponceau	S	 Roth	 Karlsruhe	
Potassium	chloride	(KCl)	 Roth	 Karlsruhe	
Potassium	dihydrogen	phosphate	(KH2PO4)	 Roth	 Karlsruhe	
Sodium	azide	 Roth	 Karlsruhe	
Sodium	carbonate	(Na2CO3)	 Roth	 Karlsruhe	
Sodium	chloride	(NaCl)	 Roth	 Karlsruhe	
Sodium	deoxycholate	 Sigma-Aldrich	 St.	Louis,	MO,	USA	
Sodium	dodecylsulphate	(SDS)	 Applichem	 Darmstadt	
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Sodium	hydrogen	carbonate	(NaHCO3)	 Roth	 Karlsruhe	
Tris	 Roth	 Karlsruhe	
	
4.1.4 Liquid	chemicals	
Acetic	acid	 Roth	 Karlsruhe	
Ampuva	(sterile,	deionized	H2O)	 B.	Braun	 Melsungen	
Antibody	diluent	for	IHC	 Dako	 Hamburg	
Chloroform	 Roth	 Karlsruhe	
Developer	for	x-ray	films	 AGFA	 Mortsel,	Belgium	
ECL	western	blotting	substrate	 Thermo	Scientific	 Waltham,	MA,	USA	
ELISA	substrate	solutions		
(H2O2,	tetramethylbenzidine)	
BD	Biosciences	 Franklin	Lakes,	NJ,	USA	
Ethanol	 Roth	 Karlsruhe	
FACS	Flow	 BD	Biosciences	 Franklin	Lakes,	NJ,	USA	
Glycerin	 Roth	 Karlsruhe	
Hydrogen	peroxide	 Roth	 Karlsruhe	
In	vivo-jetPEI®	 Polyplus	 Illkirch,	France	
Isopropanol	 Roth	 Karlsruhe	
LipofectamineTM	RNAiMAX	 Invitrogen	 Waltham,	MA,	USA	
LipofectamineTM2000	 Invitrogen	 Waltham,	MA,	USA	
Pascorbin®	 Pascoe	pharmazeutische	Präparate	 Gießen	
Rapid	fixer	for	x-ray	films	 AGFA	 Mortsel,	Belgium	
RLT	lysis	buffer	 Quiagen	 Hilden	
Roti-Quant	Bradford	reagent	 Roth	 Karlsruhe	
Rotiphorese	Gel	30,	37.5:1	 Roth	 Karlsruhe	
RW1	RNA	wash	buffer	 Quiagen	 Hilden	
Sulfuric	acid	 Roth	 Karlsruhe	
TEMED	 Roth	 Karlsruhe	
Triton-X-100	 Roth	 Karlsruhe	
Trizol	reagent	 Ambion	 Waltham,	MA,	USA	
Tween-20	 Roth	 Karlsruhe	
Zinc	fixative	 BD	Biosciences	 Franklin	Lakes,	NJ,	USA	
Zymo	RNA	wash	buffer	 Zymo	research	 Irvine,	CA,	USA	
	
4.1.5 Cell	culture	substances	
Dimethylsulfoxide	(DMSO)	 Roth	 Karlsruhe	
Dulbecco’s	modified	eagles	medium	(DMEM)	 Gibco	 Carlsbad,	CA,	USA	
Dulbecco’s	phosphate	buffered	saline	(DPBS)	 Gibco	 Carlsbad,	CA,	USA	
Fetal	calve	serum	(FCS)	 Gibco	 Carlsbad,	CA,	USA	
Hepes	 Gibco	 Carlsbad,	CA,	USA	
L-Glutamine		 Gibco	 Carlsbad,	CA,	USA	
Lysis	buffer	(10×)	for	erythrocytes	 BD	Biosciences	 Franklin	Lakes,	NJ,	USA	
Non-essential	amino	acids	(NEAA)	 Gibco	 Carlsbad,	CA,	USA	
OptiMEM	 Gibco	 Carlsbad,	CA,	USA	
Penicillin-streptomycin	 Gibco	 Carlsbad,	CA,	USA	
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RPMI	1640	medium	 Gibco	 Carlsbad,	CA,	USA	
Sodium	pyruvate	 Gibco	 Carlsbad,	CA,	USA	
Trypan	blue	 Sigma-Aldrich	 St.	Louis,	MO,	USA	
Trypsin/EDTA	 Gibco	 Carlsbad,	CA,	USA	
	
4.1.6 Buffers	
Annealing	buffer	(10×)	 250	mM	tris-/HCl;	250	mM	NaCl;	pH	7.4	
Blocking	buffer	(western	blot)	 5%	(w/v)	milk	powder	in	TBST	or	PBST	
Electrophoresis	buffer	 24	mM	tris;	192	mM	glycine;	0.1%	(w/v)	SDS	
ELISA	blocking	buffer	(CXCL10)	 2%	(v/v)	FCS	in	PBS	
ELISA	blocking	buffer	(IL-6)	 10%	(v/v)	FCS	in	PBS	
ELISA	coating	buffer	(IL-6)	 100	mM	NaHCO3;	33.6	mM	Na2CO3	in	PBS;	pH	9.5	
ELISA	wash	buffer	 0.05%	(v/v)	Tween20	in	PBS	
FACS	buffer	 2%	FCS;	2	mM	EDTA;	0.05%	NaN3	in	PBS	
Fixation	buffer	(FACS)	 3.7%	formaldehyde	in	PBS	
Laemmli	buffer	(2×)	 0.2	M	tris/HCl	pH	6.8;	4%	(w/v)	SDS;	20%	(v/v)	glycerol;	20	mM	DTT;	0.05%	(w/v)	bromphenolblue	
Luciferin	
20	mM	tricine;	2.7	mM	MgSO4*7H2O;	0.1	mM	EDTA	pH	8.0;	33	mM	
DTT;	0.5	mM	ATP;	0.3	mM	acetyl	CoA;	0.03	g	luciferin;	5	mM	NaOH;	
0,3	mM	(MgCO3)4Mg(OH)2*5H2O	
Lysis	buffer	for	cell	fractionation	 50	mM	tris;	0.5%	(v/v)	triton-X-100;	138	mM	NaCl;	10%	(v/v)	glycerol;	5	mM	EDTA;	1×	protease-;	1×	phosphatase	inhibitor	mix	
MACS	buffer	 2%	FCS;	2	mM	EDTA	in	PBS	
Permeabilization	buffer	(FACS)	 0.5%	saponin	in	FACS	buffer	
Phosphate	buffered	saline	(PBS)		 140	mM	NaCl;	8	mM	Na2HPO4;	1.5	mM	KH2PO4;		2.5	mM	KCl	
Ponceau	staining	solution	 0.1%	(w/v)	ponceau;	3%	(v/v)	acetic	acid	
RIPA	buffer	 50	mM	tris	pH	8.0;	150	mM	NaCl;	1%	(v/v)	triton-X-100;	0.5%	(w/v)	sodium	deoxycholate;	0.1%	(w/v)	SDS,	1×		protease	inhibitor	mix		
SAP	buffer	 0.2%	saponin;	50	mM	tris/HCl	pH	7.8;	15	mM	MgSO4;	4	mM	EGTA;	10%	glycerol	
Transfer	buffer	 24	mM	tris;	192	mM	glycine;	20%	(v/v)	ethanol	
Tris	buffered	saline	with	tween	
(TBST)	 10	mM	tris;	150	mM	NaCl;	0.1%	(v/v)	Tween	20;	pH	7.6	
	
4.1.7 Recombinant	proteins	/	inhibitors	/	stimulators	
Actinomycin	D	 AppliChem	 Darmstadt	
BAY11-7082	 InvivoGen	 San	Diego,	CA,	USA	
BMS-345541	 Sigma-Aldrich	 St.	Louis,	MO,	USA	
Helenalin	 Merck	Millipore	 Darmstadt	
IFNα	 Miltenyi	Biotec	 Bergisch-Gladbach	
Ionomycin	 Sigma-Aldrich	 St.	Louis,	MO,	USA	
MG132	 Selleck	Chemicals	 München	
PMA	 Sigma-Aldrich	 St.	Louis,	MO,	USA	
Protease	inhibitor	tablets	 Roche	 Basel,	Switzerland	
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4.1.8 Kits	
Annexin	V-FITC	Apoptosis	Detection	Kit	 Enzo	Life	Sciences	 Farmingdale,	NY,	USA	
CellTiter-Blue®	cell	viability	assay	 Promega	 Madison,	WI,	USA	
Dako	REAL™	Detection	System	 Dako	 Hamburg	
FlowCytomix™	Th1/Th2/Th17/Th22	13plex	 eBioscience	 San	Diego,	CA,	USA	
Hypoxyprobe™-1	Kit	 Hypoxyprobe	Inc.	 Burlington,	MA,	USA	
Mouse	CXCL10	ELISA	Set	 R&D	Systems	 Minneapolis,	MN,	USA	
Mouse	IL-6	ELISA	Set	BD	OptEIA™	 BD	Biosciences	 Franklin	Lakes,	NJ,	USA	
SuperScript®	VILO™	cDNA	Synthesis	Kit	 Invitrogen	 Waltham,	MA,	USA	
Total	ROS/Superoxide	Detection	Kit	 Enzo	Life	Sciences	 Farmingdale,	NY,	USA	
TranscriptAid	T7	High	Yield	Transcription	Kit	 Thermo	Scientific	 Waltham,	MA,	USA	
	
4.1.9 Cell	lines	
B16F10	 Murine	melanoma	cell	line	 Kindly	provided	by	Thomas	Tüting*	
HCmel17	 Murine	melanoma	cell	line	 Kindly	provided	by	Thomas	Tüting	
HCmel23	 Murine	melanoma	cell	line	 Kindly	provided	by	Thomas	Tüting	
HCmel3	 Murine	melanoma	cell	line	 Kindly	provided	by	Thomas	Tüting	
Kera	308	 Murine	epidermal	keratinocyte	cell	line	 CLS	cell	lines	service,	Eppelheim	
LL171	 Mouse	IFN	type-I	reporter	cell	line	 Kindly	provided	by	Andrea	Ablasser†	
Melan-A	 Murine	melanocyte	cell	line	 Kindly	provided	by	Thomas	Tüting	
	
4.1.10 Fluorescently-labeled	antibodies	
α	-CD11b-PE/Cy7	(M1/70)	 eBioscience	 San	Diego,	CA,	USA	
α	-CD11c-FITC	(N418)	 eBioscience	 San	Diego,	CA,	USA	
α	-CD3-APC	(145-2C11)	 BioLegend	 San	Diego,	CA,	USA	
α	-CD4-APC/Cy7	(GK1.5)	 BioLegend	 San	Diego,	CA,	USA	
α	-CD45-APC/Cy7	(104)		 BioLegend	 San	Diego,	CA,	USA	
α	-CD49b-eFluor450	(DX5)	 eBioscience	 San	Diego,	CA,	USA	
α	-CD49b-PE/Cy7	(DX5)	 eBioscience	 San	Diego,	CA,	USA	
α	-CD69-eFluor450	(H1.2F3)	 eBioscience	 San	Diego,	CA,	USA	
α	-CD69-PE/Cy7	(H1.2F3)	 eBioscience	 San	Diego,	CA,	USA	
α	-CD8-PerCP/Cy5.5	(53-6.7)	 BioLegend	 San	Diego,	CA,	USA	
α	-Gr-1-pacific	blue	(RB6-8C5)	 BioLegend	 San	Diego,	CA,	USA	
α	-IFNαR-PE	(MAR1-5A3)	 BioLegend	 San	Diego,	CA,	USA	
α	-MHC-I-APC	(AF6-88.5.5.3)	 eBioscience	 San	Diego,	CA,	USA	
α	-mouse-Alexa488,	goat	Ig	 Invitrogen	 Waltham,	MA,	USA	
α	-NK1.1-PE	(PK136)	 eBioscience	 San	Diego,	CA,	USA	
α	-PD-1-APC	(RMP1-30)	 BioLegend	 San	Diego,	CA,	USA	
α	-PDL-1-PE	(MIH5)	 eBioscience	 San	Diego,	CA,	USA	
	
																																								 																				
*	University	Clinic	for	Dermatology	and	Venerology,	University	Hospital	Magdeburg,	Magdeburg	
†	Global	Health	Institut,	École	polytechnique	fédérale	de	Lausanne,	Lausanne,	Switzerland	
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4.1.11 Western	blot	and	immunohistochemistry	antibodies	
α	-actin-HRP,	mouse	IgG	(C4)	 Santa	Cruz	 Dallas,	TX,	USA	
α	-CXCL10,	rabbit	IgG	 PeproTech	 Hamburg	
α	-goat-HRP,	donkey	IgG	 Santa	Cruz	 Dallas,	TX,	USA	
α	-gp100,	goat	Ig	 Novus	Biologicals	 Cambridge,	UK	
α	-histone	3,	rabbit	IgG	 Cell	Signaling	 Danvers,	USA	
α	-Hsp90α,	mouse	IgG	(D7a)	 Abcam	 Cambridge,	UK	
α	-Hsp90β,	mouse	IgG2a	(H9010)	 Invitrogen	 Waltham,	MA,	USA	
α	-K63	ubiquitin,	rabbit	IgG	(D7A11)	 Cell	Signaling	 Danvers,	USA	
α	-MAVS,	rabbit	IgG	 Thermo	Scientific	 Waltham,	MA,	USA	
α	-mouse-HRP,	goat	IgG	 Imgenex	 San	Diego,	CA,	USA	
α	-p65,	rabbit	IgG	(D14E12)	 Cell	Signaling	 Danvers,	USA	
α	-PMP70,	rabbit	Ig	 Thermo	Scientific	 Waltham,	MA,	USA	
α	-rabbit-HRP,	bovine	IgG	 Santa	Cruz	 Dallas,	TX,	USA	
α	-RIG-I,	mouse	Ig	 Santa	Cruz	 Dallas,	TX,	USA	
α	-TOM70,	rabbit	IgG	 ProteinTech	 Manchester	,	UK	
α	-tubulin,	rabbit	IgG	 Cell	Signaling	 Danvers,	USA	
α	-vimentin,	rabbit	IgG	(D12H3)	 Cell	Signaling	 Danvers,	USA	
	
4.1.12 Primer	sequences	
Actin	 5’-GGATGCAGAAGGAGATTACTG-3’		5’-CCACCGATCCACACAGAGTA-3’	 Metabion	
Planegg/	
Steinkirchen	
RIG-I	 5’-GAAGATTCTGGACCCCACCTA-3’		5’-TGAATGTACTGCACCTCCTCA-3’	 Invitrogen	 Waltham,	MA,	USA	
TBP	 5’-CTTCACCAATGACTCCTATGACC-3’		5’-ACAGCCAAGATTCACGGTAGA-3’	
Integrated	DNA	
Technologies	 Coralville,	IA,	USA	
Viperin	 5’-TTGGGCAAGCTTGTGAGATT-3’				5’-GATAGCAAGAATGTCCAAATACTCC-3’	 Invitrogen	 Waltham,	MA,	USA	
CXCL10	 5’-CTCATCCTGCTGGGTCTGAG-3’		5’-CCTATGGCCCTCATTCTCAC-3’	 Invitrogen	 Waltham,	MA,	USA	
IFIT1	 5’-CAAGGCAGGTTTCTGAGGAG-3’		5’-GACCTGGTCACCATCAGCAT-3’	 Invitrogen	 Waltham,	MA,	USA	
gp100	 5’-ACACAGTCCAGGGGAACTTG-3’		5’-AACCACAGAGGGTCCAGATG-3’	
Integrated	DNA	
Technologies	 Coralville,	IA,	USA	
Tyrosinase	 5’-ATAGGTGCATTGGCTTCTGG-3’		5’-TCTTCACCATGCTTTTGTGG-3’	
Integrated	DNA	
Technologies	 Coralville,	IA,	USA	
TRP2	 5’-ACTCCTTCCTGAATGGGACC-3’		5’-GCATCTGTGGAAGGGTTGTT-3’	
Integrated	DNA	
Technologies	 Coralville,	IA,	USA	
Gr-1	 5’-AGGAGGGAGCTGCTAGGTTT-3’	5’-CTGCACACAGTAGGACCACA-3’	 Invitrogen	 Waltham,	MA,	USA	
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4.1.13 Oligonucleotide	sequences	
3p-siNrf2	sense		 5’-(ppp)GCGGCGCUCAACUUGCAUUAAUUCdTdT-3’	 Axolabs	 Kulmbach	
3pGFP2	antisense	 5’-AAGAUGAACUUCAGGGUCAGCGUC-3’	 ‡	 	
3pGFP2	sense	 5’-(ppp)GACGCUGACCCUGAAGUUCAUCUU-3’	 ‡	 		
IVT4	DNA	template	
5’-TTGTAATACGACTCACTATAGGGACGCTGACCCA	
GAAGATCTACTAGAAATAGTAGATCTTCTGGGTCAGC
GTCCC-3’	
Invitrogen		 Waltham,	MA,	USA	
IVT4	promoter	 5’-CAGTAATAGGACTCACTATAG-3’	 Invitrogen		 Waltham,	MA,	USA	
polyA	 (A)n	
Sigma-
Aldrich	 St.	Louis,	MO,	USA	
polyCA	 (CA)10	 Biomers	 Ulm	
polyI:C	 5’-(I)n-3’	3’-(C)n-5’	
InvivoGen	 San	Diego,	CA,	USA	
siNrf2	antisense		 5’-GAAUUAAUGCAAGUUGAGCdTdT-3’	 Biomers	 Ulm	
siNrf2	sense		 5’-GCUCAACUUGCAUUAAUUCdTdT-3’	 Biomers	 Ulm	
	
																																								 																				
‡	Synthesized	 and	 kindly	 provided	 by	 Marion	 Goldeck,	 Institute	 for	 Clinical	 Chemistry	 and	 Clinical	
Pharmacology,	University	Hospital	Bonn,	Bonn	24		
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4.2 Methods		
4.2.1 Methods	for	handling	cell	lines	and	primary	cells	
4.2.1.1 Cultivation	of	cell	lines	
All	cell	 lines	used	for	preparation	of	this	thesis	are	 listed	 in	section	4.1.9.	Cells	were	grown	in	Petri	
dishes	or	tissue	culture	flasks	using	appropriate	culture	media	as	indicated	in	Table	1	and	were	kept	
in	a	humidified	incubator	at	37°C,	5%	CO2	and	20%	O2.	In	order	to	split	cells	they	were	rinsed	with	PBS	
and	 incubated	 with	 1	ml	 trypsin/EDTA	 until	 cells	 were	 detached.	 In	 case	 keratinocytes	 resisted	
trypsin	 treatment,	 they	were	mechanically	 unhitched	using	 a	 cell	 scraper.	 Subsequently	 cells	were	
resuspended	 in	 culture	medium	and	 the	 required	proportion	 (Table	1)	was	 transferred	 into	a	new	
culture	dish	containing	fresh	medium.	
	
Cell	line	 Medium	with	additives	 Splitting	ratio	
B16F10	 RPMI	+	10%	FCS	+	100	IU/ml	penicillin	and	100	µg/ml	streptomycin	(PS)	 1:30,	2×/week	
HCmel17	 RPMI	+	FCS	+	PS	+	1×	L-glutamine	+	NEAA	+	2	mM	HEPES	+	0,0075‰	β-Mercaptoethanol	 1:4,	2×/week	
HCmel23	 RPMI	+	FCS	+	PS	 1:10,	2×/week		
HCmel3	 RPMI	+	FCS	+	PS	 1:3,	1×/week	
Kera	308	 DMEM	+	FCS	+	PS	 1:2,	1×/week	
LL171	 DMEM	+	FCS	+	PS	+	1	mM	sodium	pyruvate	 1:10,	2×/week	
Melan-A	 RPMI	+	FCS	+	PS	+	200	nM	PMA	 1:5,	2×/week	
Table	1:	Cultivation	of	cell	 lines.	Additives	include	fetal	calve	serum	(FCS),	penicillin	and	streptomycin	(PS),	non-essential	
amino	 acids	 (NEAA),	 4-(2-hydroxyethyl)-1-piperazineethanesulfonic	 acid	 (HEPES)	 and	 phorbol	 12-myristate	 13-acetate	
(PMA).	
4.2.1.2 Seeding	of	cells	and	hypoxic	incubation	
Cells	were	harvested	with	trypsin	as	described	above	and	the	amount	of	living	cells	was	determined	
using	a	Neubauer	 chamber	and	 trypan	blue	 staining.	Depending	on	 the	assay	cells	were	 seeded	 in	
differently	sized	tissue	culture	test	plates	according	to	Table	2.	To	ensure	proper	attachment	of	the	
cells	 before	 onset	 of	 treatment,	 they	were	 incubated	 at	 37°C,	 5%	 CO2	and	 20%	O2	over	 night.	 An	
oxygen	concentration	of	20%	was	considered	as	normoxic.	Hypoxic	conditions	were	implemented	by	
keeping	cells	 for	at	 least	24	h	 in	a	humidified	 incubator	at	37°C,	5%	CO2	and	2%	O2	or	0.2%	O2.	The	
reduction	of	oxygen	was	achieved	by	inflating	the	incubator	with	nitrogen.	
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Size	 Cell	line	 Cells/well	 Medium/well	(µl)	
96	well	 B16F10,	HCmel3,	HCmel17,	HCmel23,	Kera	308,	Melan-A	LL171	
20,000	
5,000	 100	
48	well	 B16F10,	HCmel3	 50,000	 350	
12	well	
B16F10	
HCmel3	
HCmel17	
HCmel23	
Kera	308	
Melan-A	
200,000	
380,000	
110,000	
140,000	
450,000	
340,000	
1,000	
Table	2:	Cell	numbers	according	to	cell	line	and	sizes	of	tissue	culture	test	plates.		
4.2.1.3 Stimulation	of	cells	with	oligonucleotides	or	IFNα	
Transfection	 of	 oligonucleotides	 in	 eukaryotic	 cells	was	 performed	 using	 Lipofectamine,	 a	 reagent	
based	 on	 cationic	 lipids	 that	 neutralize	 the	 negative	 charge	 of	 nucleic	 acids,	 thus	 facilitating	 their	
uptake.	While	siRNA-experiments	were	performed	with	Lipofectamine	RNAiMAX,	Lipofectamine2000	
was	 used	 for	 transfection	 of	 in	 vitro-transcribed	 3pRNA,	 polyI:C	 RNA	 and	 the	 respective	 controls.	
According	to	well	size	nucleic	acids	and	Lipofectamine	were	separately	mixed	with	the	transfection	
medium	OptiMEM	and	 incubated	at	 room	 temperature	 (RT)	 for	5	min	 (Table	3	and	Table	4).	After	
combining	 both	 preparations	 the	 resulting	 transfection	 mix	 was	 incubated	 at	 RT	 for	 20	min	 and	
subsequently	added	to	the	medium	in	the	test	plates.	Cells	were	incubated	with	the	transfection	mix	
for	24	h	under	hypoxic	or	normoxic	conditions	if	not	indicated	otherwise.	
	 Alternatively,	cells	were	stimulated	with	recombinant	murine	IFNα	by	direct	addition	into	the	
culture	 medium.	 If	 not	 indicated	 otherwise	 a	 final	 concentration	 of	 1000	IU/ml	 was	 used	 and	
identical	time	spans	as	for	RNA	stimulations	were	applied.				
	
Size	 RNA/well	(ng)	 Lipofectamine2000/well	(µl)	 OptiMEM/reaction	(µl)	
96	well	 20	 0.5	 25	
48	well	 64	 1.5	 35	
12	well	 250	 4	 100	
Table	3:	Composition	of	transfection	mixes	using	Lipofectamine2000	
Size	 RNA/well	(nM)	 Lipofectamine	RNAiMAX/well	(µl)	 OptiMEM/reaction	(µl)	
96	well	 10	 0.2	 10	
Table	4:	Composition	of	transfection	mixes	using	Lipofectamine	RNAiMAX	
4.2.1.4 Treatment	of	cells	with	different	inhibitors	or	vitamin	C	
The	 inhibition	of	proteasomal	degradation	was	performed	by	 treatment	of	 cells	with	5	µM	MG132	
during	the	time	of	3pRNA	transfection.	
For	the	assessment	of	mRNA	stability	cells	were	transfected	with	3pRNA	for	4	h,	afterwards	
transcription	was	blocked	using	5	µg/ml	actinomycin	D.	Cells	were	lysed	2	h,	4	h	and	6	h	later	using	
87	µl	RLT	buffer.		
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As	 a	means	 to	prevent	hypoxia-induced	EMT	cells	were	 treated	with	 L-ascorbic	 acid	 (vitamin	C)	or	
different	 NFκB	 inhibitors.	 The	 former	 was	 used	 at	 concentrations	 of	 25	µM	 or	 200	µM	 and	 was	
applied	24	h	prior	 to	 the	onset	of	hypoxic	 incubation.	The	NFκB	 inhibitors	BAY,	BMS	and	Helenalin	
were	 added	 at	 the	 start	 of	 hypoxia	 using	 concentrations	 of	 8	µM,	 5	µM	 and	 1	µM,	 respectively.	
Vitamin	C	and	NFκB	inhibitor	treatment	continued	during	hypoxic	incubation	and	3pRNA	stimulation.	
4.2.1.5 Isolation	of	mouse	splenocytes	and	co-culture	with	melanoma	cells	
Spleens	 were	 retrieved	 from	 sacrificed	 mice,	 sieved	 through	 70	µm	 cell	 strainer	 and	 collected	 in	
MACS	buffer	 to	obtain	 single	 cell	 suspensions.	 Following	a	 centrifugation	at	1400	rpm	 for	7	min	at	
4°C,	erythrocytes	were	eliminated	from	the	cell	pellet	by	incubation	in	5	ml	1×	lysis	buffer	for	10	min	
at	37°C.	Afterwards	splenocytes	were	washed	by	addition	of	20	ml	RPMI	and	centrifugation	as	above.	
The	pellet	was	resuspended	in	5	ml	RPMI	and	the	amount	of	cells	was	determined	using	trypan	blue	
and	a	Neubauer	chamber.		
For	 co-culture	 experiments	 melanoma	 cells	 were	 seeded	 in	 48-well	 plates,	 pre-incubated	
under	 normoxia	 or	 hypoxia	 and	 stimulated	 with	 3pRNA	 or	 IFNα	 for	 6	h.	 After	 removal	 of	 the	
transfection	 mix	 and	 washing	 with	 PBS,	 freshly	 isolated	 splenocytes	 from	 T-cell	 receptor	 (TCR)	
transgenic	Pmel-1	mice	were	added	at	5	×	105	cells	per	well	in	1	ml	medium.	As	control,	splenocytes	
without	melanoma	 cells	were	 activated	 using	 5	µg/ml	 gp10025-33	 peptide	 (kindly	 provided	 by	 J.	W.	
Drijfhout§)	 or	 50	ng/ml	 phorbol	 12-myristate	 13-acetate	 (PMA)	 and	 1	µg/ml	 Ionomycin.	 Cells	were	
co-cultured	for	18	h	under	normoxic	or	hypoxic	conditions.	
4.2.1.6 Detection	of	hypoxia	in	cultured	cells	
The	hypoxic	 status	of	melanoma	cells	was	verified	using	 the	Hypoxyprobe-1	Kit.	 Therefore	B16F10	
cells	were	seeded	in	96-well	plates	and	incubated	under	hypoxic	or	normoxic	atmosphere	for	22	h.	
Subsequently,	pimonidazole	was	added	to	give	a	final	concentration	of	100	µM	and	incubation	was	
continued	 for	 2	h.	 In	 hypoxic	 but	 not	 normoxic	 cells	 pimonidazole	 is	 reductively	 activated,	
whereupon	 the	 reaction	 intermediate	 forms	 covalent	 adducts	with	 thiol	 groups	of	 proteins.	 These	
adducts	 can	be	detected	using	 a	 specific	 primary-	 and	a	 fluorescently	 labeled	 secondary	 antibody.	
The	staining	procedure	was	performed	analogously	to	section	4.2.3.3.	Briefly,	cells	were	harvested,	
washed	with	 FACS	 buffer,	 fixed	with	 3.7%	 paraformaldehyde	 in	 PBS	 for	 15	min	 at	 RT	 and	washed	
again	 with	 FACS	 buffer	 as	 well	 as	 permeabilization	 buffer.	 Afterwards,	 30	µl	 of	 primary	 antibody,	
diluted	 1:30	 in	 permeabilization	 buffer,	 were	 added	 and	 incubated	 at	 RT	 for	 30	min.	 Cells	 were	
washed	 twice	 using	 permeabilization	 buffer	 and	 subsequently	 incubated	 with	 α-mouse-Alexa488	
1:200	in	30	µl	as	above.	Following	two	wash	steps	with	FACS	buffer	cells	were	analyzed	using	a	LSRII.		
																																								 																				
§ 	Department	 of	 Immunohematology	 and	 Bloodtransfusion,	 Leiden	 University	 Medical	 Center,	
Leiden,	The	Netherlands	
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4.2.1.7 Measurement	of	reactive	oxygen	species		
Detection	of	cellular	ROS	production	was	performed	using	the	Total	ROS/Superoxide	Detection	Kit.	
Therefore	cells	in	12-well	plates	were	washed	with	PBS	and	incubated	with	200	µl	detection	reagent	
in	 wash	 buffer	 (1:5000)	 for	 60	min	 at	 37°C	 under	 hypoxia	 or	 normoxia.	 The	 non-fluorescent,	 cell-
permeable	detection	dye	meanwhile	penetrated	the	cell	membrane	and	reacted	directly	with	ROS	to	
form	 a	 fluorescent	 product.	 Afterwards	 cells	 were	 scraped	 off	 and	 fluorescence	 intensity	 was	
analyzed	by	flow	cytometry	using	a	LSRII.	
4.2.1.8 Viability	assay	and	quantification	of	apoptotic	cells		
To	assess	the	viability	of	melanoma	cells	a	CellTiter-Blue	assay	was	performed,	which	is	based	on	the	
reduction	 reaction	 of	 resazurin	 into	 a	 fluorescent	 product	 by	metabolically	 active	 cells.	 Therefore,	
the	transfection	mix	was	removed	from	cells	 in	96-well	plates	and	replaced	by	100	µl	medium	plus	
20	µl	CellTiter-Blue	reagent.	Cells	were	kept	in	the	incubator	for	approximately	1	h	and	fluorescence	
intensity	 was	 measured	 using	 an	 EnVision	 multilabel	 plate	 reader	 (excitation:	 560	nm,	 emission:	
590	nm).		
The	 Annexin	 V-FITC	 Apoptosis	 Detection	 Kit	 was	 used	 to	 quantify	 dying	 cells.	 Firstly,	 cells	
were	harvested	using	trypsin,	transferred	into	a	round-bottom	microplate,	centrifuged	(400	×	g,	4°C,	
3	min)	 and	washed	with	PBS.	 Subsequently,	 the	pellet	was	 resuspended	 in	 30	µl	 1×	binding	buffer	
containing	anti-Annexin	V-FITC	antibody	1:40	and	incubated	at	RT	for	10	min.	Following	a	wash	step,	
cells	were	 resuspended	 in	 190	µl	 binding	 buffer	 and	 supplied	with	 10	µl	 propidium	 iodide	 directly	
before	measuring	the	fluorescence	at	a	LSRII	flow	cytometer.	
4.2.1.9 IFNα/β	reporter	assay	
LL171	cells	stably	expressing	luciferase	under	the	control	of	an	ISG	promoter	were	seeded	in	96-well	
plates	 and	 treated	 with	 a	 serial	 dilution	 of	 recombinant	 mouse	 IFNα	 or	 diluted	 supernatant	 of	
stimulated	melanoma	cells.	Following	a	6	h	incubation	at	37°C	and	5%	CO2	LL171	cells	were	washed	
with	PBS	and	 lysed	for	15	min	using	40	µl	SAP-buffer.	25	µl	of	the	 lysate	were	mixed	with	an	equal	
volume	 of	 luciferin	 in	 a	 white	 Lumitrac	 96-well	 plate	 and	 IFN-induced	 luciferase-mediated	
bioluminescence	was	 immediately	measured	with	 an	 EnVision	multilabel	 plate	 reader.	 The	 sample	
concentration	of	IFNα/β	could	then	be	calculated	with	the	help	of	the	standard	curve.	
	
4.2.2 Methods	for	handling	nucleic	acids	
4.2.2.1 In	vitro	transcription	of	3pRNA	
The	 RIG-I	 ligand	 3pRNA	was	 generated	 by	 in	 vitro	 transcription	 using	 IVT4	 T7-promotor	 and	 DNA	
template	strands	as	depicted	 in	4.1.13.	First,	3.4	nmol	of	both	oligonucleotides	were	annealed	 in	a	
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final	volume	of	170	µl	1×	annealing	buffer.	The	hybridization	was	performed	in	a	thermocycler	with	
95°C	 for	 3	min	 and	 stepwise	 cooling	 of	 -1°C	 every	 30	sec	 to	 20°C.	 For	 the	 transcription	 reaction	 a	
TranscriptAid	 T7	High	 Yield	 Transcription	 Kit	was	 utilized.	 Therefore,	 100	µg	 of	 annealed	 template	
DNA	were	mixed	with	the	nucleotides	ATP,	CTP,	GTP	and	UTP	(final	concentration	of	10	mM	each),	
100	µl	enzyme	mix,	1×	reaction	buffer	and	H2O	to	give	a	final	volume	of	1	ml.	Following	an	incubation	
of	7	h	at	37°C,	100	IU	DNase	I	were	added	and	the	incubation	was	continued	for	15	min.	Finally,	the	
DNase	reaction	was	stopped	by	adding	EDTA	to	a	final	concentration	of	42	mM	and	heating	to	65°C	
for	 10	min.	 Separation	 of	 3pRNA	 from	 nucleotides	 was	 performed	 using	 mini	 quick	 spin	 oligo	
columns.	 After	 preparation	 of	 the	 columns	 by	 centrifugation	 at	 1000	×	g	 for	 2	min,	 60	µl	 of	 the	
reaction	mix	were	applied	to	each	column.	The	3pRNA	was	eluted	by	spinning	at	1000	×	g	for	4	min	
and	pooled	afterwards.	The	concentration	of	RNA	was	determined	by	applying	2	µl	 to	a	NanoDrop	
and	measuring	the	absorption	at	260	nm	wavelength.	
4.2.2.2 Annealing	of	siRNAs	and	3pGFP2	
Hybridization	 of	 sense	 and	 antisense	 strands	 to	 obtain	 double-stranded	 RNAs	was	 performed	 in	 a	
final	volume	of	150	µl,	containing	1	µM	of	each	strand	and	1×	annealing	buffer.	The	annealing	was	
carried	out	in	a	thermocycler	with	72°C	for	5	min	and	stepwise	cooling	of	-0.1°C	per	second	to	18°C.		
4.2.2.3 RNA	extraction	from	cells	using	spin	columns	
Cells	were	either	harvested	using	trypsin	and	collected	in	test	tubes	or	directly	lysed	in	12-well	tissue	
culture	 test	 plates.	 Lysis	was	performed	by	 resuspension	of	 cells	 in	 350	µl	 RLT	buffer	 and	 freezing	
at	 -80°C	 for	 at	 least	 5	min.	 Prior	 to	 loading	onto	 spin	 columns	350	µl	 of	 70%	ethanol	were	 added.	
Columns	were	placed	in	2	ml	test	tubes	and	centrifuged	for	1	min	at	10,000	rpm.	Subsequently,	two	
wash	steps	were	performed	using	350	µl	RW1	and	Zymo	RNA	wash	buffer	respectively.	Finally,	 the	
spin	columns	were	placed	in	new	test	tubes	and	RNA	was	eluted	by	addition	of	40	µl	H2O,	incubation	
for	2	min	and	centrifugation	as	above.	The	RNA	concentration	was	determined	by	applying	2	µl	to	a	
NanoDrop	and	measuring	the	absorption	at	a	wavelength	of	260	nm.	
4.2.2.4 RNA	extraction	from	tumors	using	trizol	reagent	
Cryo-conserved	tissue	samples	were	homogenized	in	1	ml	trizol	using	zirconia	beads	and	a	Precellys	
homogenizer	(2	×	30	sec,	6500	rpm).	After	incubation	at	RT	for	5	min,	200	µl	chloroform	were	added,	
the	sample	was	mixed	for	15	sec	and	incubated	for	3	min	at	RT.	Centrifugation	at	12,000	×	g	and	4°C	
for	15	min	allowed	phase	separation	of	RNA	(aqueous	upper	phase)	from	DNA	(organic	lower	phase)	
and	proteins	(interphase).	The	aqueous	phase	was	transferred	into	a	new	test	tube	and	mixed	with	
500	µl	100%	isopropanol.	Following	10	min	incubation	at	RT	the	sample	was	centrifuged	as	above	for	
10	min.	 The	 supernatant	was	 removed	and	 the	RNA	pellet	was	washed	using	1	ml	of	 75%	ethanol	
(centrifugation:	7500	×	g,	4°C,	5	min).	Residual	ethanol	was	eliminated	by	air-drying	for	5	min	and	the	
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RNA	was	 dissolved	 in	 100	µl	 H2O.	 RNA	 concentration	was	 determined	 as	 described	 in	 4.2.2.3.	 For	
reliable	 measurements	 the	 RNA	 solution	 was	 diluted	 with	 H2O	 until	 a	 concentration	 of	 maximal	
1000	ng/µl	was	achieved.	
4.2.2.5 cDNA	synthesis	and	quantitative	PCR	
Complementary	DNA	(cDNA)	was	synthesized	using	the	SuperScript®	VILO™	cDNA	Synthesis	Kit.	For	
one	reaction	3.5	µl	RNA	(=	300	ng)	were	mixed	with	1	µl	5×	reaction	buffer	and	0.5	µl	enzyme	mix	in	
PCR	 tubes.	 Using	 a	 thermocycler	 the	 sample	 passed	 through	 the	 following	 temperature	 protocol:	
25°C	for	10	min,	42°C	for	60	min,	85°C	for	5	min	and	cooling	to	4°C.	
Quantitative	polymerase	chain	reaction	(qPCR)	was	performed	using	the	fluorescent	double-
stranded	DNA-binding	dye	Sybr	GreenER.	The	fluorescent	signal	of	Sybr	Green	is	recorded	after	each	
amplification	 step	 and	 is	 proportional	 to	 the	 DNA	 concentration	 in	 the	 sample.	 Newly	 designed	
primers	 were	 initially	 tested	 for	 efficiency	 and	 specificity	 by	 amplification	 of	 a	 standard	 curve	 of	
cDNA.	These	results	were	further	used	to	identify	an	appropriate	cDNA	dilution.	One	qPCR	reaction	
mix	contained	primers	at	a	final	concentration	of	0.33	µM	each,	10	µl	Sybr	GreenER	Master	Mix	and	
H2O	to	give	a	final	volume	of	18	µl.	This	was	combined	with	2	µl	of	diluted	cDNA	in	a	qPCR	plate.	The	
PCR	reaction	was	performed	on	an	ABI	7900	HT	using	the	following	thermal	profile:	50°C	for	2	min,	
95°C	for	10	min	and	40	cycles	of	95°C	for	15	sec	and	60°C	for	1	min.	Additionally,	a	dissociation	curve	
was	 recorded	 to	 exclude	 target-unspecific	 amplification	 or	 primer	 dimerization.	 For	 comparative	
analysis	target	mRNA	expression	was	normalized	to	a	housekeeping	gene	according	to	2(CtR-CtT)	with	Ct	
=	cycle	threshold,	R	=	reference	and	T	=	target.	For	cell	culture	experiments	normalized	target	mRNA	
expression	 of	 each	 sample	 is	 shown	 relative	 to	 the	 value	 of	 3pRNA-treated	 normoxic	 cells	 if	 not	
indicated	otherwise.	
	
4.2.3 Methods	for	handling	proteins	
4.2.3.1 Protein	quantification	via	Bradford	assay	
The	 total	 amount	 of	 protein	 in	 a	 cell	 lysate	 was	 determined	 using	 Roti-Quant	 dye	 according	 to	 a	
method	by	Bradford	106.	Therefore	a	1:2	serial	dilution	of	bovine	serum	albumin	(BSA)	ranging	from	
800	µg/ml	to	25	µg/ml	was	prepared	in	H2O.	Additionally,	lysates	were	appropriately	diluted	in	H2O.	
5	µl	 of	 sample	 or	 standard	were	mixed	with	 200	µl	 1×	Roti-Quant	 in	 a	 flat-bottom	microplate	 and	
agitated	 for	 10	min	 at	 RT.	 Finally,	 light	 absorbance	 at	 562	nm	 was	 measured	 using	 an	 Epoch	
microplate	spectrophotometer.	The	sample	concentration	could	then	be	calculated	with	the	help	of	
the	standard	curve.	
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4.2.3.2 Western	blot	analysis	
Cells	were	harvested	from	12-well	plates	using	trypsin	and	lysed	with	10-30	µl	RIPA	buffer.	Following	
30	min	 incubation	 at	 4°C	 lysates	 were	 cleared	 by	 centrifugation	 (13,000	×	g	 at	 4°C	 for	 15	min).	
Alternatively,	 cells	 were	 lysed	 in	 cell	 fractionation	 buffer	 for	 15	min	 at	 4°C	 and	 centrifuged	 at	
13,000	×	g	 and	 4°C	 for	 15	min	 to	 obtain	 cytosolic	 proteins	 in	 the	 supernatant.	 For	 extraction	 of	
nuclear	 proteins	 the	 resulting	 pellet	 was	 resuspended	 in	 cell	 fractionation	 buffer	 containing	 0.5%	
(v/v)	 SDS,	 DNA	 was	 destroyed	 using	 ultrasound	 and	 the	 lysate	 was	 cleared	 by	 centrifugation.	
20-40	µg	of	total	cell	protein	were	mixed	with	an	equal	volume	of	Laemmli	buffer	and	denatured	at	
95°C	 for	5	min.	 SDS	polyacrylamide	gel	 electrophoresis	was	performed	 in	electrophoresis	buffer	at	
30	mA	 per	 gel	 for	 1.5	h.	 Afterwards	 proteins	 were	 transferred	 onto	 a	 nitrocellulose	membrane	 in	
transfer	 buffer	 at	 450	mA	 for	 1.5	h.	 Successful	 transfer	 was	 confirmed	 by	 ponceau	 staining.	
Membranes	were	then	blocked	with	5%	milk	 in	TBST	or	PBST	 for	1	h	at	RT	and	 incubated	with	the	
respective	antibodies	at	4°C	over	night	or	 for	72	h	 (RIG-I)	 (Table	5).	Horseradish	peroxidase	 (HRP)-
coupled	secondary	antibodies	α-rabbit,	α-goat	and	α-mouse	were	used	1:5000	and	were	incubated	
for	1	h	at	RT.	As	loading	control	actin	was	detected	using	α-actin-HRP	antibody	1:5000	in	0.5%	BSA	in	
PBST.	After	 incubation	with	a	1:1	mixture	of	ECL	western	blotting	substrates	for	1	min,	membranes	
were	exposed	to	x-ray	films,	which	were	mechanically	developed.	Alternatively,	chemiluminescence	
was	detected	using	 an	Odyssey	 Fc	 imaging	 system.	The	band	 intensity	was	quantified	with	 ImageJ	
1.440	software	(Wayne	Rasband,	National	Institute	of	Health)	and	target	expression	was	normalized	
to	reference	protein	expression.		
	
Antibody	 Dilution	 Antibody	 Dilution	
α-gp100	 1:500	 α-p65	 1:1000	
α-histone	3	 1:2000	 α-PMP70	 1:500	
α-HSP90α	 1:1000	 α-RIG-I	 1:100	
α-HSP90β	 1:100	 α-TOM70	 1:1000	
α-K63-ubiquitin	 1:1000	 α-tubulin	 1:1000	
α-MAVS	 1:2000	 α-vimentin	 1:1000	
α-MDA5	 1:1000	 	 	
Table	5:	Dilutions	of	primary	antibodies	for	western	blot	application.	
4.2.3.3 Flow	cytometry	
Briefly,	 cells	were	harvested,	 transferred	 into	 round-bottom	microplates,	 centrifuged	 (400	×	g,	4°C,	
3	min)	 and	 washed	 with	 FACS	 buffer.	 For	 determination	 of	 surface	 protein	 expression	 cells	 were	
stained	on	ice	for	30	min	using	the	following	antibodies	1:200	in	30	µl	FACS	buffer:	α-CD11b-PE/Cy7,	
α-CD11c-FITC,	 α-CD3-APC,	 α-CD4-APC/Cy7,	 α-CD45-APC/Cy7,	 α-CD49b-eFluor450,	 α-CD69-pacific	
blue,	 α-CD69-PE/Cy7,	 α-CD8-PerCP/Cy5.5,	 α-Gr-1-pacific	 blue,	 α-IFNαR-PE,	 α-MHC-I-APC,	 α-NK1.1-
PE,	 α-PD-1-APC,	α-PDL-1-PE	 and	 α-PDL-2-PE.	 Finally,	 100	µl	 FACS	 buffer	 were	 added	 and	 samples	
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centrifuged	 as	 above.	 For	 preservation	 cells	 were	 optionally	 fixed	 by	 treatment	 with	 3.7%	
paraformaldehyde	 in	PBS	 for	15	min	at	RT	and	 subsequently	washed	with	FACS	buffer.	Thereafter,	
cells	were	 resuspended	 in	 FACS	 buffer	 and	 fluorescence	was	measured	 using	 the	 flow	 cytometers	
LSRII	or	Canto.	
4.2.3.4 Enzyme-linked	immunosorbent	assay	(ELISA)	
For	quantification	of	the	cytokines	CXCL10	and	 IL-6	supernatants	of	stimulated	cells	were	collected	
24	h	 after	 transfection	 and	 analyzed	 using	 ELISA	 kits	 according	 to	 the	 manufacturer’s	 protocol.	
Briefly,	ELISA	plates	were	coated	with	the	respective	capture	antibody	in	50	µl	PBS	or	coating	buffer	
and	incubated	at	RT	or	4°C	over	night.	In-between	each	incubation	step	wells	were	washed	at	least	
three	times	using	ELISA	wash	buffer.	Unspecific	binding	sites	were	then	blocked	by	1	h	incubation	in	
150	µl	 or	 50	µl	 of	 the	 respective	 ELISA	 buffer.	 Samples	 and	 standards	 were	 diluted	 in	 50	µl	 ELISA	
buffer	and	incubated	for	2	h	at	RT.	Afterwards	biotinylated	detection	antibody	and	streptavidin-HRP	
were	added,	either	successively	in	50	µl	ELISA	buffer	each	or	simultaneously,	and	incubated	at	RT	for	
2	h	plus	20	min	or	1	h,	respectively.	Finally,	50	µl	of	a	1:1	mix	of	the	substrate	solutions	were	added	
to	allow	HRP-mediated	substrate	oxidation	into	the	blue-colored	product.	The	reaction	was	stopped	
using	50	µl	1	M	H2SO4	and	absorbance	at	450	nm	(reference:	570	nm)	was	measured	using	an	Epoch	
microplate	spectrophotometer.	The	sample	cytokine	concentration	could	then	be	calculated	with	the	
help	of	the	standard	curve.	
4.2.3.5 Multiplex	cytokine	flow	cytometry		
Supernatants	of	stimulated	cells	were	collected	24	h	after	transfection	and	analyzed	for	expression	of	
13	 cytokines	 (IL13,	 IL-1α,	 IL-22,	 IL-2,	 IL-5,	 IL-21,	 IL-6,	 IL-10,	 IL-27,	 IFNγ,	 TNFα,	 IL-4,	 IL-7)	 using	 a	
FlowCytomix	 Kit	 as	 described	 in	 the	manual.	 Briefly,	 the	 sample	 was	mixed	 with	 antibody-coated	
beads,	each	specific	 for	one	of	 the	analytes.	Biotin-conjugated	antibodies	with	the	same	specificity	
were	 added	 and	 subsequently	 bound	 by	 streptavidin-PE	 to	 allow	 detection	 of	 the	 cytokine.	 Flow	
cytometry	was	used	to	measure	PE	fluorescence,	which	is	proportional	to	the	amount	of	analyte,	and	
to	identify	the	analyte	with	the	help	of	different	bead	sizes	and	intensities	of	an	internal	fluorescent	
dye.		
	
4.2.4 In	vivo	methods	
4.2.4.1 Establishment	and	treatment	of	B16	tumors	
Female,	 10	weeks	old	C57BL/6	mice	 (Janvier	 Labs,	 Saint	Berthevin	Cedex,	 France)	were	 inoculated	
with	 1	×	105	 B16F10	 cells	 in	 50	µl	 PBS	 subcutaneously	 into	 the	 left	 flank.	 Treatment	 protocols	 of	
vitamin	C	 and	 3pRNA	 application	 are	 indicated.	 For	 the	 immunohistochemical	 analysis	 of	 CXCL10	
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animals	 were	 treated	 four	 times	 with	 vitamin	C	 followed	 by	 a	 single	 3pRNA	 dose	 the	 day	 before	
killing.	mRNA	 expression	 and	 FACS	 analyses	were	 performed	 after	 repeated	 treatment	 comprising	
daily	 application	 of	 vitamin	C	 and	 threefold	 3pRNA	 administration	 within	 10	 days.	 Vitamin	C	
(Pascorbin®)	 was	 injected	 intraperitoneally	 using	 30	mg/mouse.	 For	 delivery	 of	 3pRNA	 the	
oligonucleotide	 was	 first	 diluted	 in	 H2O	 and	 the	 transfection	 reagent	 JetPEI	 was	 mixed	 with	 10%	
glucose	(0,16	µl	JetPEI	per	1	µg	RNA)	and	incubated	for	5	min	at	RT.	The	JetPEI	preparation	was	then	
added	to	the	3pRNA	dilution	 in	a	1:1	ratio	and	 incubated	for	approximately	30	min.	A	final	dose	of	
20	µg	3pRNA	per	mouse	 in	50	µl	was	administered	 into	the	tumor.	Tumor	size	was	measured	daily	
using	calipers	and	mice	were	 sacrificed	when	 the	 tumor	diameter	 reached	15	mm.	Tumor	 samples	
were	 removed	and	 fixed	 for	24	h	 in	 zinc	buffer	 for	 immunohistochemistry	or	were	 frozen	 in	 liquid	
nitrogen	for	RNA	extraction	and	qPCR	analysis.	Furthermore,	tumors	and	draining	lymph	nodes	were	
processed	into	single	cell	suspensions	using	70	µm	cell	strainer	for	flow	cytometric	analysis.	
4.2.4.2 Immunohistochemistry	
Fixed	 tissue	 samples	 were	 bedded	 in	 paraffin	 and	 cut	 into	 4	µm	 slices	 using	 a	 microtome.	 After	
blocking	with	5%	BSA	in	PBS	for	1	h,	immunohistochemistry	was	performed	with	α-CXCL10	antibody	
using	 1	µg/ml	 in	 200	µl	 antibody	 diluent	 over	 night.	 The	 secondary	 antibody	 as	 well	 as	 detection	
reagents	 were	 components	 of	 the	 Dako	 REAL	 Detection	 System	 Kit.	 Accordingly,	 slices	 were	
successively	incubated	with	biotin-coupled	α-rabbit	antibody	1:300	in	200	µl	antibody	diluent	for	1	h	
and	 streptavidin-alkaline	 phosphatase	 for	 30	min.	 Finally,	 RED	 chromagen	 was	 added	 until	 red	
staining	was	visible.	The	sections	were	further	stained	with	haematoxylin	and	eosin	(H&E)	for	15	sec	
and	sealed	afterwards.	Pictures	were	taken	with	a	DMLB	immunofluorescence	microscope.	
4.2.4.3 Ethics	statement	
All	mice	were	bred	and	housed	in	individually	ventilated	cages	in	the	House	for	Experimental	Therapy	
(HET)	of	the	University	Hospital	in	Bonn.	All	mouse	experiments	were	performed	according	to	ethical	
protocols	approved	by	the	local	and	regional	ethical	committees.	
	
4.2.5 Statistical	analysis	
If	not	indicated	otherwise	data	represent	mean	and	SEM	of	at	least	three	independent	experiments.	
Statistical	differences	between	groups	were	determined	by	unpaired,	two-tailed	student’s	t	test	with	
confidence	 intervals	 of	 95%	 using	 GraphPad	 Prism	 6	 (GraphPad	 Software,	 La	 Jolla,	 CA,	 USA).	
*	(p	<	0,05),	**	(p	<	0,01),	***	(p	<	0,001),	****	(p	<	0,0001),	ns:	not	significant.	
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5 Results	
At	 the	 latest	 since	 the	 development	 of	 effective	 immune	 checkpoint-inhibitors,	 immunotherapy	 is	
considered	one	of	the	most	promising	treatment	strategies	against	cancer.	Among	the	huge	variety	
of	 immunotherapy	approaches	currently	 investigated	and	developed,	the	targeted	activation	of	the	
innate	 immune	 receptor	 RIG-I	 by	 its	 3pRNA	 ligand	 is	 unique	 in	 the	 way	 that	 it	 can	 concurrently	
activate	anti-tumor	immunity	and	act	in	a	tumoricidal	manner.	3pRNA	therapy	is	currently	tested	in	
preclinical	studies	and	is	approaching	its	clinical	trial	phase.	As	part	of	research	into	effective	tumor	
immunotherapy,	 the	 local	 tumor	 microenvironment	 has	 drawn	 increasing	 attention	 as	 it	 can	
profoundly	 influence	 local	 immune	 responses.	 The	major	 environmental	 factor	 being	 investigated	
here	 is	hypoxia,	 as	 it	 is	 a	 characteristic	 feature	of	most	 solid	 tumors	 that	 contributes	 to	metabolic	
changes,	genomic	instability	and	angiogenesis	107.	Hypoxia	also	induces	EMT	in	cancer	cells,	thereby	
favoring	 tumor	 dissemination	 and	metastasis	 formation,	 but	 also	 providing	 an	 escape	mechanism	
from	T-cell-mediated	immune	attack	97.	Since	hypoxia	also	negatively	affects	chemo-	and	irradiation	
therapy,	 it	 has	 become	 an	 established	 negative	 prognostic	 marker.	 Although	 knowledge	 on	 the	
devastating	effects	of	hypoxia	on	anti-tumor	immune	responses	is	 increasing,	the	impact	of	oxygen	
deprivation	 on	 the	 functioning	 of	 tumor-intrinsic	 innate	 PRR	 like	 RIG-I	 and	 the	 outcome	 of	 RIG-I-
mediated	immunotherapy	are	still	unknown.	This	thesis	delivers	insights	into	hypoxia-induced	effects	
on	 the	 expression	 of	 cytosolic	 PRRs	 as	 well	 as	 into	 the	 influence	 of	 hypoxia	 on	 RIG-I	 signaling	
outcome	and	its	involved	regulatory	components.	The	attained	findings	were	ultimately	used	to	test	
measures	to	enhance	RIG-I	 function	under	hypoxia	 in	vitro	and	steps	were	undertaken	to	translate	
these	results	to	the	in	vivo	therapeutic	setting.	
	
5.1 Hypoxia	and	EMT	in	B16F10	melanoma	cells	
Throughout	 this	 thesis	 comparisons	 have	 been	 made	 between	 normoxic	 cells	 incubated	 at	 20%	
oxygen	and	hypoxic	 cells,	which	were	kept	at	2%	oxygen.	To	ensure	 that	 the	 chosen	conditions	of	
oxygen	 concentration	 and	 pre-incubation	 time	 induced	 intracellular	 hypoxia,	 B16F10	 cells	 were	
analyzed	 for	 hypoxia-dependent	 pimonidazole-adducts.	 Figure	 5	 demonstrates	 that	 a	 24-hour	
incubation	 at	 2%	 oxygen	 resulted	 in	 an	 entirely	 pimonidazole-positive	 population	 confirming	 the	
hypoxic	status	of	the	cells.		
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Figure	5:	Hypoxia	in	B16F10	cells.	Hypoxia-dependent	pimonidazole-adducts	were	detected	using	flow	cytometry	after	24	h	
at	 20%	 or	 2%	 oxygen.	 A	 representative	 histogram	 of	 three	 independent	 experiments	 is	 shown.	 w/o:	 without,	 max:	
maximum.	
	
Although	 hypoxia-induced	 EMT	 is	 a	widely	 accepted	 phenomenon,	 vast	 variations	 on	 investigated	
cell	 types	 and	 oxygen	 concentrations	 can	 be	 found	 in	 the	 literature.	 Since	 the	 chosen	 setting	 of	
oxygen	 deprivation	 induced	 a	 hypoxic	 status	 of	 the	 cells	 while	 being	 reasonably	 well	 tolerated,	
B16F10	cells	were	tested	under	these	specific	conditions	for	a	selection	of	EMT	markers.	Firstly,	the	
transfer	 of	 normoxic	 melanoma	 cells	 to	 an	 oxygen	 concentration	 of	 2%	 led	 to	 a	 time-dependent	
increase	 in	 the	 production	 of	 ROS	 as	 shown	 in	 Figure	 6A.	 Furthermore,	 cellular	 fractionation	 into	
cytosolic	 and	 nuclear	 components	 with	 subsequent	 western	 analysis	 revealed	 an	 enhanced	
translocation	of	the	NFκB	subunit	p65	into	the	nucleus	upon	24	hours	of	hypoxia	(Figure	6B).	Both,	
ROS	 production	 and	 activation	 of	 NFκB,	 have	 been	 associated	with	 EMT	94,95.	 Additionally,	 a	more	
direct	 representation	 of	 dedifferentiation	 was	 provided	 by	 protein	 expression	 analysis	 of	 the	
intermediate	 filament	 vimentin,	 representing	 a	 mesenchymal	 marker,	 and	 the	 melanocyte	
differentiation	 antigen	 gp100.	 Following	 a	 24-hour	 incubation	 under	 hypoxic	 conditions	 vimentin	
expression	 in	 B16F10	 cells	 was	 increased,	 whereas	 gp100	 was	 extensively	 downregulated,	 firmly	
indicating	melanoma	cell	dedifferentiation	by	the	hypoxia	regimen	used	(Figure	6C,D).		
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Figure	6:	Hypoxia	induces	epithelial-to-mesenchymal	transition	(EMT)	via	reactive	oxygen	species	(ROS)-production	and	
NFκB	 activation.	 (A)	 Time-dependent	 ROS	 production	 upon	 transfer	 of	 B16F10	 cells	 to	 hypoxia	 was	 detected	 by	 flow	
cytometry	 using	 a	 ROS-reactive	 dye.	 Mean	 and	 +SEM	 of	 three	 independent	 experiments	 are	 shown.	 (B)	 Nuclear	
translocation	 of	 p65	 after	 24	h	 of	 hypoxia	 as	 determined	 by	western	 blot.	 Tubulin	 and	 histone	3	 represent	 controls	 for	
cellular	fractionation.	Representative	blots	of	three	independent	experiments	are	shown.	(C-D)	Expression	of	vimentin	(C)	
and	 gp100	 (D)	 in	 B16F10	 cells	 upon	 24	h	 of	 hypoxia.	 Actin	 is	 shown	 as	 loading	 control.	 Representative	 blots	 of	 three	
independent	 experiments	 are	 depicted.	 Statistical	 analysis	 was	 performed	 using	 student’s	 t	 test.	 **	(p	<	0.01),	
****	(p	<	0.0001).	N:	normoxia,	H:	hypoxia,	mfi:	mean	fluorescence	intensity,	h:	hours.	
	
Bhattacharya	 et	 al.	 recently	 provided	 evidence	 for	 hypoxia-elicited	 robust	 downregulation	 of	 the	
IFNαR	 in	 human	 melanoma	 cells	105.	 Therefore,	 the	 expression	 of	 IFNαR	 was	 investigated	
additionally,	 using	 the	 here	 established	 hypoxia	 regimen	 on	 B16F10	 cells.	 As	 shown	 in	 Figure	 7,	
oxygen	deprivation	 led	 to	a	50%	reduction	of	 IFNαR	expression,	which	might	have	 implications	 for	
cellular	 IFN	 sensitivity	 and	 the	 IFN-dependent	 feed-forward	 loop	 important	 for	 efficient	 RIG-I	
signaling.		
	
Figure	 7:	 Reduced	 interferon	 α	
receptor	 (IFNαR)	expression	under	
hypoxia.	 IFNαR	 expression	 in	
B16F10	 cells	 was	 determined	 by	
flow	 cytometry	 after	 24	h	 of	
hypoxia.	 Left	 panel:	 Mean	 and	
+SEM	 of	 four	 independent	
experiments.	 Right	 panel:	 A	
representative	 histogram	 is	
depicted.	 Statistical	 analysis	 was	
performed	 using	 student’s	 t	 test.	
****	(p	<	0.0001).	 N:	 normoxia,	 H:	
hypoxia,	 mfi:	 mean	 fluorescence	
intensity,	 max:	 maximum,	 IgG:	
immunoglobulin	G.	
	
Taken	together	these	results	validate	the	suitability	of	the	experimental	setup	for	the	investigation	of	
intracellular	 hypoxia,	 and	 confirm	 ROS-	 and	 NFκB-dependent	 EMT	 coinciding	 with	 reduced	 IFNαR	
expression	in	hypoxic	B16F10	cells.	Of	note,	EMT	and	IFNα	desensitization	might	ultimately	influence	
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the	outcome	of	studies	testing	RIG-I	function	in	the	hypoxia	setting	by	alterations	of	transcriptomes	
and	proteomes	or	hampered	feed-forward	signaling	as	discussed	below.	
	
5.2 Hypoxia-mediated	effects	on	pattern	recognition	receptor	expression	
To	uncover	the	effects	of	hypoxia	on	3pRNA-induced	RIG-I	activation,	the	expression	of	the	receptor	
itself	 was	 initially	 investigated.	 The	 observed	 reduction	 of	 IFNαR	 expression	 in	 hypoxic	 cells	 was	
thereby	suggestive	of	likewise	decreased	RIG-I	expression,	given	that	an	IFN-dependent	feed-forward	
loop	leads	to	a	strong	upregulation	of	the	receptor	after	3pRNA	transfection	(Figure	8).	Since	hypoxia	
is	 only	 one	 of	 several	 environmental	 stress	 factors	 that	 can	 be	 encountered	 within	 a	 tumor,	 the	
influence	of	hypoxia	on	RIG-I	upregulation	was	compared	to	starvation	(0%	FCS)	and	necrotic	cell	co-
incubation	(Figure	8A).	While	the	latter	factors	did	not	have	an	impact	on	the	RIG-I	response,	oxygen	
deprivation	 strongly	 reduced	3pRNA-stimulated	 receptor	expression.	 Shortening	 the	RIG-I	 signaling	
pathway	 by	 direct	 treatment	 with	 recombinant	 IFNα	 likewise	 resulted	 in	 hypoxia-mediated	
attenuation	 of	 RIG-I	 protein	 upregulation	 (Figure	 8B).	 The	 comparison	 of	 3pRNA	 and	 IFNα	 is	 of	
particular	 interest	as	 the	 latter	 is	 already	approved	 for	 the	 treatment	of	malignant	melanoma	and	
other	solid	tumors.	These	results	indicate	hypoxia	to	influence	ISG	upregulation	that	might	result	in	
decreased	RIG-I	signaling	and	diminished	3pRNA-mediated	anti-tumor	immunity.		
	
	
Figure	 8:	Hypoxia	 attenuates	RIG-I	 protein	 upregulation.	 (A-B)	B16F10	cells	were	exposed	 to	0%	FCS	or	co-culture	with	
necrotic	 B16F10	 cells	 (A)	 or	 were	 incubated	 at	 2%	 oxygen	 for	 24	h	 (B)	 and	 subsequently	 stimulated	with	 the	 indicated	
oligonucleotides	or	IFNα.	RIG-I	expression	was	determined	by	western	blot	24	h	after	stimulation.	Actin	served	as	loading	
control.	Representative	blots	of	two	and	three	independent	experiments	are	shown	respectively.	w/o:	without	treatment,	
pA:	poly-A,	3p:	3pRNA,	FCS:	fetal	calve	serum,	IFN:	recombinant	IFNα.	
	
The	 reduced	 upregulation	 of	 RIG-I	 was	 independent	 of	 its	 basal	 expression	 level,	 as	 unstimulated	
cells	 showed	 equal	 RIG-I	 amounts	 on	 average	 (Figure	 9,	 time	 point	 0	h).	Moreover,	 the	 observed	
difference	was	not	due	 to	a	delay	of	 the	RIG-I	 response,	because	prolongation	of	 stimulation	 time	
from	24	hours	to	48	hours	did	not	equalize	hypoxic	and	normoxic	RIG-I	expression	(Figure	9).	
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Figure	9:	RIG-I	expression	kinetics	upon	3pRNA	stimulation.	(A-B)	RIG-I	expression	was	detected	by	western	blot	following	
a	 24	h	 hypoxic	 pre-incubation	 and	 3pRNA	 stimulation	 for	 the	 indicated	 time	 spans.	 (A)	 Quantified	 RIG-I	 expression	
normalized	to	actin	as	mean	and	+/-SEM	of	three	independent	experiments.	(B)	A	representative	western	blot	illustrating	
RIG-I	 expression	 8	h	 and	 48	h	 after	 3pRNA	 transfection.	 Statistical	 analysis	 was	 performed	 using	 student’s	 t	 test.	
*	(p	<	0.05).	ns:	not	significant,	w/o:	without	treatment,	N:	normoxia,	H:	hypoxia,	h:	hours,	a.u:	arbitrary	units.	
	
Since	 hypoxia	 is	 not	 defined	 as	 one	 specific	 pO2-value,	 but	 rather	 describes	 a	 range	 of	 oxygen	
concentrations	between	anoxia	(0%	O2)	and	the	physiologic	tissue-pO2,	3pRNA-induced	RIG-I	protein	
upregulation	 was	 additionally	 investigated	 using	 the	 near-anoxia	 oxygen	 concentration	 of	 0.2%.	
Interestingly,	 this	 further	 reduction	 of	 oxygen	 supply	 did	 not	 result	 in	 stronger	 inhibition	 of	 RIG-I	
responsiveness,	therefore	indicating	an	uncompromising	event	upon	oxygen	deprivation	rather	than	
a	dose-dependent	effect	(Figure	10).		
	
	
Figure	10:	Attenuation	of	RIG-I	 upregulation	
is	 not	 aggravated	 by	 increased	 hypoxia.	
B16F10	 cells	 were	 pre-incubated	 under	
normoxic	 (20%)	 or	 hypoxic	 (2%	 and	 0.2%)	
conditions	and	transfected	with	the	indicated	
oligonucleotides.	 RIG-I	 expression	 was	
determined	24	h	later.	Actin	served	as	loading	
control.	 A	 representative	blot	 is	 shown.	w/o:	
without	treatment,	pA:	poly-A,	3p:	3pRNA,	
	
As	RIG-I	 activation	was	achieved	by	3pRNA	 transfection,	 it	had	 to	be	verified	whether	 the	blunted	
RIG-I	upregulation	was	caused	by	deteriorated	transfection	efficiency	under	hypoxia.	This	was	ruled	
out	 by	 transfection	 of	 B16F10	 cells	 with	 fluorescein	 amidite	 (Fam)-labeled	 3pRNA,	 which	 showed	
equal	cellular	fluorescence	intensities	under	normoxia	and	hypoxia	(Figure	11).	
Having	observed	a	hypoxia-mediated	inhibition	of	RIG-I	protein	induction,	consequently	the	
influence	of	oxygen	deprivation	on	 the	 receptor’s	mRNA	expression	was	 investigated.	 Surprisingly,	
3pRNA-triggered	 RIG-I	 mRNA	 upregulation	 took	 place	 equally	 well	 under	 normoxia	 and	 hypoxia.	
Importantly,	 IFNα	 substantially	 lost	 its	 potential	 to	 stimulate	 RIG-I	 mRNA	 expression	 following	
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oxygen	deprivation	 (Figure	12A).	Taking	 into	account	 that	hypoxia	equally	attenuates	RIG-I	protein	
upregulation,	 but	 differentially	 acts	 on	 RIG-I	 mRNA	 expression	 induced	 by	 3pRNA	 or	 IFNα,	 these	
results	suggest	at	 least	partly	 independent	mechanisms	for	regulation	of	 IFNα-	and	3pRNA-induced	
RIG-I	responsiveness	under	hypoxia.	
	
	
Figure	 11:	 Transfection	 efficiency	 is	 not	 affected	 by	 hypoxia.	
Normoxic	 and	hypoxic	B16F10	 cells	were	 transfected	with	 a	 Fam-
labeled	 3pRNA.	 Transfection	 efficiency	 was	 determined	 by	 flow	
cytometry	 5	h	 later.	 Mean	 and	 +SEM	 of	 two	 independent	
experiments	 are	 shown.	 Statistical	 analysis	 was	 performed	 using	
student’s	 t	 test.	 **	(p	<	0.01).	 ns:	 not	 significant,	 w/o:	 without	
treatment,	 Fam:	 fluorescein	 amidite,	 mfi:	 mean	 fluorescence	
intensity,	3pGFP2:	3pRNA	
	
Possibly,	posttranscriptional	regulation	might	explain	the	observation	of	unaffected	mRNA	levels	and	
yet	 reduced	RIG-I	protein	expression.	One	potential	mechanism	of	posttranscriptional	 regulation	 is	
the	degradation	of	mRNA.	Using	actinomycin	D	as	transcription	inhibitor,	the	time	dependent	decay	
of	RIG-I	mRNA	was	tested	under	normoxia	and	hypoxia.	While	degradation	of	RIG-I	mRNA	occurred	
less	rapidly	following	3pRNA	transfection	as	compared	to	unstimulated	cells,	no	difference	in	mRNA	
stability	was	detectable	between	both	oxygen	conditions	(Figure	12B).	Accordingly,	it	is	unlikely	that	
enhanced	mRNA	degradation	is	the	ultimate	cause	for	reduced	RIG-I	protein	amounts	under	hypoxia.		
	
	
Figure	12:	Hypoxia	differentially	influences	3pRNA-	or	IFNα-induced	RIG-I	mRNA	expression.	(A)	Expression	of	RIG-I	mRNA	
in	B16F10	cells	was	determined	6	h	after	stimulation	with	the	indicated	oligonucleotides	or	IFNα	and	is	shown	relative	to	
TBP.	Mean	and	+SEM	of	three	independent	experiments,	each	normalized	to	3pRNA	treatment	under	normoxia,	are	shown.	
(B)	 Expression	 of	 RIG-I	 mRNA	 was	 quantified	 2	h,	 4	h	 and	 6	h	 after	 transcription	 blockade	 with	 actinomycin	D	 in	
unstimulated	(left)	or	3pRNA-treated	(right)	cells.	Values	were	normalized	to	actin	and	are	shown	relative	to	the	2	h	time	
point	for	each	oxygen	condition.	Mean	and	+/-SEM	of	one	or	three	biological	replicates,	each	consisting	of	two	technical	
replicates,	 are	 depicted	 respectively.	 Statistical	 analysis	 was	 performed	 using	 student’s	 t-test.	 *	(p	<	0.05),	 ns:	 not	
significant,	pA:	poly-A,	h:	hours.			
Results	
	
41	
To	 verify	 whether	 the	 reduction	 of	 receptor	 upregulation	 caused	 by	 hypoxia	 might	 also	 apply	 to	
another	RIG-I	 like	receptor	family	member,	the	expression	of	MDA5	was	analyzed.	Although	MDA5	
differs	from	RIG-I	in	terms	of	ligand	specificity,	it	employs	the	same	downstream	signaling	complexes	
to	 elicit	 an	 immune	 response	 and	 also	 initiates	 an	 IFN-mediated	 feed-forward	 loop	108,109.	 While	
treatment	of	melanoma	cells	with	3pRNA,	poly-I:C	or	IFNα	each	led	to	a	profound	increase	of	MDA5	
protein	 expression	 under	 normoxic	 conditions,	 this	was	 practically	 lost	 under	 hypoxia	 (Figure	 13).	
Attenuation	of	 the	MDA5	responsiveness	by	oxygen	deprivation	appeared	 to	be	even	more	severe	
than	for	RIG-I,	since	3pRNA	or	IFNα	treatment	was	still	able	to	enhance	RIG-I	expression	over	basal	
levels,	which	was	not	the	case	for	MDA5.		
	
	
Figure	13:	Hypoxia	prevents	MDA5	protein	upregulation	upon	stimulation.	B16F10	cells	were	incubated	at	2%	oxygen	for	
24	h	and	subsequently	stimulated	with	the	indicated	oligonucleotides	or	IFNα.	MDA5	expression	was	determined	24	h	later.	
Actin	served	as	loading	control.	A	representative	blot	of	three	independent	experiments	is	shown.	pA:	poly-A,	3p:	3pRNA,	
pIC:	poly-I:C.	
	
In	 summary	 these	 results	 show	for	 the	 first	 time	that	hypoxia	attenuates	RLR	protein	upregulation	
triggered	 by	 ligand	 transfection	 as	 well	 as	 IFNα	 treatment.	 Importantly,	 the	 inhibitory	 effect	 of	
oxygen	deprivation	is	less	severe	for	RIG-I	expression	than	for	MDA5.	The	desensitization	of	hypoxic	
melanoma	 cells	 to	 IFNα,	 shown	 on	 RIG-I	 mRNA	 and	 protein	 level,	 relates	 well	 to	 the	 diminished	
IFNαR	 expression	 at	 2%	 oxygen.	 On	 the	 other	 hand,	 the	 attenuated	 3pRNA-induced	 RIG-I	 protein	
responsiveness	 does	 not	 derive	 from	 transcriptional	 effects	 and	 seems	 to	 be	 independent	 of	
hampered	IFN	signaling.		
	
5.3 Hypoxia-mediated	effects	on	RIG-I	signaling	outcome		
The	discovery	of	the	inhibiting	impact	of	hypoxia	on	3pRNA-induced	RIG-I	expression	gave	rise	to	the	
question	 whether	 also	 RIG-I	 signaling	 outcome	 might	 be	 negatively	 affected.	 Concerning	 3pRNA-
based	cancer	immunotherapy,	the	influence	of	hypoxia	on	RIG-I-mediated	tumoricidal	effects	as	well	
as	 cytokine	 production	 and	 lymphocyte	 activation	 is	 of	 outmost	 interest	 and	 is	 described	 in	 the	
following	section.		
The	analysis	of	cell	death	via	 flow	cytometry	 indicated	mild	 induction	of	apoptosis	 through	
transfection	 of	 3pRNA	 in	 normoxic	 B16F10	 cells	 (Figure	 14).	 This	 related	 well	 to	 the	 low	 dose	 of	
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3pRNA	used	 throughout	 this	 thesis,	as	 the	main	 focus	was	 to	 investigate	different	aspects	of	RIG-I	
signaling	in	living	cells.	Importantly,	while	the	hypoxic	incubation	itself	induced	noticeable	apoptosis	
as	compared	to	normoxic	untreated	cells,	the	pro-apoptotic	potential	of	3pRNA	was	preserved	under	
oxygen	deprivation	 (Figure	14).	 These	 results	 suggest	 that	 the	attenuation	of	3pRNA-induced	RIG-I	
protein	expression	is	not	necessarily	reflected	in	reduced	tumoricidal	activity	of	3pRNA.		
	
	
Figure	14:	Hypoxia	does	not	influence	3pRNA-induced	apoptosis.	B16F10	cells	were	incubated	under	hypoxic	atmosphere	
for	 24	h	 and	 subsequently	 stimulated	 with	 3pRNA.	 Apoptosis	 was	measured	 24	h	 later	 using	 Annexin-V	 and	 propidium	
iodide	detection	by	flow	cytometry.	Representative	plots	of	three	experiments	are	shown.	w/o:	without	treatment	
	
Interferon-stimulated	 genes	 and	 pro-inflammatory	 cytokines	 are	 commonly	 used	 as	 surrogate	
markers	 for	 functional	activation	of	 the	RIG-I	signaling	pathway	and	represent	major	players	 in	the	
establishment	 of	 an	 early	 immune	 response	 upon	 3pRNA-sensing	 by	 RIG-I.	 To	 determine	 the	
influence	of	hypoxia	on	RIG-I	signaling	the	mRNA	expression	of	a	selection	of	ISGs	and	cytokines	was	
assessed	below.	 Furthermore,	 since	 recombinant	 IFNα	had	 turned	out	 to	be	 likewise	 ineffective	 in	
inducing	 RIG-I	 under	 hypoxia,	 3pRNA-dependent	 RIG-I	 signaling	 outcome	 was	 compared	 to	 IFNα	
treatment	 in	melanoma	 cells.	 As	 shown	 in	 Figure	 15A	 hypoxia	 caused	 an	 almost	 complete	 loss	 of	
IFNα-induced	 mRNA	 upregulation	 of	 IFIT1	 (interferon-induced	 protein	 with	 tetratricopeptide	
repeats	1),	CXCL10	(interferon-dependent	lymphocyte-attracting	chemokine)	and	viperin,	which	was	
comparable	 to	 the	 reduction	of	 IFNα-stimulated	RIG-I	expression	 (Figure	12A).	 In	 contrast,	3pRNA-
mediated	mRNA	 induction	 of	 all	 target	 genes	was	 not	 significantly	 altered	 by	 oxygen	 deprivation.	
Furthermore,	 mRNA	 stability	 of	 IFIT1	 and	 CXCL10	 following	 3pRNA	 transfection	 was	 equal	 under	
normoxia	and	hypoxia	(Figure	15B).	These	results	again	demonstrate	a	superior	function	of	3pRNA-
based	RIG-I	activation	to	direct	IFNα	stimulation	in	a	hypoxic	environment	and	suggest	that	3pRNA-
triggered	RIG-I	signaling	outcome	resists	hypoxia-mediated	IFNα	desensitization.		
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Figure	15:	3pRNA-	and	IFNα-induced	interferon-stimulated	gene	(ISG)	mRNA	expression	and	-stability.	(A)	Expression	of	
IFIT1,	 CXCL10	 and	 viperin	 mRNA	 in	 hypoxic	 B16F10	 cells	 was	 determined	 6	h	 after	 stimulation	 with	 the	 indicated	
oligonucleotides	or	IFNα	and	is	shown	relative	to	TBP.	Mean	and	+SEM	of	three	independent	experiments,	each	normalized	
to	3pRNA	treatment	under	normoxia,	are	shown.	(B)	Expression	of	IFIT1	and	CXCL10	mRNA	was	quantified	2	h,	4	h	and	6	h	
after	 transcription	 blockade	with	 actinomycin	D	 in	 3pRNA-treated	 cells.	 Values	were	 normalized	 to	 actin	 and	 are	 shown	
relative	to	the	2	h	time	point	for	each	oxygen	condition.	Mean	and	+/-SEM	of	two	independent	experiments	are	depicted.	
Statistical	analysis	was	performed	using	student’s	t-test.	*	(p	<	0.05),	ns:	not	significant,	pA:	poly-A,	h:	hours.	Experiments	
depicted	in	(A)	were	performed	by	Dorottya	Horváth.	
		
Expanding	the	investigation	of	3pRNA-induced	cytokine	expression	by	the	quantification	of	secreted	
type-I	IFN,	TNFα,	CXCL10	and	IL-6	finally	revealed	functional	modulation	of	the	3pRNA-induced	RIG-I	
response	 under	 oxygen	 deprivation.	 Interestingly,	 hypoxia	 caused	 a	 significant	 increase	 of	 the	
3pRNA-triggered	 production	 of	 type-I	 IFN	 and	 TNFα	 (Figure	 16A-B).	 On	 the	 other	 hand	 3pRNA-
induced	CXCL10	protein	secretion	was	reduced,	an	effect	not	observed	on	the	mRNA	expression	level	
(Figure	16C).	Lastly,	the	amount	of	IL-6	was	not	affected	by	hypoxia	(Figure	16D).	Altogether,	oxygen	
deprivation	 influenced	 translation	 or	 secretion	 of	 cytokines	 that	 was	 not	 necessarily	 reflected	 by	
their	mRNA	expression.	These	results	 indicate	a	modulation	of	RIG-I	signaling	under	hypoxia	rather	
than	an	inhibition,	and	might	suggest	 interplay	between	hypoxia-	and	EMT-mediated	influencing	of	
translation.		
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Figure	 16:	 Hypoxia	 modulates	 the	 3pRNA-induced	 cytokine	 pattern.	 (A-D)	 Normoxic	 or	 hypoxic	 B16F10	 cells	 were	
stimulated	with	 the	 indicated	oligonucleotides	 for	24	h.	 (A)	Type-I	 IFN	 in	 the	 supernatant	was	quantified	using	a	 cellular	
reporter	assay.	 (B)	TNFα	secretion	was	determined	by	multiplex	 flow	cytometry-based	cytokine	analysis.	 (C)	 IL-6	and	 (D)	
CXCL10	amounts	were	measured	using	ELISA.	Diagrams	depict	mean	and	+SEM	of	 three	 independent	experiments,	each	
normalized	 to	 3pRNA	 treatment	 under	 normoxia.	 Statistical	 analysis	was	 performed	 using	 student’s	 t-test.	 **	(p	<	0.01),	
***	(p	<	0.001),	****	(p	<	0.0001).	ns:	not	significant,	pA:	poly-A,	pCA:	poly-CA,	f.i.:	fold	induction.	
	
To	 investigate	whether	 the	hypoxia-mediated	suppression	of	RIG-I	upregulation	and	modulation	of	
cytokine	 secretion	 is	 a	 general	 phenomenon	or	 is	 restricted	 to	 certain	 cell	 types,	 a	 comparison	 of	
different	cell	lines	and	primary	cells	was	conducted.	Firstly,	a	panel	of	three	melanoma	cell	lines	was	
tested	 for	 RIG-I-,	 CXCL10-	 and	 IL-6	 expression	 after	 3pRNA	 stimulation	 under	 hypoxia.	 The	
investigated	cell	lines	HCmel23,	HCmel17	and	HCmel3	were	all	derived	from	the	HGF-Cdk4R24C	model	
of	 spontaneous	 autochthonous	 melanoma	 and	 closely	 mirror	 the	 histopathology	 and	 immune-
ignorance	of	spontaneous	human	cutaneous	melanoma	110.	 In	concordance	with	B16F10	melanoma	
cells	 all	 three	 cell	 lines	 displayed	 a	 suppressed	 3pRNA-induced	 RIG-I	 protein	 upregulation	 under	
hypoxic	 conditions	 (Figure	 17A-C,	 left	 panel).	 Moreover,	 cytokine	 production	 by	 HCmel23	 and	
HCmel17	 resembled	 the	 pattern	 of	 B16F10	 cells	 with	 a	 reduction	 of	 CXCL10	 and	 unaffected	 IL-6	
(Figure	 17A-B,	middle	 and	 right	 panel).	 In	 HCmel3	 cells	 CXCL10	 showed	 a	 trend	 towards	 hypoxia-
mediated	decrease,	but	also	a	significant	suppression	of	IL-6	(Figure	17C,	middle	and	right	panel).	As	
conclusion,	despite	 variations	 in	 the	extent,	 the	attenuation	of	 3pRNA-induced	RIG-I	 response	and	
the	modulation	 of	 cytokine	 expression	 under	 hypoxia	 could	 generally	 be	 recapitulated	 in	 a	 set	 of	
syngeneic	mouse	melanoma	cell	lines.	
As	representatives	for	non-malignant	cells	of	the	same	tissue	the	murine	melanocyte	cell	line	
Melan-A	 and	 the	 murine	 epidermal	 keratinocyte	 cell	 line	 Kera	 308	 were	 tested	 for	 RIG-I	
responsiveness	under	hypoxia.	In	contrast	to	melanoma,	these	cell	lines	did	not	show	a	reduction	in	
RIG-I	 protein	 expression	 upon	 3pRNA	 stimulation	 at	 2%	 pO2	 (Figure	 18A-B,	 left	 panel).	While	 the	
CXCL10	 production	 was	 equally	 suppressed	 in	 malignant	 and	 non-malignant	 cells,	 only	 the	 latter	
exhibited	significantly	reduced	amounts	of	IL-6	(Figure	18A-B,	middle	and	right	panel).	
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Figure	 17:	 Hypoxia	 influences	 the	 3pRNA-triggered	 RIG-I	 response	 in	 various	 melanoma	 cell	 lines.	 (A-C)	 Normoxic	 or	
hypoxic	 murine	 melanoma	 cells	 HCmel23	 (A),	 HCmel17	 (B)	 and	 HCmel3	 (C)	 were	 stimulated	 with	 the	 indicated	
oligonucleotides	 for	 24	h.	Left	 panel:	 RIG-I	 expression	as	determined	by	western	blot.	Actin	 is	 shown	as	 loading	 control.	
Representative	 blots	 of	 three	 independent	 experiments	 are	 depicted.	 Middle	 and	 right	 panel:	 CXCL10	 and	 IL-6	 were	
measured	 using	 ELISA.	 Diagrams	 show	mean	 and	 +SEM	 of	 three	 independent	 experiments,	 each	 normalized	 to	 3pRNA	
treatment	under	normoxia.	Statistical	analysis	was	performed	using	student’s	t-test.	*	(p	<	0.05),	****	(p	<	0.0001).	ns:	not	
significant,	w/o:	without	treatment,	3p:	3pRNA,	pA:	poly-A,	f.i.:	fold	induction.	
	
A	third	class	of	cell	types	that	would	inevitably	encounter	the	hypoxic	tumor	microenvironment	upon	
3pRNA	 therapy	 is	 immune	 cells.	 Interestingly,	 in	primary	murine	 splenocytes	hypoxia	did	not	have	
any	effect	on	3pRNA-induced	RIG-I	upregulation	or	IL-6	production,	whereas	CXCL10	was	significantly	
reduced	(Figure	19).	Of	note,	the	difference	between	basal-	and	3pRNA-induced	RIG-I	expression	was	
low,	with	an	increase	of	approximately	2-fold	in	contrast	to	a	10-fold	increment	for	B16F10	cells.		
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Figure	 18:	 Hypoxia-mediated	 effects	 on	 the	 3pRNA-induced	 RIG-I	 response	 in	 non-malignant	 cells.	 (A-B)	 Normoxic	 or	
hypoxic	cells	of	the	murine	melanocyte	cell	line	Melan-A	(A)	and	of	the	murine	epidermal	keratinocyte	cell	line	Kera	308	(B)	
were	stimulated	with	the	indicated	oligonucleotides	for	24	h.	Left	panel:	Western	blots	showing	RIG-I	expression	and	actin	
as	loading	control.	A	representative	blot	of	three	independent	experiments	is	depicted.	Middle	and	right	panel:	CXCL10	and	
IL-6	amounts	as	mean	and	+SEM	of	three	independent	experiments,	each	normalized	to	3pRNA	treatment	under	normoxia.	
Statistical	 analysis	was	 performed	using	 student’s	 t-test.	 **	 (p	 <	 0.01),	 ***	 (p	 <	 0.001),	 ****	(p	 <	 0.0001).	w/o:	without	
treatment,	3p:	3pRNA,	pA:	poly-A,	f.i.:	fold	induction.	
	
In	summary,	the	here	investigated	cell	types,	namely	malignant	melanoma	cell	lines,	non-malignant	
melanocyte	and	keratinocyte	cell	lines	as	well	as	primary	splenocytes,	all	showed	that	hypoxia	had	an	
inhibitory	 effect	 on	 3pRNA-triggered	 CXCL10	 production,	 whereas	 the	 influence	 on	 IL-6	 varied	
between	 cell	 types	 and	 cell	 lines.	 Still,	 reduction	 of	 RIG-I	 protein	 upregulation	 was	 restricted	 to	
malignant	melanoma	cells	and	was	absent	in	the	investigated	non-malignant	cell	types.	
	
	
Figure	19:	Hypoxia-mediated	effects	on	the	3pRNA-induced	RIG-I	 response	 in	murine	splenocytes.	Normoxic	or	hypoxic	
mouse	 splenocytes	 were	 stimulated	 with	 the	 indicated	 oligonucleotides	 for	 24	h.	 Left	 panel:	 Western	 blot	 of	 RIG-I	
expression	and	actin	as	loading	control.	A	representative	blot	of	three	independent	experiments	is	shown.	Middle	and	right	
panel:	CXCL10	and	 IL-6	amounts	are	depicted	as	mean	and	+SEM	of	 three	 independent	experiments,	each	normalized	to	
3pRNA	 treatment	 under	 normoxia.	 Statistical	 analysis	 was	 performed	 using	 student’s	 t-test.	 ****	(p	 <	 0.0001).	 ns:	 not	
significant,	w/o:	without	treatment,	3p:	3pRNA,	pA:	poly-A,	f.i.:	fold	induction.	
	
Apart	from	the	induction	of	cytokines	and	type-I	IFN,	an	important	function	of	3pRNA-mediated	RIG-I	
activation	 is	 the	upregulation	of	MHC	class-I	 on	 the	 cell	 surface.	 This	 allows	enhanced	melanocyte	
differentiation	 antigen	 presentation	 to	 cytotoxic	 T-cells,	 enabling	 their	 activation	 via	MHC	class-I	 –	
T-cell	 receptor/CD8	 receptor	 interaction.	 The	 RIG-I-induced	 MHC	class-I	 upregulation	 thus	 spurs	
cytotoxic	T-cell	effector	function,	and	thereby	bridges	innate	and	adaptive	immunity.	A	comparison	
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of	3pRNA-	and	 IFNα	treatment	of	B16F10	cells	showed	a	strong	 increase	of	MHC	class-I	expression	
triggered	by	both	components	under	normoxia.	Interestingly,	oxygen	deprivation	almost	completely	
abrogated	 IFNα-induced	 MHC	class-I	 upregulation,	 while	 its	 3pRNA-triggered	 expression	 was	 not	
affected	on	average	(Figure	20A).	Similar	results	were	obtained	for	the	analysis	of	PDL-1	expression	
on	 B16F10	 cells,	 upregulation	 of	 which	 has	 been	 found	 to	 be	 an	 additional	 indicator	 of	 RIG-I	
activation	in	our	lab.	This	immune	checkpoint	molecule	confers	inhibition	of	T-cell	proliferation	and	
cytokine	 production	 upon	 interaction	 with	 its	 corresponding	 receptor	 PD-1	 on	 lymphocytes	111.	
Importantly,	 activation	of	RIG-I	 by	3pRNA	 strongly	upregulated	PDL-1	as	 compared	 to	 control-RNA	
transfection	(Figure	20B).	In	concordance	with	MHC	class-I,	hypoxia	did	not	alter	PDL-1	upregulation	
upon	3pRNA	stimulation,	whereas	 its	 IFNα-induced	expression	was	clearly	diminished	 (Figure	20B).	
Furthermore,	 analysis	 of	 the	 respective	 receptor	 PD-1	 on	 splenocytes	 upon	 PMA/ionomycin	
activation	revealed	equal	expression	under	normoxic	and	hypoxic	conditions	(Figure	20C),	indicating	
the	existence	of	 a	 fully	 intact	PD-1/PDL-1	 inhibitory	axis	under	hypoxia.	 In	brief	 summary,	hypoxia	
strongly	 suppressed	 IFNα-mediated	 MHC	class-I	 and	 PDL-1	 expression	 on	 B16F10	 cells,	 whereas	
upregulation	of	both	molecules	by	3pRNA	treatment	was	not	reduced.	These	results	again	 indicate	
functional	immune	activation	by	RIG-I	under	hypoxia	and	suggest	that	tumor	antigen	presentation	by	
MHC	class-I	 on	 melanoma	 cells	 is	 still	 working.	 Yet,	 since	 also	 PDL-1	 and	 PD-1	 expression	 are	
maintained	 upon	 oxygen	 deprivation,	 the	 inhibiting	 impact	 of	 this	 immune	 checkpoint	 likely	 is	
preserved	 as	 well.	 This	 opens	 up	 a	 new	 avenue	 of	 research	 into	 anti-PD-1/PDL-1	 –	 3pRNA	
combinations,	to	further	release	the	brakes	on	anti-tumor	immunity.		
	
Figure	20:	Hypoxia	abrogates	IFNα-	but	not	3pRNA-induced	MHC	class-I	and	PDL-1	expression.	(A-B)	Normoxic	or	hypoxic	
B16F10	cells	were	stimulated	with	the	indicated	oligonucleotides	or	IFNα.	Expression	of	MHC	class-I	(A)	and	PDL-1	(B)	was	
determined	24	h	later	by	flow	cytometry.	Mean	and	+SEM	of	four	to	seven	independent	experiments,	each	normalized	to	
normoxic,	untreated	cells,	are	depicted.	(C)	Pmel-1	splenocytes	were	left	untreated	or	activated	with	PMA/ionomycin	for	
18	h	 and	 expression	 of	 PD-1	 was	 analyzed	 by	 flow	 cytometry.	 Diagrams	 show	 mean	 and	 +SEM	 of	 three	 independent	
experiments,	 each	 normalized	 to	 normoxic,	 unstimulated	 conditions.	 Statistical	 analysis	 was	 performed	 using	 student’s	
t-test.	*	(p	<	0.05).	ns:	not	significant,	pA:	poly-A,	3p:	3pRNA,	SPL:	splenocytes,	PMA:	phorbol	12-myristate	13-acetate,	Iono:	
ionomycin,	f.i.:	fold	induction.	
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The	different	parameters	of	RIG-I	signaling	outcome	investigated	above	are	supposed	to	eventually	
contribute	 to	 the	 activation	 of	 T-	 and	 NK	 cells	 to	 induce	 tumor	 specific	 cell	 killing.	 Since	 oxygen	
deprivation	was	found	to	modulate	the	3pRNA-induced	cytokine	profile,	 the	question	was	whether	
immune	cells	might	react	differently	to	stimulated	melanoma	cells.	A	co-culture	protocol	of	3pRNA-
transfected	melanoma	cells	together	with	gp10025-33	antigen-specific	Pmel-1	splenocytes	was	applied,	
to	 uncover	 the	 hypoxia-mediated	 effects	 on	 their	 mutual	 interaction	 (Figure	 21A).	 Compared	 to	
control-RNA-transfected	cells,	 3pRNA-treated	B16F10	cells	were	 indeed	capable	of	activating	CD8+	
T-cells	 and	 NK	 cells	 as	 indicated	 by	 upregulation	 of	 the	 activation	 marker	 CD69	 (Figure	 21B-C).	
Furthermore,	 incubation	 at	 hypoxic	 atmosphere	 resulted	 in	 slightly,	 but	 not	 significantly,	 lower	
responses	 to	 3pRNA-transfected	melanoma	 cells.	 In	 contrast,	 treatment	 of	 B16F10	 cells	with	 IFNα	
induced	only	minimal,	if	any,	detectable	activation	of	CD8+	T-cells	and	NK	cells,	even	when	applying	
high	doses	of	IFNα	under	normoxic	conditions	(up	to	5000	IU/mL).	
	Importantly,	 comparable	 results	 could	 be	 obtained	 when	 the	 co-culture	 procedure	 was	
performed	using	HCmel3	melanoma	cells	together	with	Pmel-1	splenocytes	(Figure	21D-E).	Notably,	
the	general	ability	of	T-	or	NK	cells	to	become	activated	was	not	influenced	by	the	employed	hypoxia-
regimen,	since	different	control	incubations	did	not	show	an	altered	CD69	expression	under	hypoxia	
(Figure	22).	These	results	indicate	no	influence	of	oxygen	deprivation	on	the	immune	cell	activating	
potential	of	3pRNA-treated	melanoma	cells.	This	 is	especially	remarkable	when	taking	 into	account	
that	hypoxia-induced	EMT	 in	B16F10	and	HCmel3	cells	 leads	 to	a	near-complete	 loss	of	melanoma	
differentiation	 antigen	 gp100	 expression	 (Figure	 6	 and	 data	 not	 shown),	 the	 cognate	 antigen	 for	
Pmel-1	T-cells.	
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Figure	21:	In	vitro	CD8+	T-	and	NK	cell	activation	through	3pRNA-treated	melanoma	cells	remains	fully	functional	under	
hypoxia.	 (A)	 Schematic	 representation	 of	 the	 co-culture	 protocol	 of	 melanoma	 cells	 and	 Pmel-1	 splenocytes.	 (B-E)	
Activation	of	immune	cells	was	determined	by	flow	cytometric	analysis	of	CD69	expression.	Left	panels:	Mean	and	+SEM	of	
three	 to	 nine	 independent	 experiments.	 Right	 panels:	 Representative	 flow	 cytometry	 plots	 of	 co-cultures	 with	 3pRNA-
stimulated	melanoma	cells.	(B)	Activated	CD8+	T-cells	in	B16F10	co-culture.	(C)	Activated	NK	cells	in	B16F10	co-culture.	(D)	
Activated	CD8+	T-cells	in	HCmel3	co-culture.	(E)	Activated	NK	cells	in	HCmel3	co-culture.	Statistical	analysis	was	performed	
using	 student’s	 t-test.	 *	(p	<	0.05),	 **	(p	<	0.01),	 ***	(p	<	0.001),	 ****	(p	<	0.0001).	 ns:	 not	 significant,	 w/o:	 without	
treatment,	pA:	poly-A.	
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Altogether,	 the	 investigation	 of	 RIG-I	 signaling	 outcome	 revealed	 a	 sustained	 immune	 stimulatory	
function	of	3pRNA	treatment	under	hypoxia.	While	protein	expression	or	release	of	type-I	interferon	
and	different	cytokines	was	modulated	upon	oxygen	deprivation,	MHC	class-I	and	PDL-1	expression	
as	 well	 as	 T-	 and	 NK	 cell	 activation	 worked	 equally	 well	 under	 normoxia	 and	 hypoxia.	Moreover,	
3pRNA	 proved	 to	 be	 superior	 to	 IFNα	 treatment	 concerning	 all	 investigated	 immune-related	
functions,	 indicating	 RIG-I	 activation	 resists	 IFNαR-downregulation	 and	 IFNα-desensitization	 under	
hypoxia.	
	
	
Figure	22:	Hypoxia	does	not	affect	the	capability	of	cytotoxic	effector	cells	to	become	activated.	(A-B)	Pmel-1	splenocytes	
were	activated	with	gp10025-33	peptide	or	with	PMA/ionomycin	for	18	h	under	normoxic	or	hypoxic	conditions.	Activation	of	
CD8+	T-cells	(A)	and	activation	of	NK	cells	(B)	was	assessed	by	flow	cytometric	analysis	of	CD69	expression.	Mean	and	+SEM	
of	five	to	seven	independent	experiments	are	shown.	w/o:	without	treatment,	PMA:	phorbol	12-myristate	13-acetate,	iono:	
ionomycin.	
	
5.4 Hypoxia-mediated	effects	on	regulatory	components	of	RIG-I	signaling	
To	exert	its	manifold	anti-viral	effector	functions	the	RIG-I	signaling	pathway	is	composed	of	various	
interacting	proteins	and	tight	regulation	is	necessary	for	 its	proper	function.	Since	on	the	one	hand	
3pRNA-induced	 RIG-I	 protein	 upregulation	was	 attenuated	 by	 hypoxia,	 but	 on	 the	 other	 hand	 the	
functional	RIG-I	 response	was	upheld,	 the	 influence	of	 hypoxia	on	 regulatory	 components	of	RIG-I	
signaling	required	more	detailed	 investigation.	Therefore	the	following	section	presents	the	effects	
of	oxygen	deprivation	on	some	of	the	most	important	molecules	and	mechanisms	that	control	signal	
transmission	from	RIG-I	to	transcription	factors	of	pro-inflammatory	proteins.	
	 Interestingly,	 the	 molecular	 chaperone	 HSP90	 forms	 a	 link	 between	 hypoxia	 and	 RIG-I-
signaling	 as	 its	 expression	 is	 upregulated	by	HIF	 activation	 and	 it	 is	 involved	 in	 the	 recruitment	 of	
TBK1/IRF3	 to	 mitochondria	41,112.	 Importantly,	 HSP90	 also	 protects	 RIG-I	 against	 degradation	40.	
Therefore,	a	possible	hypoxia-induced	change	in	HSP90	expression	can	also	affect	RIG-I	protein	levels	
or	 signaling	outcome.	Nevertheless	a	24-hour	 incubation	of	B16F10	cells	 at	2%	oxygen	did	neither	
alter	the	protein	expression	of	the	isoform	HSP90α	nor	of	HSP90β	(Figure	23).	
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Figure	23:	HSP90	expression	is	not	affected	by	hypoxia.	Expression	
of	HSP90α	(left	panel)	and	HSP90β	(right	panel)	in	B16F10	cells	was	
determined	by	western	blot	upon	24	h	of	hypoxia.	Representative	
blots	of	three	independent	experiments	are	shown.	Actin	served	as	
loading	control.	N:	normoxia,	H:	hypoxia		
	
To	 alternatively	 test	 the	 possibility	 that	 the	 reduced	 RIG-I	 upregulation	 after	 3pRNA	 stimulation	
under	hypoxia	 resulted	 from	enhanced	proteasomal	degradation,	RIG-I	expression	was	determined	
upon	proteasome	 inhibition.	 Surprisingly,	MG132	 treatment	of	 B16F10	 cells	 caused	 a	 reduction	of	
3pRNA-triggered	 RIG-I	 expression	 predominantly	 under	 hypoxic	 atmosphere	 (Figure	 24A).	 This	
indicates	 enhanced	 proteasomal	 degradation	 is	 not	 responsible	 for	 attenuated	 RIG-I	 protein	
upregulation.	 Instead	 one	might	 speculate	 that	 degradation	 of	 another	 component	 is	 required	 to	
maintain	the	remaining	RIG-I	expression	upon	oxygen	deprivation.		
The	 component	 that	 is	 typically	 associated	 with	 protein	 degradation	 is	 the	 8	kDa	 protein	
ubiquitin,	which	additionally	plays	a	role	in	signal	transduction	in	signaling	cascades.	Lysine	63	(K63)-
linked	ubiquitin	chains	for	example	are	conjugated	to	RIG-I	and	are	necessary	for	the	interaction	of	
RIG-I	with	MAVS	36.	As	seen	in	Figure	24B	a	whole	cell	protein	analysis	of	K63-ubiquitin-conjugates	by	
western	blot	did	not	show	differences	between	normoxic	and	hypoxic	B16F10	cells,	neither	with	and	
without	3pRNA	treatment	nor	with	and	without	proteasome	inhibition	using	MG132.	Thus,	enhanced	
K63-ubiquitination	 cannot	 be	 made	 responsible	 for	 fostering	 signal	 transmission	 from	 RIG-I	 to	
transcription	factors	and	thereby	compensating	for	reduced	RIG-I	expression	under	hypoxia.	
	
	
Figure	 24:	 Effects	 of	 hypoxia	 on	 K63-ubiquitin	 expression	 and	 RIG-I	 expression	 upon	 proteasome	 inhibition.	 (A-B)	
Normoxic	or	hypoxic	B16F10	cells	were	transfected	with	the	indicated	oligonucleotides	for	24	h	and	simultaneously	treated	
with	 the	 proteasome	 inhibitor	MG132	where	 indicated.	 RIG-I	 (A)	 and	 K63-ubiquitin	 expression	 (B)	 were	 determined	 by	
western	blot.	Representative	blots	of	three	and	two	independent	experiments	are	depicted	respectively.	Actin	is	shown	as	
loading	control.	w/o:	without	treatment,	pA:	poly-A,	3p:	3pRNA,	K63:	lysine	63.	
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Lastly,	 three	 other	 important	 RIG-I	 signaling	 components	 were	 tested	 for	 differential	 protein	
expression	 under	 hypoxia	 and	 normoxia:	 MAVS,	 which	 represents	 the	 central	 signaling	 adaptor	
protein	 of	 the	 RIG-I	 pathway	 by	 providing	 a	 scaffold	 for	 the	 assembly	 of	 RIG-I	 and	 a	 variety	 of	
effector	molecules	 at	mitochondria.	 Secondly,	 the	mitochondrial	 import	 receptor	 subunit	 TOM70,	
which	 is	 required	 for	 the	 HSP90-dependent	 recruitment	 of	 TBK1	 and	 IRF3	 to	 the	 mitochondrial	
signaling	complex	41.	And	lastly,	the	peroxisomal	membrane	protein	PMP70	was	analyzed	as	indicator	
of	peroxisome	abundance,	because	MAVS	also	locates	to	these	organelles	28.	As	shown	in	Figure	25A	
PMP70	 expression	 was	 slightly	 reduced	 by	 hypoxia	 independent	 of	 RNA	 transfection,	 which	 is	 in	
concordance	with	Walter	et	al.	113.	However,	this	did	not	coincide	with	loss	of	MAVS	protein,	instead	
the	overall	MAVS	expression	was	not	changed	(Figure	25B).	Interestingly,	TOM70	detection	revealed	
an	additional	55	kDa	product	exclusively	 in	hypoxic	samples,	whereas	 the	expression	of	 the	70	kDa	
protein	was	equal	to	normoxic	conditions	(Figure	25B).	
	
	
Figure	 25:	 Influence	 of	 hypoxia	 on	 the	 protein	 expression	 of	 RIG-I	 signaling	 components.	 (A-B)	 Normoxic	 or	 hypoxic	
B16F10	cells	were	transfected	with	the	indicated	oligonucleotides	for	24	h.	Expression	of	PMP70	(A)	and	MAVS	and	TOM70	
(B)	were	 determined	 by	western	 blot.	 TOM70	was	 detected	 after	 stripping	MAVS-specific	 antibodies.	 Actin	 is	 shown	 as	
loading	control.	Representative	blots	of	three	independent	experiments	are	depicted.	w/o:	without	treatment,	pA:	poly-A,	
3p:	3pRNA		
	
Altogether,	 these	 data	 show	 that	 hypoxia-mediated	 reduced	 RIG-I	 upregulation	 is	 not	 caused	 by	
enhanced	 RIG-I	 degradation	 through	 the	 proteasome.	 Further,	 attenuated	 RIG-I	 expression	 is	 not	
compensated	 by	 changes	 in	 K63-ubiquitination	 or	 HSP90,	 MAVS	 and	 TOM70	 protein	 expression,	
which	 can	 maintain	 functional	 RIG-I	 signaling	 outcome.	 Instead	 it	 remains	 unclear	 whether	 a	
different	 distribution	 of	 MAVS	 between	 mitochondria	 and	 peroxisomes	 or	 the	 additional	 55	kDa	
protein	 detected	 by	 TOM70	 antibody	 exert	 effects	 on	 3pRNA-induced	 RIG-I	 signaling.	 Taking	 into	
account	that	RIG-I	mRNA	expression	and	the	functional	RIG-I	response	was	not	hampered	by	hypoxia	
argues	 for	 specific	 changes	 in	 translational	 regulation,	 posttranslational	 modifications	 or	 miRNA	
functions	that	lead	to	reduced	RIG-I	protein	upregulation.	Importantly,	all	of	these	play	a	role	in	EMT,	
which	is	induced	by	oxygen	deprivation	in	the	here-investigated	melanoma	cells.			
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5.5 Enhancing	RIG-I	function	under	hypoxia	and	normoxia	
Having	discovered	an	attenuation	of	3pRNA-induced	RIG-I	protein	upregulation	under	hypoxia	 that	
coincided	 with	 EMT,	 the	 resulting	 question	 was	 whether	 counteracting	 EMT	 could	 restore	 RIG-I	
expression	and	thus	enhances	its	immune-activating	function.	Since	the	increased	production	of	ROS	
as	 well	 as	 enhanced	 NFκB	 activation	 can	 be	 held	 responsible	 for	 hypoxia-induced	 EMT,	 ROS	
scavenging	 and	 NFκB-inhibition	 were	 tested	 for	 their	 effects	 on	 RIG-I	 expression.	 L-ascorbic	 acid	
(vitamin	C)	was	 utilized	 as	 ROS	 scavenger,	 which	 exhibited	 an	 approximate	 50%	 reduction	 of	 ROS	
production	 by	 B16F10	 cells	 under	 hypoxic	 conditions	 (Figure	 26A).	 To	 investigate	 the	 effects	 of	
vitamin	C	or	NFκB	inhibition	on	the	differentiation	status	of	hypoxic	melanoma	cells,	the	expression	
of	gp100	was	analyzed	(Figure	26B).	Interestingly,	3pRNA	transfection	alone	led	to	a	small	increase	in	
gp100	 expression	 under	 oxygen	 deprivation.	While	 the	 addition	 of	 vitamin	C	 to	 the	 cells	 24	 hours	
prior	to	onset	of	hypoxia	had	only	marginal	effects,	prevention	of	NFκB	activation	by	applying	the	IκB	
phosphorylation	inhibitor	BAY	during	hypoxic	incubation	potently	reinstated	gp100	expression.		
	
		
Figure	 26:	 Rescue	 of	melanocyte	 differentiation	 antigen	 expression	 under	 hypoxia.	 (A)	During	a	24	h	 incubation	under	
hypoxia	B16F10	cells	were	treated	with	200	µM	vitamin	C.	ROS	production	was	determined	by	flow	cytometry	using	a	ROS	
reactive	dye.	Results	of	one	performed	experiment	are	shown.	(B)	gp100	differentiation	antigen	expression	was	detected	
by	 western	 blot	 following	 vitamin	C	 or	 NFκB	 inhibitor	 treatment	 under	 hypoxia.	 Actin	 served	 as	 loading	 control.	 A	
representative	blot	 of	 three	 independent	 experiments	 is	 shown.	w/o:	without	 treatment,	Vit	 C:	 vitamin	C,	 ROS:	 reactive	
oxygen	species,	N:	normoxia,	mfi:	mean	fluorescence	intensity.	
	
In	 contrast,	 ROS	 scavenging	 via	 vitamin	C	 and	 NFκB	 inhibition	 by	 BAY	 both	 significantly	 restored	
3pRNA-induced	 RIG-I	 protein	 expression	 under	 hypoxia	 as	 seen	 in	 Figure	 27A.	 Likewise,	 two	
additional	 NFκB	 inhibitors,	 namely	 BMS	 (an	 IKKα-complex	 blocker)	 and	 helenalin	 (a	 p65	 inhibitor)	
were	 also	 able	 to	 re-establish	 RIG-I	 responsiveness	 under	 hypoxia	 (Figure	 27B),	while	 none	 of	 the	
treatments	exerted	an	effect	under	normoxic	conditions.	Figure	27C	summarizes	the	quantification	
of	RIG-I	expression	upon	3pRNA	transfection,	 indicating	that	vitamin	C	was	comparably	effective	as	
NFκB	 inhibitors	 in	 restoring	 RIG-I	 upregulation.	 Taken	 together,	 although	 the	 effects	 on	 gp100	
expression	 varied,	 ROS	 scavengers	 or	NFκB	 inhibitors	 open	up	 a	 possibility	 to	 rescue	RIG-I	 protein	
expression	in	response	to	3pRNA	stimulation	under	hypoxia.	
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Figure	 27:	 NFκB	 inhibition	 and	 vitamin	C	 treatment	 partially	 restore	
3pRNA-induced	 RIG-I	 upregulation	 under	 hypoxia.	 (A-B)	 RIG-I	 expression	
was	 analyzed	 upon	 3pRNA	 stimulation	 of	 B16F10	 cells	 that	 were	 treated	
with	200	µM	vitamin	C	or	NFκB	inhibitor	BAY	(A)	or	NFκB	inhibitors	BMS	or	
helenalin	 (B).	 Actin	 served	 as	 loading	 control.	 Representative	 blots	 of	 five	
independent	experiments	are	shown.	 (C)	3pRNA-triggered	RIG-I	expression	
was	 quantified	 and	 normalized	 to	 actin.	 Mean	 and	 +SEM	 of	 five	 or	 nine	
independent	 experiments	 are	 depicted.	 Statistical	 analysis	 was	 performed	
using	 student’s	 t-test.	 *	(p	<	0.05),	 **	(p	<	0.01),	 ****	(p	<	0.0001).	 ns:	 not	
significant,	 w/o:	 without	 treatment,	 Vit	 C:	 vitamin	C,	 Hel:	 helenalin,	 N:	
normoxia,	a.u.:	arbitrary	units.		
	
At	this	point	it	is	important	to	refer	to	the	heterogeneous	role	of	ROS	in	RIG-I	signaling.	In	contrast	to	
hypoxia-induced	 ROS,	 which	 contribute	 to	 EMT	 and	 therefore	 supposedly	 correlate	 with	 an	
attenuation	 of	 RIG-I	 expression,	 intrinsic	 NADPH	 oxidase	 (NOX2)-produced	 ROS	 and	 ROS	
accumulated	 through	 dysfunctional	 autophagy	 have	 been	 shown	 to	 be	 required	 for	 proper	 RIG-I	
signaling	or	 its	amplification	respectively	42,114.	 Importantly,	ROS	accumulation	can	also	be	achieved	
by	siRNA-mediated	suppression	of	the	anti-oxidative	transcription	factor	nuclear	factor	erythroid	2-
related	 factor	 2	 (Nrf2).	 Thus,	 it	 seemed	 worth	 additionally	 investigating	 a	 method	 to	 boost	 RIG-I	
function	that	was	intrinsically	linked	to	the	3pRNA	agent	as	3p-siNrf2.	Such	dual-functional	RNA	that	
combines	RIG-I	activating	capacity	and	ROS	induction	via	Nrf2	silencing,	would	deliver	both	functions	
to	 the	 same	 cell,	 whereas	 vitamin	C	 treatment	 might	 not	 reach	 all	 3pRNA-stimulated	 cells	 in	
sufficient	 amounts.	 The	 superior	 function	 of	 the	 3p-siRNA	 combination	 over	 3pRNA	 alone	 was	
demonstrated	 in	 vitro	 in	 B16F10	 cells	 in	 terms	 of	 enhanced	 CXCL10	 production	 and	 augmented	
tumor	 cell	 apoptosis	 (Figure	 28A-B).	 As	 3pRNA-induced	 RIG-I	 mRNA	 expression	 was	 not	 further	
enhanced	by	the	siRNA	function	(Figure	28C),	 the	superior	performance	of	3p-siNrf2	was	shown	to	
be	 independent	 of	 Nrf2	 knockdown-related	 direct	 RIG-I	 upregulation.	 Despite	 these	 promising	 in	
vitro	results,	preliminary	data	investigating	the	therapeutic	potential	of	3p-siNrf2	in	a	transplantable	
B16	tumor	model,	showed	the	strongest	effect	when	extra	ROS	were	induced	through	the	additional	
application	 of	 depigmenting-agent	monobenzone	 (data	 not	 shown).	 Since	 further	 elaboration	was	
beyond	 the	 scope	of	 this	 thesis,	 studies	were	 focused	on	 the	 ability	 of	 vitamin	C	 to	 enhance	RIG-I	
expression	under	hypoxia.	
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Figure	28:	 Superior	 cytokine	 release	and	 tumor	 cell	 toxicity	of	bi-functional	3p-siNrf2	over	3pRNA	alone.	 (A-C)	B16F10	
cells	were	transfected	with	the	indicated	oligonucleotides	for	24	h.	(A)	CXCL10	amounts	were	quantified	in	the	supernatant	
using	ELISA.	 (B)	Cell	viability	was	measured	using	CellTiter-Blue	assay.	 (C)	RIG-I	mRNA	expression	was	determined	by	RT-
qPCR	 and	 normalized	 to	 TBP.	 Results	 are	 shown	 relative	 to	 untreated	 cells.	Mean	 and	 +SEM	of	 technical	 triplicates	 are	
shown.	 Statistical	 analysis	 was	 performed	 using	 student’s	 t-test.	 *	(p	<	0.05),	 **	(p	<	0.01),	 ***	(p	<	0.001),	
****	(p	<	0.0001).	 w/o:	 without	 treatment,	 siCTRL:	 control	 siRNA,	 siNrf2:	 Nrf2-specific	 siRNA,	 3pGFP2:	 3pRNA	 without	
target,	3p-siNrf2:	Nrf2-specific	siRNA	with	3p-function.	Experiments	were	performed	by	Christian	Hagen.	
	
In	conclusion,	accumulation	of	ROS	by	downregulation	of	anti-oxidative	proteins	can	act	 in	favor	of	
RIG-I-mediated	anti-viral	or	anti-tumoral	effects	under	normoxia,	whereas	under	hypoxic	conditions	
ROS	scavenging	protects	against	attenuation	of	RIG-I	expression.	
	
5.6 EMT	and	immune	activation	in	vitamin	C-supported	3pRNA	therapy	in	vivo	
Since	the	induction	of	EMT	is	one	of	the	major	impacts	of	hypoxia	on	tumor	cells,	the	main	focus	of	
this	 work	 remained	 to	 counteract	 EMT	 and	 thus	 investigate	 a	 potential	 means	 to	 enhance	 RIG-I	
function	 in	 vivo.	 In	 contrast	 to	 a	 prolonged	 inhibition	 of	 NFκB	 in	 vivo,	 application	 of	 systemic	
vitamin	C	 has	 little	 side	 effects	 and	 is	 already	 in	 use	 for	 the	 treatment	 of	 different	 indications	 in	
humans.	 That	 is	 why	 ROS	 scavenging	 via	 vitamin	C	 was	 chosen	 for	 tests	 in	 combination	 with	
therapeutic	3pRNA-mediated	immunotherapy	in	a	transplantable	B16	mouse	model.	Investigation	of	
intratumoral	RIG-I	 levels	showed	a	weak	basal	expression	 in	untreated	as	well	as	vitamin	C-treated	
mice,	which	was	considerably	boosted	in	the	3pRNA-treated	group.	Yet,	additional	administration	of	
vitamin	C	did	not	further	enhance	RIG-I	protein	expression	(Figure	29).	Of	note,	this	analysis	included	
whole	 tumor	 lysates	 consisting	 of	 normoxic	 and	 hypoxic	 areas,	 whereas	 in	 vitro	 experiments	
compared	two	distinct	setups	of	20%	versus	2%	oxygen.		
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Figure	29:	3pRNA	therapy	enhances	RIG-I	expression	in	B16	tumors.	Established	subcutaneous	tumors	were	treated	with	
3pRNA	(i.t.)	and	vitamin	C	(i.p.)	as	indicated	and	RIG-I	expression	was	determined	in	tumor	lysates.	Actin	served	as	loading	
control.	Three	to	four	mice	per	group	are	shown.		
	
Immunohistochemistry	 studies	 further	 revealed	 profoundly	 induced	 CXCL10	 production	 in	 tumors	
upon	intratumoral	3pRNA	transfection	as	indicated	by	Figure	30A.	Importantly,	addition	of	vitamin	C	
to	 3pRNA	 therapy	 further	 augmented	 the	 expression	 of	 the	 immunostimulatory	 cytokine,	 while	
vitamin	C	alone	did	not	induce	CXCL10	expression.	Similar	results	were	obtained	when	CXCL10	mRNA	
was	quantified	in	tumor	biopsies	(Figure	30B).		
The	tumors	were	additionally	analyzed	 for	expression	of	melanoma	differentiation	markers	
to	assess	the	influence	of	vitamin	C	on	EMT	in	vivo.	In	concordance	with	gp100	protein	expression	in	
hypoxic	 B16F10	 cells	 (Figure	 26B),	 tumors	 also	 exhibited	 significantly	 increased	 gp100	 mRNA	
expression	upon	3pRNA	therapy,	either	with	or	without	vitamin	C	treatment	(Figure	31A).	Likewise,	
the	mRNA	expression	of	tyrosinase-related	protein-2	(TRP2)	was	upregulated	by	3pRNA	alone	and	in	
combination	with	vitamin	C	(Figure	31B).	The	combinatorial	approach	furthermore	led	to	a	slight	but	
significant	enhancement	of	tyrosinase	expression	as	compared	to	untreated	tumors	(Figure	31C).	
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Altogether,	these	results	indicate	the	transition	of	melanoma	cells	into	a	more	differentiated	state	by	
3pRNA	 treatment	 in	 vivo.	 Although	 vitamin	C	 did	 not	 significantly	 enhance	 differentiation,	 it	
supported	 the	 formation	 of	 a	 pro-inflammatory	 tumor	 microenvironment	 by	 enhancing	 3pRNA-
mediated	CXCL10	production,	thus	potentially	facilitating	immune	cell	responses.	
	
Figure	 30:	 Vitamin	C	 enhances	 3pRNA-induced	 CXCL10	 release	 in	 B16	
tumors.	(A-B)	Established	subcutaneous	tumors	were	treated	with	3pRNA	
(i.t.)	 and	 vitamin	C	 (i.p.)	 as	 indicated.	 (A)	 Immunohistochemistry	 of	
CXCL10	 (red)	 and	 H&E-staining	 (blue)	 on	 tumor	 slices.	 Left	 panel:	
magnification	 of	 10x,	 scale	 bar	 represents	 200	µm.	 Right	 panel:	
magnification	of	40x,	scale	bar	represents	50	µm.	Representative	pictures	
of	two	mice	per	group	are	shown.	(B)	CXCL10	mRNA	expression	in	tumors	
as	normalized	to	actin.	Mean	and	+/-SEM	of	three	to	five	mice	per	group	
are	 shown.	 Statistical	 analysis	 was	 performed	 using	 student’s	 t-test.	
*	(p	<	0.05),	 **	(p	<	0.01).	 ns:	 not	 significant,	 w/o:	 without	 treatment,	
Vit	C:	vitamin	C	
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Figure	 31:	 Differentiation	 antigen	 expression	 in	 vitamin	C-	 and	 3pRNA-treated	 B16	 tumors.	 (A-C)	 Established	
subcutaneous	 tumors	 were	 treated	 with	 vitamin	C	 (i.p.)	 and	 3pRNA	 (i.t.)	 as	 indicated.	 mRNA	 expression	 of	 the	
differentiation	antigens	gp100	(A),	TRP2	(B)		and	tyrosinase	(C)	was	determined	in	tumor	samples	and	normalized	to	actin.	
Mean	 and	 +/-SEM	 of	 three	 to	 five	mice	 per	 group	 are	 shown.	 Statistical	 analysis	 was	 performed	 using	 student’s	 t-test.	
*	(p	<	0.05),	**	(p	<	0.01).	ns:	not	significant,	w/o:	without	treatment,	Vit	C:	vitamin	C	
	
Investigation	of	 immune	 cell	 activity	within	B16	 tumors	 firstly	 revealed	an	 increase	of	MDSC	upon	
3pRNA	 treatment.	 This	 was	 indicated	 by	 a	 significant	 increase	 in	 Gr-1	mRNA	 expression	 in	 tumor	
samples	(Figure	32A)	and	higher	numbers	of	CD11b+	Gr-1+	NK1.1-	CD3-	cells	as	determined	by	flow	
cytometry	(Figure	32B).	On	the	one	hand,	this	observation	revealed	a	negative	side	effect	of	3pRNA	
therapy	 as	 MDSC	 are	 known	 to	 suppress	 anti-tumor	 immunity	115.	 On	 the	 other	 hand,	 3pRNA	
treatment	was	able	to	strongly	induce	NK	cell	activation	in	tumor-draining	lymph	nodes	as	shown	by	
upregulation	of	the	activation	markers	CD69	and	CD11c	(Figure	32C).	Both,	MDSC	infiltration	and	NK	
cell	 activation	 were	 not	 significantly	 influenced	 by	 addition	 of	 vitamin	C	 to	 3pRNA	 therapy.	 In	
contrast,	 solely	 the	combination	of	both	compounds	enabled	NK	cell	 infiltration	 into	 the	 tumors,	a	
necessary	prerequisite	to	exert	their	anti-tumor	effects	(Figure	32D).	
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Figure	32:	Effects	of	vitamin	C-supported	3pRNA	therapy	on	immune	cell	subsets.	(A-D)	Established	subcutaneous	tumors	
were	 treated	 as	 indicated.	 (A)	 Expression	 of	 Gr-1	mRNA	 in	 tumor	 samples	 as	 normalized	 to	 actin.	 (B)	 Quantification	 of	
CD11b+	Gr-1+	MDSC	in	tumors	by	FACS	analysis.	(C)	Activation	of	NK	cells	in	tumor-draining	lymph	nodes	as	determined	by	
their	CD69	(left	panel)	and	CD11c	(right	panel)	expression.	Mean	and	+/-SEM	of	three	to	five	mice	are	shown.	(D)	Amount	
of	NK1.1+	 cells	 in	 tumor	 samples.	 Left	 panel:	Mean	 and	+/-SEM	of	 four	 to	 five	mice.	Right	 panel:	 A	 representative	 flow	
cytometry	 analysis.	 Statistical	 analysis	 was	 performed	 using	 student’s	 t-test.	 *	(p	<	0.05),	 **	(p	<	0.01),	 ***	(p	<	0.001),	
****	(p	<	0.0001).	ns:	not	significant,	w/o:	without	treatment,	Vit	C:	vitamin	C,	dLN:	draining	lymph	node	
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The	 overall	 beneficial	 role	 of	 vitamin	C	 addition	 to	 3pRNA	 therapy	was	 finally	 demonstrated	 by	 a	
more	profound	inhibition	of	tumor	growth	in	comparison	to	3pRNA	alone	(Figure	33A)	and	improved	
survival	of	mice	treated	with	the	combinatorial	approach	(Figure	33B).	
In	 summary,	 vitamin	C	 proved	 suitable	 for	 the	 re-establishment	 of	 3pRNA-triggered	 RIG-I	
expression	 in	 hypoxic	 melanoma	 cell	 cultures	 and	 could	 enhance	 3pRNA-induced	 anti-tumor	
immunity	in	a	transplantable	murine	melanoma	model.			
	
	
Figure	 33:	 Improved	 3pRNA-mediated	 inhibition	 of	 tumor	 growth	 by	 vitamin	C	 supplementation.	 (A-B)	 Established	
subcutaneous	tumors	were	treated	with	vitamin	C	(i.p.)	and	3pRNA	(i.t.)	at	the	indicated	time	points.	(A)	Tumor	growth	as	
measured	 daily.	 Mean	 and	 +/-SEM	 of	 five	 mice	 per	 group	 are	 shown.	 (B)	 Survival	 curves	 using	 five	 mice	 per	 group.	
Statistical	analysis	was	performed	using	student’s	t-test.	*	(p	<	0.05),	**	(p	<	0.01),	***	(p	<	0.001).	ns:	not	significant,	Vit	C:	
vitamin	C	
	
All	 in	 all,	 the	 here	 presented	 results	 establish	 that	 functional	 3pRNA-triggered	 RIG-I	 signaling	
outcome	 is	 not	 substantially	 affected	 by	 hypoxia.	 This	 was	 demonstrated	 by	 unchanged	 ISG,	
MHC	class-I	 and	 PDL-1	 expression	 as	 well	 as	 functional	 T-	 and	 NK	 cell	 activation,	 although	 the	
cytokine	expression	of	melanoma	cells	was	modulated.	Thus,	3pRNA-induced	RIG-I	 signaling	seems	
to	 resist	 the	 hypoxia-mediated	 attenuation	 of	 RLR	 protein	 upregulation	 and	 IFNα	 desensitization.	
Thereby	 3pRNA	 is	 superior	 to	 IFNα	 regarding	 anti-tumor	 therapy	 of	 hypoxic	melanoma	 cells.	 The	
results	further	suggest	vitamin	C	 is	a	suitable	adjuvant	to	3pRNA	therapy	as	 it	allows	restoration	of	
RIG-I	expression	in	hypoxic	cells	in	vitro	and	boosts	cytokine	release	and	anti-tumor	immunity	in	vivo.		
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6 Discussion	
	
To	ensure	efficient	and	successful	development	of	novel	anti-cancer	therapeutics	it	is	fundamental	to	
study	the	influence	of	tumor	microenvironmental	factors	like	hypoxia	on	drug	function.	This	premise	
also	holds	true	for	the	translation	of	RIG-I-activating	3pRNA	compounds	into	the	clinics,	which	have	
so	 far	 achieved	encouraging	pre-clinical	 results	 in	 immunotherapy	of	malignant	melanoma,	 among	
other	 tumors.	 The	 present	 study	 therefore	 investigated	 the	 impact	 of	 oxygen	 deprivation	 on	 the	
RIG-I	 response	 in	melanoma	cells,	 finding	RIG-I	protein	upregulation	 to	be	 reduced	under	hypoxia.	
Intriguingly,	major	regulatory	components	of	the	RIG-I	signaling	pathway	were	not	affected,	 just	as	
the	overall	signaling	outcome,	comprising	the	induction	of	apoptosis,	expression	of	ISGs,	MHC	class-I	
and	 PDL-1	 as	 well	 as	 the	 activation	 of	 melanocyte	 antigen-specific	 CD8+	 T-cells	 and	 NK	 cells.	 In	
contrast,	 recombinant	 IFNα	 lost	 its	capacity	to	 induce	 immune	activation	upon	oxygen	deprivation.	
Assuming	that	3pRNA	therapy	could	still	benefit	from	reestablishment	of	RIG-I	levels	under	hypoxia,	
ROS	 scavenging	 via	 vitamin	C	was	 discovered	 to	 reinstate	 protein	 expression	 in	 vitro	 and	 enhance	
intratumoral	 cytokine	 production	 and	 anti-tumor	 efficacy	 in	 vivo.	 These	 results	 shed	 light	 on	 the	
function	of	RIG-I	under	oxygen	conditions	 likely	encountered	 in	many	 solid	 tumors,	 reasoning	 that	
3pRNA-mediated	 immunotherapy	 is	 superior	 to	 IFNα	 treatment	 and	 offering	 additional	
combinatorial	strategies	to	further	improve	anti-tumor	reactivity.	
	
6.1 Dissecting	IFNα	desensitization	and	differential	RIG-I	mRNA	and	protein	levels	
Since	 1995	 recombinant	 IFNα	 is	 an	 approved	 therapy	 for	 melanoma	 and	 other	 types	 of	 cancer.	
Therefore	it	was	quite	surprising	to	find	that	IFNα	lost	its	potential	to	induce	mRNA	expression	of	the	
cytokine	CXCL10	and	different	ISGs	as	well	as	to	trigger	upregulation	of	MHC	class-I	and	PDL-1	under	
hypoxia,	indicative	for	loss	of	its	anti-tumor	activity.	Yet,	these	results	can	be	explained	by	reduction	
of	IFNαR	expression	on	hypoxic	melanoma	cells,	limiting	initiation	of	the	Jak/STAT	signaling	cascade.	
This	is	in	line	with	previously	described	hypoxia-induced	IFNαR1	downregulation	in	a	PERK	(PRKP-like	
endoplasmic	reticulum	kinase)-	and	eIF2α	(eukaryotic	translation	initiation	factor	2	alpha)-dependent	
manner,	which	 resulted	 in	 reduced	 cancer	 cell	 sensitivity	 to	 IFNα	 and	 prevention	 of	 apoptosis	105.	
Even	much	 earlier	 Naldini	 et	 al.	 had	 also	 observed	 an	 inhibition	 of	 the	 anti-proliferative	 effect	 of	
interferons	 under	 hypoxia	116.	 Of	 note,	 this	 observation	was	 restricted	 to	 tumor	 cell	 lines	 showing	
increased	proliferation	upon	reduction	of	oxygen	tension.	On	the	other	hand	the	same	group	found	
hypoxia	 to	 enhance	 the	 antiviral	 activity	 of	 IFNα	 and	 IFNγ	117.	 Importantly,	 the	 latter	 study	 was	
performed	with	those	cells	that	did	not	lose	their	sensitivity	to	IFN	in	the	proliferation	study.	These	
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findings	 indicate	 that	 the	 effect	 of	 hypoxia	 on	 the	 function	 of	 IFNα	 largely	 depends	 on	 the	
investigated	 cell	 lines	 as	 their	 differentiation,	 proliferation	 and	metabolic	 behavior	 are	 differently	
influenced	 by	 oxygen	 deprivation.	 Altogether	 hypoxia-mediated	 desensitization	 to	 IFNα	 might	
explain	 the	 group	 of	 non-responders	 among	 patients	 receiving	 IFNα	 therapy.	 As	 part	 of	 future	
personalized	cancer	treatment	it	might	thus	be	worthwhile	to	assess	the	hypoxic	status	of	individual	
tumors	and	deduce	their	IFNα	sensitivity.	
	
In	 contrast	 to	 IFNα,	 the	3pRNA-induced	mRNA	expression	and	overall	RIG-I	 signaling	outcome	was	
not	suppressed	upon	oxygen	deprivation.	How	is	this	possible	taking	into	account	that	RIG-I	protein	
amounts	were	significantly	reduced	and	that	proper	RIG-I	signaling	function	relies	on	an	intact	 IFN-
mediated	 feed-forward	 loop	30?	 Firstly,	 remaining	 RIG-I	 and	 IFNαR	 expression	 levels	might	 still	 be	
high	enough	to	enable	the	establishment	of	a	complete	response	to	3pRNA	transfection.	Secondly,	
the	 function	 of	 signaling	 molecules	 downstream	 of	 the	 IFNαR,	 for	 example	 of	 the	 transcriptional	
activators	 STAT1,	 STAT2	or	 STAT5,	might	 be	 enhanced	 and	 thus	 compensate	 for	 reduced	 receptor	
expression.	While	 studies	 on	 STAT1	 reported	 hypoxia-mediated	 repression	 of	 transcription	 on	 the	
one	hand	and	enhanced	activation	through	phosphorylation	on	the	other	hand,	STAT5	is	consistently	
found	to	be	activated	upon	oxygen	deprivation	 in	different	cell	 types	118–120.	These	 two	hypotheses	
would	further	include	the	assumption	that	IFN,	which	is	produced	as	a	secondary	signaling	molecule	
upon	 RIG-I	 activation	 (and	 that	 is	 actually	 increased	 under	 hypoxia),	 holds	 a	 stronger	 potential	 to	
initiate	 transcription	 of	 ISGs	 than	 recombinant	 IFN,	 that	 is	 added	 to	 cell	 culture	 medium	 and	
functions	as	the	first	and	only	signal.	Alternatively	and	more	simple,	 this	might	also	be	a	matter	of	
IFNα	 concentrations	 produced	 upon	 RIG-I	 activation	 versus	 direct	 treatment.	 Lastly,	 mRNA	
expression	of	the	 investigated	targets	might	not	exclusively	rely	on	 IFN	signaling,	but	could	also	be	
induced	 directly	 by	 RIG-I-dependent	 IRF3/IRF7	 and	 NFκB	 activation.	 Transcription	 of	 CXCL10	 for	
example	 can	 be	 elicited	 by	 both	 transcription	 factors	 and	 a	NFκB	 binding	 site	 is	 predicted	 for	 the	
RIG-I	promoter	121,122.	This	hypothesis	is	further	supported	by	an	observation	of	Ellermeier	et	al.	who	
found	functional	3pRNA-stimulated	RIG-I	signaling,	including	CXCL10	and	MHC	class-I	upregulation,	in	
a	pancreatic	cancer	cell	line	that	lacked	IFNβ	production	due	to	a	deletion	in	the	respective	gene	68.	
	
Interestingly,	 hypoxia	 has	 been	 found	 to	 decrease	 expression	 of	 another	 PRR,	 namely	 TLR4,	 in	
endothelial	 cells	 in	 a	 ROS	 dependent	 manner	123.	 This	 process	 relied	 on	 attenuation	 of	 the	
transcriptional	activity	of	activator	protein	1	(AP-1)	and	a	respective	binding	site	is	predicted	to	exist	
also	 in	the	RIG-I	promoter.	Still,	 it	 is	unlikely	that	a	similar	mechanism	prevents	RIG-I	expression	 in	
hypoxic	melanoma	cells,	 since	3pRNA-induced	RIG-I	mRNA	upregulation	was	unaffected	by	oxygen	
deprivation.	 In	contrast,	RIG-I	and	CXCL10	expression	was	solely	reduced	on	the	protein	level.	Such	
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differences	 can	 be	 either	 caused	 by	 posttranscriptional	 mechanisms,	 translational	 regulation	 or	
protein	turnover.	While	the	latter	could	be	largely	ruled	out,	as	inhibition	of	protein	degradation	by	
proteasome-blockade	 did	 not	 reinstate	 hypoxic	 RIG-I	 levels	 to	 normoxic	 amounts,	 changes	 in	
translational	 regulation	 definitely	 play	 an	 important	 role	 during	 cellular	 adaptation	 to	 hypoxic	
microenvironments.	 Although	 translation	 can	 be	 regulated	 within	 every	 step	 of	 the	 translation	
process,	 that	 is	 initiation,	elongation	and	 termination,	hypoxia	generally	 causes	a	 switch	 from	cap-
dependent	to	cap-independent	translation	124.	As	a	result,	a	global	reduction	of	translational	activity	
is	 induced	125,	 whereas	 protein	 synthesis	 of	 certain	 mRNA	 transcripts	 is	 enhanced.	 This	 can	 be	
mediated	 for	 example	 by	 inhibitory	 upstream	 open	 reading	 frames,	 that	 are	 translated	 under	
normoxic,	 but	 ignored	 under	 hypoxic	 conditions,	 depending	 on	 eIF2α	 phosphorylation	126.	
Furthermore,	 internal	 ribosomal	 entry	 sites,	 like	within	 the	 5’-untranslated	 region	 of	 VEGF	mRNA,	
enable	 cap-independent	 initiation	 of	 translation	 upon	 oxygen	 deprivation	127.	 Such	 modulation	 of	
translational	 activity	 might	 well	 be	 involved	 in	 the	 observed	 differential	 expression	 of	 RIG-I	 and	
CXCL10	mRNA	and	protein	amounts.	It	is	additionally	tempting	to	speculate	on	a	role	for	microRNAs	
(miRNA)	 in	 this	 process,	 as	 these	 short,	 endogenous,	 non-coding	 RNAs	 mediate	 degradation	 or	
translational	 suppression	of	 their	 specific	 target	mRNAs.	Not	very	surprisingly,	hypoxia	possesses	a	
very	 specific	 miRNA	 signature,	 with	 some	 of	 the	 transcripts	 being	 directly	 induced	 by	 HIF1α	128.	
Among	 these	 hypoxia-regulated	miRNAs	miR-210	 is	 the	 only	 one	 consistently	 upregulated	 in	 both	
healthy	 and	 cancerous	 hypoxic	 cells	 and	 thus	 is	 considered	 a	 master	 regulator	 of	 the	 hypoxic	
response	129.	 Interestingly,	 miR-210	 has	 been	 found	 to	 inhibit	 the	 LPS-induced	 production	 of	
proinflammatory	 cytokines	 by	 targeting	 NFκB1	 in	 murine	 macrophages	130.	 This	 links	 hypoxia-
dependent	 miRNA	 upregulation	 with	 reduced	 expression	 of	 inflammatory	 proteins	 following	 PRR	
activation.	Although	degradation	of	RIG-I	and	CXCL10	mRNA	was	not	enhanced	 in	hypoxic,	3pRNA-
transfected	 cells	 in	 this	 study,	 a	 miRNA-mediated	 inhibition	 of	 translation	 is	 conceivable	 and	
deserves	further	investigation.	
Translational	 regulation,	 including	 the	 switch	 from	 cap-dependent	 to	 cap-independent	
protein	synthesis,	likewise	plays	an	important	role	in	the	process	of	EMT,	which	is	characterized	by	a	
shift	of	the	protein	expression	profile	from	a	proliferative,	epithelial-like	to	a	motile,	mesenchymal-
like	state	131.	Hence,	inhibition	of	RIG-I	upregulation	might	be	a	direct	consequence	of	hypoxia	itself	
or	result	from	hypoxia-induced	EMT.	A	relation	between	RIG-I	and	the	differentiation	status	of	cells	is	
not	very	 farfetched,	 since	RIG-I	was	originally	 identified	as	being	 induced	 in	 retinoic	acid-mediated	
cell	differentiation	15.	Moreover,	within	this	thesis	prevention	of	EMT	through	the	treatment	of	cells	
with	 NFκB	 inhibitors	 allowed	 partial	 reestablishment	 of	 3pRNA-triggered	 RIG-I	 expression	 under	
hypoxia.	Together,	this	argues	for	an	involvement	of	EMT	in	the	attenuation	of	RIG-I	translation	and	
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suggests	 a	 consecutive	process	of	 hypoxia,	 EMT	and	3pRNA-dependent	RIG-I	 expression	 in	murine	
melanoma	cells.		
	
6.2 Differential	regulation	of	RIG-I	and	MDA5	under	hypoxia	
Even	though	3pRNA-induced	RIG-I	protein	upregulation	was	reduced	under	hypoxia	as	compared	to	
normoxic	 conditions,	protein	 levels	were	 still	 increased	above	basal	 expression.	 In	 contrast,	MDA5	
expression,	activated	by	its	ligand	poly-I:C	or	the	induction	of	IFN-signaling	by	3pRNA	or	recombinant	
IFNα,	was	not	enhanced	above	basal	 levels	upon	oxygen	deprivation.	Consequently,	RIG-I	 function	
not	 only	 seems	 superior	 to	 IFNα	 treatment	 but	 also	 provides	 advantages	 over	MDA5	 targeting	 in	
hypoxic	 tumor	 cells.	 The	 remaining	question	 is	 how	 these	 closely	 related	RIG-I	 like	 receptors,	 that	
employ	identical	signaling	cascades	and	share	a	characteristic	domain	structure,	can	be	differentially	
affected	by	oxygen	deprivation.	If	attenuation	of	RIG-I	as	well	as	MDA5	protein	upregulation	relies	on	
EMT-related	modulation	of	translation,	this	observation	might	be	explained	by	individual	regulation	
of	 RIG-I-	 and	MDA5	 translation.	 This	would	 consequently	 raise	 the	question	why	 such	 functionally	
similar	 proteins	 are	 regulated	 differentially.	 It	 might	 thus	 well	 be,	 that	 additional	 or	 alternative	
mechanisms	are	involved.	
Initiation	 of	 downstream	 signaling	 involves	 the	 assembly	 of	 MDA5	 into	 ATP-sensitive	
filaments	 using	 dsRNA	 as	 a	 scaffold.	 Thereby,	 several	 CARDs	 are	 brought	 into	 close	 proximity	 and	
subsequently	 stack	 with	MAVS	 CARDs,	 which	 allows	 signalosome	 formation	132.	 RIG-I	 can	 similarly	
form	 filaments	upon	activation,	albeit	 these	are	 shorter	and	 less	 stable	 than	 those	of	MDA5	133,134.	
Alternatively,	 K63-polyubiquitin	 chains	 promote	 RIG-I	 tetramerization,	 leading	 to	 the	 assembly	 of	
MAVS	 into	 its	 active	 polymeric	 form	39.	 Although	 polyubiquitin	 may	 also	 play	 a	 role	 in	 MDA5-
signaling,	 its	 physiological	 role	 is	 less	 well	 understood	 and	MDA5	 is	 considered	 to	 have	 a	 higher	
propensity	 to	 form	 filaments	 than	 RIG-I	38,135.	 Increased	 availability	 of	 K63-polyubiquitin	 under	
hypoxic	conditions	could	thus	favor	RIG-I-mediated	signaling,	leaving	MDA5	without	any	benefit.	Yet,	
although	recently	peroxide	was	found	to	induce	the	accumulation	of	K63-polyubiquitin	and	the	here	
applied	 hypoxia	 regimen	 enhanced	 the	 production	 of	 ROS	 in	 melanoma	 cells,	 differences	 in	 K63-
polyubiquitination	 of	 whole	 cell	 lysates	 could	 not	 be	 observed	 between	 normoxic	 and	 hypoxic	
conditions	136.		
Another	potential	mechanism	that	would	allow	sophisticated	regulation	of	RIG-I	and	MDA5	
signaling	 involves	 the	 third	RLR	 family	member	LGP2,	which	 is	capable	of	binding	dsRNA,	but	 lacks	
any	 CARDs,	 therefore	 being	 unable	 to	 signal	 via	 MAVS.	 Instead,	 LGP2	 represses	 RIG-I	 signaling	
potentially	by	competing	 for	 its	 ligand	and	on	 the	contrary	enhances	MDA5	signaling	via	an	as	yet	
unknown	mechanism	137,138.	 Hypoxia-induced	 loss	 of	 LGP2	 expression	 or	 function	 could	 hence	 free	
RIG-I	 from	 its	 inhibitory	 ties	 and	 at	 the	 same	 time	 withdraw	 a	 stimulating	 co-factor	 from	MDA5	
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signaling.	This	hypothesis	deserves	closer	investigation	in	the	future	and	should	help	understanding	
the	individual	regulation	of	two	closely	related	signaling	pathways.			
	
6.3 Cytokine	expression	patterns	and	cellular	differentiation			
Investigating	the	influence	of	oxygen	deprivation	on	3pRNA-induced	cytokines	revealed	an	increase	
of	 type-I	 IFN	 and	 TNFα,	 whereas	 CXCL10	 was	 decreased	 and	 IL-6	 remained	 stable.	 The	 fact	 that	
certain	 molecules	 are	 up-	 and	 others	 are	 downregulated	 argues	 for	 a	 distinct	 hypoxia-mediated	
modulation	 of	 cytokine	 expression,	 rather	 than	 a	 mere	 change	 of	 3pRNA	 dose-sensitivity,	 which	
would	equally	reduce	all	3pRNA-induced	factors.	Hypothetically,	the	enhanced	type-I	IFN	production	
might	at	least	in	part	compensate	for	loss	of	IFNαR	expression	in	hypoxic	cells	and	thereby	contribute	
to	 the	preservation	of	3pRNA-induced	 signaling	outcome	 in	 contrast	 to	direct	 IFNα	 treatment	 (see	
above).		
	
3pRNA-induced	 expression	 of	 selected	 cytokines,	 namely	 CXCL10	 and	 IL-6,	 exhibited	 variable	
sensitivity	 towards	 oxygen	 deprivation	 in	 different	 cell	 lines.	 Additionally,	 attenuation	 of	 RIG-I	
protein	 upregulation	 was	 restricted	 to	 malignant	 melanoma	 cells	 and	 did	 not	 occur	 in	 the	
melanocyte	 cell	 line	Melan-A	 and	 keratinocyte	 cell	 line	Kera-308.	 It	 is	 not	 surprising	 that	 cell	 lines	
react	differently	to	environmental	stress	factors	depending	on	their	tissue	of	origin	and	variations	in	
their	 differentiation	 status.	 For	 example,	 Melan-A	 is	 a	 cell	 line	 of	 non-tumorigenic	 pigmented	
melanocytes	 that	 require	 a	 tumor	 promoter	 for	 growth	139.	 Together	 with	 Kera-308,	 which	 were	
generated	from	DMBA	(7,12-Dimethylbenzo(a)anthracen)-initiated	mouse	skin	and	resemble	normal	
epidermal	 basal	 cells,	 Melan-A	 rank	 among	 the	 differentiated	 cells	 of	 the	 investigated	 panel	140.	
HCmel17	 and	 HCmel23	 that	 derive	 from	 the	 HGF-Cdk4R24C	 model	 of	 spontaneous	 autochthonous	
melanoma	110	 are	 characterized	by	 their	 chemoresistance	 and	 ability	 to	metastasize	 and	 represent	
the	 most	 dedifferentiated	 cells		 (unpublished	 data,	 T.	 Tüting).	 The	 obtained	 results	 suggest	 a	
stepwise	modification	of	 the	3pRNA-induced	RIG-I	 and	cytokine	pattern	 from	unaffected	RIG-I	 and	
reduced	CXCL10	and	IL-6	expression	 in	differentiated	cell	 lines	to	attenuated	RIG-I	and	CXCL10	and	
unaffected	IL-6	expression	in	dedifferentiated	cells,	when	comparing	hypoxic	to	normoxic	incubation.	
HCmel3	 cells,	 which	 have	 an	 intermediate	 differentiation	 status,	 exhibited	 diminished	 RIG-I	
upregulation	 alike	 dedifferentiated	 cells,	 but	 cytokine	 expression	 resembled	 differentiated	 cells.	
Together	these	observations	strengthen	evidence	for	a	relation	of	EMT	and	RIG-I	protein	expression.		
Like	 the	 other	 non-malignant	 cell	 lines	 (Melan-A,	 Kera	 308)	 primary	 murine	 splenocytes	
induced	RIG-I	protein	levels	equally	well	under	both	oxygen	conditions.	The	finding	that	attenuation	
of	RIG-I	 upregulation	was	 restricted	 to	malignant	 cell	 lines	 raises	 the	question	of	 how	cancer	 cells	
might	benefit	from	a	reduction	of	their	RIG-I	translation	under	hypoxia.	Protein	translation	is	a	major	
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ATP-consumer	141,	hence	limiting	RIG-I	upregulation	in	hypoxic	cancer	cells	might	save	much-needed	
energy,	while	maintaining	sufficient	anti-viral	immunity	with	residual	RIG-I	expression.	Yet,	tumor	cell	
growth	is	not	necessarily	limited	by	its	energy	demands,	as	the	ATP	amount	required	for	proliferation	
may	not	exceed	that	for	cellular	maintenance	142.	Alternatively,	one	might	envision	the	existence	of	
an	evolutionary	pressure	that	favors	survival	of	those	tumor	cells,	which	do	not	increase	their	RIG-I	
expression	upon	3pRNA	detection	under	hypoxia.	This	hypothesis	 is	based	on	 the	assumption	 that	
very	 low	cytosolic	concentrations	of	RIG-I	 ligands	might	not	be	able	to	elicit	a	 fully	 functional	RIG-I	
response	 under	 hypoxia,	 other	 than	 the	 here	 investigated	 3pRNA	 amounts.	 Genetic	 instability,	 a	
well-established	 trait	 of	 cancer	 cells	 describing	 elevated	 levels	 of	 mutations,	 chromosomal	
aberrations	 and	 epigenetic	 alterations,	 can	 be	 fostered	 by	 oxygen	 deprivation	 and	 might	 lead	 to	
accumulation	of	misplaced	or	aberrant	nucleic	acids	143,144.	Thus,	in	hypoxic	cancer	cells	endogenous	
RIG-I	ligands	may	be	generated,	driving	immunity	and	apoptosis,	although	eukaryotic	mRNA	normally	
does	 not	 activate	 the	 receptor	 due	 to	 its	 5’-cap	 structure	 and	 2’-O-methylation	 of	 the	 terminal	
nucleotide	23.	Therefore,	those	cancer	cells	within	the	heterogeneous	tumor	cell	population	that	are	
inert	to	unmodified	self-RNAs	by	being	unable	to	upregulate	RIG-I	may	have	a	growth	advantage	and	
are	evolutionary	selected.		
In	 summary,	 malignant	 melanoma	 cells	 attenuate	 3pRNA-induced	 RIG-I	 protein	 expression	
upon	 oxygen	 deprivation	 in	 relation	 to	 EMT.	 This	 possibly	 provides	 cancer	 cells	 with	 survival-
advantages	 in	 a	 hypoxic	 environment	 such	 as	 energy-savings	 or	 resistance	 to	 enhanced	 immune	
activation	by	self-RNA.		
	
6.4 Mechanisms	of	sustained	3pRNA-dependent	immune	cell	activation	
The	functional	activation	of	immune	effector	cells	by	melanoma	cells	during	hypoxia	is	fundamental	
to	 establish	 3pRNA-mediated	 therapy	 against	 hypoxic	 solid	 tumors.	 Therefore,	 a	 very	 important	
finding	 of	 this	 study	 is	 the	 unaltered	 activation	 of	 CD8+	 T-	 and	 NK	 cells	 in	 response	 to	 hypoxic,	
3pRNA-treated	 B16F10	 and	 HCmel3	 melanoma	 cells.	 At	 the	 same	 time	 this	 observation	 is	 quite	
surprising,	 taking	 into	 account	 the	 hypoxia-induced	 loss	 of	 melanocyte	 differentiation	 antigen	
expression	 and	 a	 number	 of	 previous	 studies	 that	 rather	 point	 towards	 hypoxia-mediated	 tumor	
immune	escape.		
Since	 T-cell	 receptors	 of	 Pmel-1	 CD8+	 T-cells	 are	 genetically	manipulated	 to	 recognize	 the	
gp10025-33	antigen	145,	 a	 strong	 reduction	 in	gp100	expression,	as	observed	 for	hypoxic	B16F10	and	
HCmel3	 cells,	would	 argue	 for	 diminished	 receptor	 –	 antigen	 interaction	 and	 less	 T-cell	 activation.	
Yet,	 attenuation	 of	 the	 protein’s	 expression	 does	 not	 instantly	 have	 to	 result	 in	 reduced	 antigen	
presentation,	for	the	respective	processing	machinery	might	still	be	saturated	with	gp100	peptides.	
Moreover,	 a	 genome-wide	 mRNA	 expression	 analysis	 in	 human	 umbilical	 vein	 endothelial	 cells	
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showed	 upregulation	 of	 the	 antigen	 processing	 and	 presentation	 pathway	 upon	 cobalt	 chloride-
induced	hypoxia	146.	Such	mechanism	could	allow	for	more	efficient	processing	and	MHC	loading	of	
residual	 gp100	 antigen	 stably	 present	 in	 the	melanosome	 pigment	 granules.	 Additionally,	 hypoxia	
has	been	shown	to	augment	the	capacity	of	DCs	and	macrophages	to	present	antigen,	for	example	
by	 likewise	 enhanced	 expression	 of	 the	 antigen	 processing	 machinery	 or	 via	 upregulation	 of	 co-
stimulatory	molecules	147–149.	 Utilizing	 an	 in	 vivo	model	 Calzascia	 et	 al.	 reported	 that	 TNFα	 and	 its	
respective	 receptors	 are	 required	 for	 effective	 T-cell	 priming,	 proliferation	 and	 optimal	 cytokine	
production	 in	 a	 situation	where	 other	 immunostimulatory	 components	 are	 limited,	 like	within	 the	
tumor	 microenvironment	150.	 Since	 3pRNA-induced	 TNFα	 expression	 was	 enhanced	 in	 hypoxic	
B16F10	 cells,	 this	 cytokine	 could	 be	 additionally	 responsible	 for	 sustained	 T-cell	 activation	 in	 co-
culture	experiments.		
Importantly,	several	studies	have	found	impaired	cancer	cell	susceptibility	to	NK	cell	and	CTL-
mediated	 lysis	 under	 hypoxia.	 One	 of	 the	 underlying	 mechanisms	 is	 the	 hypoxia-induced,	 HIF1α-
dependent	upregulation	of	PDL-1	leading	to	increased	apoptosis	of	CTLs	103.	In	contrast	to	this	latter	
report,	 PDL-1	 expression	 on	 the	 here-investigated	 B16F10	 cells	 was	 not	 intensified	 under	 hypoxia	
and	 could	 thus	 not	 reduce	 numbers	 of	 activated	 CD8+	 T-cells.	 Secondly,	 concomitant	
phosphorylation	of	STAT3	and	stabilization	of	HIF1α	as	well	as	 the	hypoxia-inducible	miR-210	have	
been	ascribed	a	role	in	the	impairment	of	cancer	cell	susceptibility	to	CTL-mediated	lysis	151,152.	Yet,	
these	studies	did	not	observe	an	alteration	of	CTL	reactivity,	which	is	 in	concordance	with	the	here	
presented	 results.	 Similarly,	 hypoxic	 tumor	 cells	 can	 escape	 NK	 cell-mediated	 killing	 through	
autophagic	degradation	of	NK	cell-derived	cytotoxic	granzyme	B,	a	mechanism	that	does	not	argue	
against	functional	initial	activation	of	NK	cells	101.	On	the	other	hand,	autophagy	has	been	shown	to	
enhance	 the	 presentation	 of	 endogenous	 viral	 antigens	 via	 an	 alternative	 MHC	class-I	 loading	
pathway	153,154.	 Taking	 into	 account	 that	 hypoxia	 can	 induce	 autophagy	 in	 a	 HIF-dependent	
and	 -independent	 manner,	 this	 mechanism	 possibly	 contributes	 to	 sustained	 T-cell	 activation	 by	
melanoma	 cells	 with	 reduced	 gp100	 expression	 by	 elevating	 their	 autophagy	 of	 melanosome	
pigment	 granules	 stably	 containing	 structural	 gp100	 proteins	155.	 To	 conclude,	 as	 tumor	 cells	 have	
different	options	to	escape	immune	cell-mediated	killing	without	directly	acting	on	the	effector	cells	
themselves,	 it	 is	 feasible	 that	 3pRNA-treated	 melanoma	 cells	 are	 destroyed	 less	 efficiently	 under	
hypoxia	although	activation	of	CD8+	T-	and	NK	cells	is	not	reduced.				
Co-culture	experiments	with	melanoma	cells	and	splenocytes	also	revealed	superior	function	
of	 3pRNA	 to	 IFNα	 therapy	 even	 under	 normoxic	 conditions.	 This	 is	 because	 high	 doses	 of	
recombinant	IFNα	only	marginally	induced	immune	cell	activation	in	contrast	to	3pRNA	transfection,	
although	 both	 treatments	 significantly	 enhanced	 MHC	class-I	 expression.	 Of	 note,	 standard	 IFNα	
therapy	is	administered	systemically,	also	acting	directly	on	immune	cells,	which	was	not	the	case	in	
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the	present	experimental	 setup.	 Still,	 in	 terms	of	 intratumoral	 application,	 the	anti-tumor	 immune	
response	initiated	by	RIG-I	targeting	can	be	considered	more	versatile	than	by	direct	IFNα	treatment,	
including	activation	of	CD8+	T-	and	NK	cells.		
	
6.5 Modulation	of	regulatory	components	in	hypoxic	RIG-I	signaling	
Although	 attenuation	 of	 3pRNA-induced	 RIG-I	 protein	 expression	 under	 hypoxia	 could	 be	 largely	
attributed	to	posttranscriptional	or	translational	effects,	the	investigation	of	regulatory	components	
of	the	RIG-I	signaling	pathway	revealed	some	interesting	hypoxia-related	changes.		
Firstly,	 inhibition	of	the	proteasome	led	to	a	reduction	of	3pRNA-triggered	RIG-I	expression	
particularly	 in	hypoxic	 cells.	 This	argues	against	 increased	RIG-I	protein	degradation	under	hypoxia	
being	 responsible	 for	 diminished	 protein	 upregulation	 as	 discussed	 above.	 Instead,	 proteasomal	
degradation	 of	 some	 other	 factor	 seems	 to	 be	 necessary	 to	 maintain	 residual	 RIG-I	 expression,	
leaving	 the	 question	 for	 the	 identity	 of	 this	 molecule.	 Since	 LGP2	 can	 repress	 RIG-I	 signaling	
potentially	by	competing	for	its	 ligand,	maintained	LGP2	degradation	might	be	required	for	3pRNA-
induced	 RIG-I	 protein	 expression	137.	 Also,	 according	 to	 findings	 of	 Castanier	 and	 colleagues	
proteasomal	 cleavage	 of	MAVS	 is	 necessary	 to	 liberate	 the	 assembled	 signaling	 complex	 into	 the	
cytosol,	which	 then	 allows	 IRF3	 phosphorylation	156.	 Additionally,	 functional	 protein	 degradation	 is	
essential	 for	 the	 release	 of	 NFκB	 from	 its	 inhibitory	 partner	 IκB	 and	 its	 subsequent	 nuclear	
translocation.	 Consequently,	 clearance	of	 the	 competitive	 receptor	 LGP2,	 direct	 RIG-I	 induction	by	
putative	 NFκB	 binding	 sites	 as	 well	 as	 IFN-dependent	 feed-forward	 signaling	 is	 hampered	 upon	
proteasome-blockade.	 Under	 hypoxia	 this	 could	 add	 to	 translational	 repression	 by	 EMT	 and	 be	
responsible	for	absent	RIG-I	protein	upregulation.	
	 Secondly,	 the	 expression	 of	 the	 peroxisomal	 marker	 protein	 PMP70	 was	 found	 to	 be	
decreased	 in	 hypoxic	 melanoma	 cells,	 indicating	 reduced	 peroxisome	 abundance.	 This	 is	 in	
concordance	 with	 previous	 results	 showing	 hypoxia-mediated	 induction	 of	 autophagy	 and	 HIF2α-
dependent	 pexophagy	 (autophagy	 of	 peroxisomes),	 aiming	 at	 a	 reduction	 of	 those	 highly	 oxygen	
consuming	organelles	113,157.	Intriguingly,	although	hypoxia	likewise	induces	mitophagy	(autophagy	of	
mitochondria)	 and	 both	 organelles	 are	 platforms	 for	 MAVS	 signalosome	 formation,	 the	 overall	
amount	of	MAVS	was	not	significantly	altered	upon	oxygen	deprivation	158.	Of	note,	the	performed	
western	blot	analysis	 indicated	total	MAVS	protein	amounts	 in	whole	cell	 lysates	without	providing	
information	of	 its	 intracellular	 localization.	 Thus,	 it	 cannot	be	excluded	 that	 the	adaptor	protein	 is	
retained	within	 autophagosomes	not	being	 accessible	 for	RIG-I	 binding	under	hypoxia.	 Still,	 as	 the	
reduction	 of	 PMP70	 expression	was	moderate	 and	 RIG-I	 signaling	 remained	 functional,	 it	 is	more	
likely	 that	 the	extent	of	pexophagy	and	mitophagy	 remained	 low	upon	oxygen	deprivation	 so	 that	
sufficient	signaling	platforms	could	be	provided.	Moreover,	autophagic	sequestration	of	MAVS	could	
Discussion						
	
69	
be	 compensated	 for	 by	 enhanced	MAVS	mRNA	 expression,	 for	 example	 induced	 by	NOX2-derived	
ROS	as	shown	by	Soucy-faulkner	et	al.	114.	
Lastly,	when	expression	of	the	RIG-I	signaling	component	and	mitochondrial	import	receptor	
subunit	TOM70	was	investigated,	an	additional	protein	of	reduced	size	appeared	to	be	detected	by	
the	TOM70	 specific	 antibody	exclusively	 in	hypoxic	 cells.	 To	date,	no	 splice	 variants	of	 TOM70	are	
known	 that	 might	 be	 activated	 upon	 oxygen	 deprivation	 and	 could	 account	 for	 the	 respective	
western	blot	band.	Furthermore,	TOM70	assembles	with	at	 least	six	other	proteins	to	make	up	the	
TOM	complex,	which	 functions	 in	 the	 import	of	mitochondrial	precursor	proteins.	 Yet,	 all	 of	 these	
related	 proteins	 are	 smaller	 than	 the	 observed	 55	kDa	 (TOM5,	 TOM6,	 TOM7,	 TOM20,	 TOM22,	
TOM40)	and	even	though	some	of	them	can	be	posttranslationally	modified,	their	effective	position	
after	electrophoretic	separation	is	below	55	kDa	159.	Therefore,	either	a	so	far	unknown	splice	variant	
of	TOM70	is	expressed	under	hypoxia	or	the	utilized	antibody	cross-reacts	with	an	unrelated	protein	
that	 is	 specifically	 induced	 upon	 oxygen	 deprivation.	 Since	 the	 nature	 and	 function	 of	 such	 a	
potential	splice	variant	is	highly	interesting,	this	finding	longs	for	more	detailed	investigation.		
In	 summary,	 these	 observations	 indicate	 that	 many	 metabolic	 mechanisms	 influenced	 by	
hypoxia	 overlap	 with	 the	 RIG-I	 signaling	 pathway	 and	 presumably	 do	 not	 leave	 immune	 signaling	
unaffected.	While	autophagy	and	proteasomal	function	can	influence	the	RIG-I	response	as	discussed	
above,	 also	 the	 unfolded-protein	 response	 (UPR),	 that	 is	 primarily	 activated	 upon	 ER	 stress,	 is	
involved	 in	 innate	 immune	activation	via	RIG-I	as	 recently	 shown	by	Cho	and	colleagues	160.	 In	 this	
process	the	UPR	constituent	inositol-requiring-1α	(IREα)	binds	bacterial	cholera	toxin	in	the	ER	lumen	
and	 thereupon	 degrades	 endogenous	 mRNAs	 that	 subsequently	 function	 as	 RIG-I	 ligands	 in	 the	
cytosol.	Alike	autophagy,	the	UPR	can	be	induced	by	hypoxia	161.	Lastly,	also	ROS	can	have	different	
effects	on	RIG-I	signaling,	which	is	explicitly	discussed	below.	
	
6.6 The	two-sided	role	of	ROS	
Assuming	 that	 hypoxia-induced	 RIG-I	 attenuation	 related	 to	 EMT,	 it	 was	 hypothesized	 that	
prevention	of	EMT	by	ROS	scavenging	could	reinstate	RIG-I	levels	and	further	enhance	RIG-I	signaling	
in	 hypoxic	 tumor	 cells.	 This	 strategy	 is	 supported	 by	 studies	 reporting	 the	 involvement	 of	 ROS	 in	
hypoxic	 stabilization	 of	 HIF1α	 and	 the	 induction	 of	 EMT	 via	 HIF1α	 and	 TGFβ	 following	 H2O2	
treatment	162–164.	Additionally,	Shimojo	et	al.	have	successfully	deployed	ROS	scavengers	to	suppress	
hypoxia-induced	EMT	 in	pancreatic	cancer	cells	94.	Moreover,	ROS	scavenging	could	prevent	HIF1α-	
and	 HIF2α-induced	 mitophagy	 and	 pexophagy,	 thereby	 allowing	 longer	 interaction	 of	 RIG-I	 with	
MAVS,	augmenting	its	upregulation	and	function.	
On	the	contrary,	ROS	have	been	assigned	 important	stimulatory	 functions	 for	RLR	signaling	
by	 being	 critical	 for	 MAVS	 expression	 and	 efficient	 IRF3	 activation	 as	 well	 as	 by	 enhancing	 IFN	
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production	and	resistance	to	viral	infection	42,114.	That	is	why	in	parallel,	a	project	evolved	around	the	
targeted	inhibition	of	the	antioxidant	transcription	factor	Nrf2	in	combination	with	RIG-I	stimulation	
using	 a	 bi-functional	 3p-siRNA.	 Intriguingly,	 both	 approaches	 were	 successful:	 ROS	 scavenging	
reinstated	RIG-I	levels	under	hypoxia	on	the	one	hand	and	ROS	increase	by	Nrf2	silencing	enhanced	
3pRNA-triggered	cytokine	production	and	apoptosis	under	normoxia	on	the	other	hand.	This	raises	
the	question	how	inhibition	of	ROS	or	their	amplification	can	both	positively	affect	RIG-I	signaling.		
For	 a	 long	 time	 ROS	were	 solely	 known	 as	 destructive	 by-products	 that	 confer	 damage	 to	
DNA,	lipids	and	proteins.	Yet,	at	the	end	of	the	last	century,	it	became	more	and	more	appreciated	
that	ROS	additionally	function	as	distinct	signaling	molecules.	For	example,	ROS	are	 involved	 in	the	
activation	of	the	NLRP3	(NACHT,	LRR	and	PYD	domains-containing	protein	3)	inflammasome	leading	
to	 the	 secretion	 of	 proinflammatory	 IL-1β	 and	 IL-18	165.	 Furthermore,	 they	 function	 as	 second	
messengers	 in	 signal	 transduction	 from	 activated	 cytokine	 receptors	 to	 effector	 proteins,	 like	 in	
TNFα-	and	IL-1-induced	activation	of	c-Jun	NH2-terminal	kinase	(JNK)	166.	In	hypoxic	human	umbilical	
vein	endothelial	 cells	ROS	have	been	 found	 to	 regulate	 the	secretion	of	 IL-6	and	 thereby	 influence	
endothelial	permeability	167.	The	multitude	of	ROS-mediated	signaling	events	is	further	illustrated	by	
a	number	of	different	transcription	factors	that	can	be	activated	by	ROS,	including	HIF1α,	NFκB	and	
AP-1	168,169.	The	different	types	of	ROS,	mainly	superoxide	anion	(O2-.),	hydrogen	peroxide	(H2O2)	and	
the	 hydroxyl	 radical	 (OH.),	 can	 be	 generated	 enzymatically	 or	 non-enzymatically	 at	 different	
intracellular	 locations.	 Thus,	 hypoxia-induced	 ROS	 are	 produced	 at	 mitochondria,	 whereas	 the	
antioxidant	targets	of	Nrf2	regulate	ROS	made	at	mitochondria	as	well	as	in	the	cytosol	170,171.	Taking	
all	 these	 observations	 into	 account,	 it	 is	 likely	 that	 under	 normoxic	 conditions	 a	 specific	 ROS	
composition	generated	by	Nrf2	knockdown	 favors	enhanced	RIG-I	 signaling,	while	under	hypoxia	a	
different	 ROS	 composition	 induces	 EMT	 and	 concomitant	 RIG-I	 attenuation.	 Within	 the	 hypoxia	
setting	investigated	here,	it	was	hence	reasonable	to	pursue	the	strategy	of	ROS	scavenging	in	vivo.	
	
Vitamin	C	 is	 a	 commonly	 known	antioxidant	 that	has	 the	potential	 to	detoxify	ROS	by	donation	of	
one	 or	 two	 electrons	172.	 Since	 vitamin	C	 is	 also	 safe	 and	 would	 be	 readily	 applicable	 for	 clinical	
usage,	 it	was	here	considered	 to	be	 the	most	 suitable	ROS	scavenger	 in	a	model	of	 transplantable	
B16	melanoma.	Intriguingly,	the	additional	application	of	vitamin	C	improved	3pRNA	function	in	vivo,	
as	 indicated	 by	 enhanced	 CXCL10	 cytokine	 production,	 ameliorated	 tumor	 growth-inhibition	 and	
prolonged	animal	survival,	although	intratumoral	RIG-I	expression	was	not	increased	as	compared	to	
3pRNA	alone.	Whereas,	vitamin	C	efficiently	restored	diminished	RIG-I	upregulation	 in	hypoxic	cells	
in	 vitro.	 Consideration	 of	 technical	 limitations	 can	 provide	 a	 clue	 for	 this	 observation.	 Increased	
CXCL10	production	was	demonstrated	by	immunohistochemistry	of	fixed	tumor	slices,	thus	providing	
spatial	information,	showing	areas	of	low	as	well	as	very	high	cytokine	abundance.	In	contrast,	RIG-I	
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expression	was	determined	by	western	blot	analysis	of	whole	tumor	lysates,	containing	hypoxic	and	
normoxic	regions,	and	thus	reflects	the	average	intratumoral	RIG-I	expression.	Immunohistochemical	
staining	 of	 RIG-I	 can	 provide	 the	 yet	 missing	 information	 whether	 regions	 of	 increased	 CXCL10	
production	also	exhibit	enhanced	RIG-I	expression.		
In	 case	RIG-I	 expression	 remains	 to	be	unaffected	by	 supportive	 vitamin	C	 treatment	upon	
elimination	of	 these	 technical	 limitations,	 vitamin	C	might	actually	 function	differently	 as	expected	
from	the	in	vitro	situation.	Cellular	vitamin	C	uptake	is	mediated	by	two	transmembrane	transporter	
systems:	Sodium	vitamin	C	co-transporters	 (SVCTs)	 import	reduced	vitamin	C	that	 is	able	to	donate	
electrons	and	thus	eliminate	ROS	intracellularly	173.	Glucose	transporters	(mainly	GLUT1)	take	up	the	
oxidized	form	of	vitamin	C,	which	is	then	converted	into	the	reduced	state	in	a	process	that	depletes	
the	 antioxidant	 protein	 glutathione	174.	 This	 in	 turn	 causes	 the	 accumulation	 of	 ROS,	 ultimately	
leading	to	inhibition	of	glycolysis,	ATP-depletion	and	death	of	KRAS-	and	BRAF-mutated	cancer	cells,	
as	 recently	 demonstrated	 by	 Yun	et	 al.	175.	 Accordingly,	 it	 is	 conceivable	 that	 such	ROS	 increase	 is	
responsible	for	enhanced	RLR	signaling	as	discussed	above.	Yet,	the	effects	shown	by	Yun	et	al.	were	
restricted	 to	 KRAS-	 and	 BRAF-mutated	 cancer	 cells	 due	 to	 their	 increased	 GLUT1	 expression	 and	
oncogene-induced	 dependency	 on	 glycolysis,	 whereas	 B16F10	 cells	 do	 not	 possess	 these	
mutations	176.	 Together	 with	 the	 remark	 that	 plasma	 levels	 of	 oxidized	 vitamin	C	 are	 very	 low,	 as	
measured	 in	 healthy	 human	 beings,	 this	 argues	 against	 a	 similar	 ROS	 increase	 upon	 vitamin	C	
application	in	the	here	investigated	mouse	model	177.		
The	use	of	vitamin	C	 in	combination	with	 immunotherapy	would	add	a	new	chapter	 to	 the	
long-standing	 history	 of	 vitamin	C	 in	 anti-cancer	 therapy,	 which	 started	 in	 the	 mid	 1970s	 when	
double	 Nobel	 Prize	 laureate	 Linus	 Pauling	 first	 claimed	 anti-cancer	 efficacy	 of	 high-dose	
vitamin	C	178,179.	 Together	 with	 Ewan	 Cameron	 he	 showed	 that	 supplemental	 vitamin	C	 therapy	 in	
addition	 to	 routine	 treatment	 significantly	 prolonged	 survival	 of	 patients	 with	 terminal	 cancer,	 as	
22%	of	patients	receiving	vitamin	C	were	still	alive	one	year	after	date	of	untreatability	in	contrast	to	
0.4%	of	the	control	group.	While	these	promising	studies	failed	to	be	reproduced	by	two	clinical	trials	
in	 the	 beginning,	 these	 discrepancies	 could	 now	be	 ascribed	 to	 the	 different	 application	 routes	 of	
vitamin	C	 (intravenous	 vs.	 oral)	 resulting	 in	 different	 plasma	 levels	180,181.	 Moreover,	 recent	
publications	 elucidating	 the	 mechanisms	 of	 anti-tumorigenic	 effects	 have	 reactivated	 interest	 in	
vitamin	C	as	anti-cancer	agent,	in	particular	against	KRAS-	and	BRAF-mutated	tumors,	which	could	be	
effectively	 treated	 in	 the	 applied	 mouse	 model	 of	 colorectal	 cancer	175.	 Mechanistically	 vitamin	C	
induces	inhibition	of	glycolysis	resulting	in	ATP	depletion	and	tumor	cell	death	175,182.	Interestingly,	a	
key	role	of	vitamin	C	treatment	could	also	be	attributed	to	a	diminished	expression	and	activation	of	
HIF1	183,184.	Therefore,	a	combinatorial	 therapy	of	RIG-I	 ligand	and	vitamin	C	might	not	only	benefit	
from	an	enhanced	immunostimulatory	microenvironment,	but	also	from	the	inhibition	of	metabolic	
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changes.	An	additional	advantage	is	the	established	safety	profile	of	vitamin	C,	which	makes	it	readily	
applicable	 for	 3pRNA	 combination	 therapy.	 In	 conclusion,	 the	ROS	 scavenging	 activity	of	 vitamin	C	
presumably	mediated	 its	 positive	 effects	 on	 3pRNA-mediated	 RIG-I	 upregulation	 in	 vitro	 and	 anti-
tumor	 function	 in	 vivo,	 rendering	 vitamin	C	 a	 promising	 adjuvant	 for	 RIG-I-targeted	 cancer	
immunotherapy.		
	
6.7 3pRNA-triggered	modulation	of	tumor	differentiation,	MDSC	and	NK	cells	
in	vivo	
To	 unravel	 the	 mechanism	 of	 vitamin	C-boosted,	 3pRNA-mediated	 anti-tumor	 immunity	 in	 the	
transplantable	melanoma	model	in	more	detail,	tumor	cell	differentiation	and	alterations	of	immune	
cell	 populations	 were	 thoroughly	 investigated.	 In	 concordance	 with	 in	 vitro	 findings	 the	 mRNA	
expression	 of	melanocytic	 differentiation	 antigens	within	 tumors	was	 hardly	 affected	 by	 vitamin	C	
treatment,	but	interestingly	was	increased	upon	3pRNA	stimulation,	again	suggesting	a	relationship	
between	RIG-I	and	differentiation.	This	work	thus	provides	evidence	for	hypoxia-induced	EMT	being	
accompanied	 by	 reduced	 3pRNA-triggered	 RIG-I	 upregulation	 as	 well	 as	 a	 direct	 role	 for	 RIG-I-
activation	in	stimulation	of	differentiation	antigen	expression	in	melanoma	cells.	Studies	performed	
on	acute	promyelocytic	leukemia	cells	indeed	established	a	function	of	RIG-I	in	all-trans	retinoic	acid-
induced	 cellular	 differentiation	 already	 before	 its	 anti-viral	 properties	 were	 uncovered	15.	 One	
underlying	mechanism	was	recently	described	by	Li	and	colleagues	who	showed	that	RIG-I	prevents	
the	 activation	 of	 AKT	 (RAC-alpha	 serine/threonine	 protein	 kinase)	 -	 mTOR	 (mammalian	 target	 of	
rapamycin)	signaling,	which	otherwise	inhibits	differentiation	185.	This	process	at	least	partly	involved	
activation	of	autophagy,	which	is	 likewise	regulated	by	mTOR.	Enhanced	autophagic	degradation	of	
melanosomes,	 containing	 melanoma	 differentiation	 antigens,	 might	 provide	 a	 stimulus	 for	 short-
term	increase	of	differentiation	antigen	transcription	to	maintain	sufficient	expression	levels.	Yet,	the	
effect	of	RIG-I	activation	on	autophagy	still	is	a	matter	of	debate,	due	to	contradictory	observations.	
While	Tormo	et	al.	 found	 that	 the	RLR	 family	member	MDA5	 induces	autophagy	upon	 stimulation	
with	poly-I:C,	RIG-I	activation	has	been	shown	to	block	autophagic	degradation	of	mitochondria	by	
Meng	and	colleagues	186,187.	Furthermore,	autophagy	proteins	ATG5-ATG12	complexes	associate	with	
RIG-I,	 thereby	 inhibiting	 its	 antiviral	 activity	188.	 This	 association	might	 then	 again	 also	 prevent	 the	
autophagy-promoting	 function	 of	 ATG5-ATG12.	 In	 summary,	 involvement	 of	 RIG-I	 in	 cellular	
differentiation	 is	 supported	by	several	 studies,	however	 the	underlying	mechanism	and	 the	 role	of	
autophagy	remains	unclear.	Furthermore,	the	rather	small	changes	in	differentiation	antigen	mRNA	
expression	 induced	 by	 3pRNA	 treatment	 possibly	 do	 not	 translate	 into	 an	 overall	 profoundly	
differentiated	tumor	phenotype	in	vivo.	
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The	ultimate	goal	of	immunotherapy	is	the	activation	of	immune	effector	cells	against	malignant	cells	
in	 primary	 tumors	 and	 metastases.	 Therefore,	 modulations	 of	 immune	 cell	 behavior,	 initiated	 by	
3pRNA	alone	or	in	combination	with	vitamin	C,	in	the	transplantable	melanoma	model	deserve	close	
examination	and	discussion.	As	 indicated	by	 increased	Gr-1	mRNA	expression	and	enhanced	tumor	
infiltration	 of	 CD11b+	Gr-1+	 cells,	 intratumoral	 application	 of	 3pRNA	 caused	 an	 accumulation	 of	
MDSC,	 which	 could	 not	 be	 prevented	 by	 vitamin	C	 supplementation.	 These	 results	 contradict	
previous	findings	of	Ellermeier	et	al.	who	found	reduced	frequencies	of	MDSC	upon	RIG-I	activation	
by	a	bi-functional	3p-siRNA	68.	Notably,	 in	 this	 report	a	 large	part	of	MDSC	 loss	was	attributable	 to	
the	 siRNA	 function	and	a	pure	3pRNA	control	was	missing.	 Interestingly,	 Zoglmeier	and	colleagues	
observed	an	expansion	of	CD11b+	Gr-1+	cells	following	TLR9	stimulation	with	CpG,	but	at	the	same	
time	the	 immunosuppressive	potential	of	these	MDSC	was	reduced	owing	to	their	 IFNα-dependent	
maturation	69.	 Thus,	 a	 similar	 mechanism	 very	 probably	 is	 induced	 by	 3pRNA-triggered	 IFN	
production.	It	 is	 likely	that	tumor	type	and	3pRNA	dosage	can	easily	tip	the	balance	towards	MDSC	
support	or	inhibition,	taking	into	account	that	3pRNA-induced	cytokines	can	do	both,	suppress	MDSC	
(via	 IFN)	 or	 stimulate	MDSC	 (via	 IL-6)	115,189.	 In	 this	 regard	 it	 is	 noteworthy	 that	 hypoxia	 enhanced	
3pRNA-induced	 IFN	 production	 in	 cell	 culture,	 but	 IL-6	was	 not	 influenced	 by	 oxygen	 deprivation,	
arguing	 for	 a	 cytokine	milieu	 that	 favors	 suppression	of	MDSC	 function	 in	 hypoxic,	 3pRNA-treated	
tumors.	 To	 ensure	 MDSC	 do	 not	 annihilate	 the	 immune	 stimulatory	 effects	 achieved	 by	 RIG-I	
activation,	 3pRNA	 therapy	 can	 be	 combined	 with	 antibody-mediated	 blockade	 of	 IL-6	 or	 CD40	
agonists,	 the	 latter	of	which	 is	 involved	 in	 the	 induction	of	 apoptosis	 in	MDSC	190,191.	 For	 example,	
Scarlett	 and	 colleagues	 already	established	anti-tumor	 immunity	 in	 an	ovarian	 cancer	model	 using	
CD40	agonist	in	combination	with	TLR3	stimulation	192.		
Addressing	 the	 question	 for	 the	 major	 immune	 cell	 players	 in	 RIG-I-induced	 tumor	
eradication,	this	study	found	3pRNA	therapy	to	enhance	the	percentage	of	activated	NK	cells	within	
tumor-draining	 lymph	 nodes,	 whereas	 no	 significant	 effects	 on	 CD8+	 T-cell	 activation	 could	 be	
observed.	 This	 is	 in	 line	with	 findings	 of	 Poeck	et	 al.	 demonstrating	NK	 cell	 dependent	 anti-tumor	
activity	 of	 RIG-I	 ligands	 in	 a	 B16	 melanoma	 lung	 metastasis	 model	67.	 In	 contrast,	 another	 report	
showed	that	therapeutic	effects	against	pancreatic	cancer	completely	relied	on	CD8+	T-cells	without	
any	 involvement	 of	 NK	 cells	68.	 The	 activation	 of	 CD8+	 T-cells	 and	 NK	 cells	 both	 requires	 the	
expression	of	specific	 ‘kill	me’	signals	by	their	 target	cells.	These	 include	tumor	antigens	presented	
on	 MHC	class-I	 to	 activate	 CD8+	 T-cells,	 whereas	 NK	 cells	 typically	 react	 to	 cells	 missing	 MHC	
molecules,	however	 can	also	 respond	 to	expressed	 ligands	 for	activating	 receptors	 like	 the	NKG2D	
receptor.	The	availability	of	such	signals	varies	between	tumor	types	and	can	be	influenced	by	3pRNA	
treatment.	 B16	 melanoma	 cells	 are	 characterized	 by	 lacking	 NKG2D	 ligands	 and	 a	 very	 low	
MHC	class-I	 expression,	 making	 them	 poorly	 immunogenic	 to	 CD8+	 T-cells	 but	 prone	 to	 NK	 cell	
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attack	193,194.	 Since	 it	 has	 been	 shown	 that	 NK	 cells	 can	 reject	 tumors	 even	 in	 the	 presence	 of	
MHC	class-I	 when	 these	 tumor	 cells	 express	 the	 activating	 ligand	 retinoic	 acid	 early-inducible	
protein	1	(RAE-1),	it	is	likely	that	RIG-I	activation	within	B16	cells	increases	NK	cell	ligand	expression	
to	 an	 extent	 that	 outrivals	MHC	class-I	 induction	195.	 Taken	 together,	 the	 type	 of	malignancy	 likely	
plays	 a	 decisive	 role	 in	 shaping	 the	 3pRNA-elicited	 anti-tumor	 immune	 response	 by	 providing	
different	‘kill	me’	signals.		
Other	 than	expected	 from	the	study	of	Poeck	and	colleagues,	an	 increase	 in	 tumor	NK	cell	
infiltration	 was	 not	 observed	 in	 the	 context	 of	 3pRNA	 treatment	 in	 the	 here-applied	 model	 of	
subcutaneous	 B16	 melanoma	67.	 This	 might	 hint	 at	 technical	 limitations	 of	 the	 performed	 FACS	
analysis.	 Possibly,	 NK	 cells	 irregularly	 infiltrated	 tumors	 upon	 3pRNA	 application,	 but	 this	 spatial	
information	was	lost	after	single	cell	suspensions	were	generated	from	whole	tumors	and	stained	for	
NK	 cell	 markers	 amongst	 others.	 If	 this	 is	 not	 the	 case,	 the	 inhibition	 of	 tumor	 outgrowth	 and	
prolonged	survival	in	this	model	must	result	from	the	direct	tumoricidal	function	of	3pRNA.	Of	note,	
in	 this	 thesis	 in	vivo	experiments	were	conducted	by	 intratumoral	application	of	 in	vitro-generated	
3pRNA,	 in	 contrast	 to	 Poeck	 et	 al.	 who	 utilized	 a	 bi-functional	 3p-siRNA.BCL2	 construct	 via	
intravenous	 injection.	 Together	 with	 diverse	 tumor	 locations	 (local	 disease	 vs.	 metastases)	 these	
technical	 variations	 can	 contribute	 to	 differences	 in	 tumor	 NK	 cell	 infiltration.	 Interestingly,	
supplementation	 of	 3pRNA	 therapy	 with	 vitamin	C	 enhanced	 NK	 cell	 numbers	 within	 the	 tumor,	
although	it	did	not	have	an	effect	on	their	3pRNA-mediated	activation	in	the	draining	lymph	nodes.	
This	 observation	 might	 relate	 to	 the	 anti-angiogenic	 function	 of	 vitamin	C.	 On	 the	 one	 hand	 it	
prevents	 VEGF	 expression	 in	 B16	 melanoma	 cells	 via	 the	 inhibition	 of	 p42/44	 MAPK	 and	
downregulation	of	cyclooxygenase-2	196.	On	the	other	hand	vitamin	C	suppresses	HIF1α,	which	is	the	
major	 transcription	 factor	 for	 VEGF	 mRNA	 expression	183,184.	 Thus,	 similar	 to	 low-dose	 anti-VEGF	
receptor	2	 antibody	 therapy	 that	 normalizes	 tumor	 vasculature	 resulting	 in	 a	more	 homogeneous	
distribution	of	functional	tumor	vessels,	vitamin	C	treatment	might	improve	tumor	NK	cell	infiltration	
by	VEGF	downregulation	197.			
In	 summary,	 the	 combination	 of	 3pRNA	 with	 vitamin	C	 exerted	 its	 improved	 anti-tumoral	
function	against	subcutaneous	B16	melanoma	through	the	tumoricidal	activity	of	the	RIG-I	ligand	and	
possibly	 also	 vitamin	C,	 3pRNA-mediated	 NK	 cell	 activation	 and	 facilitated	 tumor	 infiltration	 by	
vitamin	C-dependent	stabilization	of	tumor	vasculature.	
			
6.8 Evolving	combinatorial	treatment	strategies	
Hypoxia	has	long	been	known	to	induce	resistance	to	chemo-	and	irradiation	therapy	of	cancer	and	
accumulating	 data	 points	 towards	 the	 existence	 of	 multiple	 hypoxia-dependent	 immune	 escape	
mechanisms	of	tumor	cells	101–104,198.	To	counteract	these	detrimental	effects,	two	different	strategies	
Discussion						
	
75	
can	be	pursued.	Firstly,	tumor	oxygenation	can	be	improved	before	or	during	treatment	to	overcome	
hypoxia-related	 restrictions.	 This	 can	 be	 achieved	 for	 example	 by	 breathing	 100%	 oxygen	 under	
increased	atmospheric	pressure,	a	method	called	hyperbaric	oxygen	therapy,	which	can	improve	the	
response	 to	 radiation	 and	 chemotherapy	 of	 many	 solid	 tumors	199.	 Recently	 Hatfield	 et	 al.	
demonstrated	 that	 respiratory	 hyperoxia	 (breathing	 60%	 oxygen)	 significantly	 improves	 tumor	
regression	 by	 reversing	 immunosuppression	 in	 the	 tumor	 microenvironment	200.	 Mechanistically,	
increased	oxygen	pressure	prevents	the	hypoxia-dependent	accumulation	of	extracellular	adenosine	
that	activates	A2A	adenosine	receptors,	causing	the	establishment	of	an	immunosuppressive	milieu.	
Alternatively,	restoring	healthy	vasculature	within	the	tumor	using	inositol	trispyrophosphate	or	low-
dose	 anti-VEGF	 receptor	 2	 antibody,	 enhances	 the	 activity	 of	 chemotherapeutic	 drugs	 and	 cancer	
vaccines	 by	 improving	 drug	 delivery	 and	 reducing	 the	 expression	 of	 multi-drug	 efflux	 pumps	 or	
reprogramming	 the	 immunosuppressive	 tumor	 microenvironment,	 respectively	197,201.	 The	 latter	
thereby	 involves	 a	 reduction	 of	 MDSC,	 polarization	 of	 tumor	 infiltrating	 macrophages	 from	 an	
immunosuppressive	 M2	 to	 an	 immunostimulatory	 M1	 phenotype	 and	 facilitated	 infiltration	 of	
immune	effector	cells.		
The	second	approach	to	overcome	hypoxia-induced	resistance	rather	exploits	the	low	oxygen	
tension	 in	hypoxic	 tissues	 for	selectively	 targeting	 tumor	cells,	 leaving	healthy	cells	unaffected.	For	
instance	by	utilizing	pro-drugs	that	only	become	activated	within	the	reducing	microenvironment	of	
hypoxic	 tumors.	 Exemplarily,	 TH-302,	 a	 pro-drug	 that	 releases	 the	 cytotoxic	DNA	 alkylator	 bromo-
isophosphoramide	nitrogen	mustard	upon	activation,	significantly	improved	progression-free	survival	
and	 tumor	 responses	 in	 a	 phase	 II	 clinical	 trial	 in	 combination	 with	 the	 cytostatic	 compound	
gemcitabine	against	metastatic	pancreatic	cancer	202.	Another	DNA	alkylating	pro-drug,	apaziquone,	
is	 tested	 in	 several	 ongoing	 phase	 III	 trials	 to	 prevent	 recurrence	 of	 non-muscle	 invasive	 bladder	
cancer	 following	 tumor	 resection	 (NCT01410565,	 NCT01469221,	 NCT02563561).	 Moreover,	 also	
gene	 therapy	 can	 harness	 tumor	 hypoxia	 by	 inserting	 HIF	 binding	 sites	 into	 the	 promoter	 of	
expression	plasmids,	thereby	restricting	target	gene	expression	to	HIF-enriched	areas.	Fukui	et	al.	for	
example	deployed	an	 IFNα2b	gene	construct	with	 repetitive	HIF	binding	 sites	 in	 renal	 cancer	 cells,	
showing	 enhanced	 expression	 upon	 application	 of	 a	 hypoxia-mimicking	 agent	 and	 resulting	 in	
suppressed	 cell	 viability	203.	 Although	 no	 negative	 influence	 of	 hypoxia	 on	 3pRNA	 treatment	 was	
detected	 in	 this	 study,	 combinatorial	 strategies	might	 still	 improve	RIG-I-targeted	 immunotherapy.	
Such	can	involve	the	simultaneous	administration	of	hypoxia-activated	pro-drugs,	which	enhance	the	
release	of	 tumor	antigens	and	 immune	stimulating	danger	signals	 through	 their	cytotoxic	 function.	
Alternatively,	 a	 combination	 with	 respiratory	 hyperoxia	 could	 free	 hypoxic	 tumor	 cells	 from	 the	
immunosuppressive	 microenvironment	 of	 extracellular	 adenosine	 and	 thus	 enhance	 3pRNA-
mediated	immune	activation.	
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Considering	 the	 observation	 that	 3pRNA	 transfection	 elicited	 a	 strong	 upregulation	 of	 PDL-1	 on	
melanoma	 cells,	 that	 was	 maintained	 under	 hypoxic	 conditions,	 a	 simultaneous	 blockade	 of	 the	
respective	 immune	 checkpoint	might	 release	 the	 brakes	 from	 the	 immune	 system,	 allowing	 even	
more	 efficient	 and	 prolonged	 anti-tumor	 immunity.	 Since	 anti-PD1	 antibodies	 nivolumab	 and	
pembrolizumab	 are	 already	 approved	 for	melanoma	 treatment	 and	 several	 anti-PDL-1	 compounds	
have	completed	phase	I	clinical	trials	with	encouraging	results,	this	approach	offers	a	fast	and	easy-
to-apply	 possibility	 to	 further	 improve	 the	 therapeutic	 potential	 of	 RIG-I	 ligands	204.	 In	 summary,	
immune	checkpoint-inhibition	as	well	as	vitamin	C	supplementation	can	be	realized	most	rapidly	for	
combined	3pRNA	therapy	and	represent	very	promising	strategies	to	gain	highest	benefit	of	 future	
RIG-I-targeted	immunotherapy	for	patients	suffering	from	malignant	melanoma.	
	
6.9 Conclusion	
A	 reduction	 in	 oxygen	 supply	 has	 repeatedly	 been	 shown	 to	 affect	 immune	 cell	 functions	 during	
inflammation	 as	 well	 as	 to	 enable	 tumor	 immune	 escape,	 thus	 indicating	 the	 (currently	 largely	
unmet)	importance	of	taking	into	account	the	correct	tissue-representative	oxygen	tension	in	in	vitro	
experiments	when	investigating	anti-tumor	immunity.	In	this	regard,	this	thesis	studied	the	effect	of	
hypoxia	on	the	innate	immune	receptor	RIG-I	in	murine	melanoma	cells,	demonstrating	inhibition	of	
the	 3pRNA-induced	 RIG-I	 protein	 upregulation	 upon	 oxygen	 deprivation.	 On	 the	 contrary,	 RIG-I	
mRNA	expression	was	not	 affected.	 Furthermore,	RIG-I	 signaling	outcome	 remained	uninvolved	as	
MHC	class-I	 and	 PDL-1	 increase,	 induction	 of	 ISGs	 as	 well	 as	 CD8+	 T-cell	 and	 NK	 cell	 activation	 in	
3pRNA-treated	melanoma	cell	co-cultures	worked	equally	well	under	normoxia	and	hypoxia.	Instead,	
IFNα	 lost	 its	 capacity	 to	 induce	 an	 immune	 response	 altogether.	 Thus,	 while	 hypoxia-dependent	
downregulation	 of	 IFNαR	 expression	 desensitized	 cells	 to	 treatment	 with	 recombinant	 IFNα,	
remaining	 RIG-I	 and	 IFNαR	 levels	 were	 sufficient	 to	 establish	 a	 complete	 and	 functional	 RIG-I	
response	 to	 3pRNA	 stimulation.	 Still	 it	 remains	 possible	 that	 RIG-I	 signaling	 outcome	 becomes	
restricted	at	very	low	3pRNA	concentrations.	Figure	34	summarizes	different	cellular	processes	that	
are	influenced	by	hypoxia	and	can	contribute	to	altered	protein	translation	of	RIG-I,	 including	EMT,	
mTOR	 inhibition,	 miRNA	 expression	 and	 activation	 of	 the	 unfolded	 protein	 response.	 The	
involvement	 of	 ROS	 and	 NFκB-dependent	 EMT	 in	 RIG-I	 attenuation	 was	 demonstrated	 by	
reestablishment	of	RIG-I	protein	expression	upon	NFκB	 inhibition	or	antioxidant	 treatment	 in	vitro.	
Moreover,	 vitamin	C	 as	 ROS	 scavenger	 also	 enhanced	 intratumoral	 proinflammatory	 CXCL10	
production	and	anti-tumor	efficacy	in	a	subcutaneous	melanoma	model	in	vivo.	
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Figure	34:	Cellular	pathways	that	regulate	translation	under	hypoxia	and	their	influence	on	RIG-I	signaling.	Production	of	
reactive	oxygen	species	(ROS)	and	activation	of	NFκB	are	involved	in	hypoxia-induced	epithelial-to-mesenchymal-transition	
(EMT)	of	cancer	cells,	which	affects	regulation	of	 translation.	Contribution	of	 this	process	to	attenuated	3pRNA-triggered	
RIG-I	expression	was	shown	by	reestablishment	of	RIG-I	upregulation	upon	NFκB	 inhibition	and	ROS	scavenging.	Besides,	
translation	can	be	modulated	by	inhibition	of	mammalian	target	of	rapamycin	(mTOR)	signaling,	induced	miRNA	expression	
and	 activation	 of	 the	 unfolded	 protein	 response	 (UPR).	 While	 mTOR	 inhibition	 is	 also	 responsible	 for	 the	 induction	 of	
autophagy,	the	UPR	results	in	reduced	IFNαR	expression.	A	dashed	line	indicates	the	existence	of	even	more	mechanisms	
that	 regulate	 translation	under	hypoxia.	 The	here	presented	 results	 show	 that	 reduced	3pRNA-tiggered	RIG-I	 expression	
under	 hypoxia	 does	 not	 repress	 the	 RIG-I	 signaling	 outcome.	 Still	 it	 remains	 possible	 that	 the	 RIG-I	 response	 becomes	
restricted	 at	 very	 low	 3pRNA	 concentrations.	 IFNα	 desensitization	 does	 likewise	 not	 affect	 RIG-I	 signaling	 outcome,	 but	
inhibits	immune	activation	in	response	to	recombinant	IFNα.		
	
Taken	 together,	 this	 thesis	 provides	 evidence	 for	 functional	 RIG-I	 activation	 in	 hypoxic	 tumor	 cells	
that	 resists	 attenuation	 of	 RIG-I	 protein	 expression	 and	 IFNα	 desensitization,	 rendering	 3pRNA-
mediated	 immunotherapy	 a	 very	 encouraging	 treatment	 also	 for	 tumors	 lacking	 sufficient	 oxygen	
supply.	 To	 become	 fully	 devoid	 of	 other	 hypoxia-induced	 inhibiting	 mechanisms	 on	 anti-tumor	
effector	 functions,	 it	 is	 advisable	 to	 combine	 3pRNA	 treatment	with	 additional	 immune	 activating	
therapies.	 These	may	 include	 antibody-mediated	 depletion	 of	MDSC,	 inhibition	 of	 the	 PD-1/PDL-1	
immune	checkpoint	or	blockade	of	the	immunosuppressive	pathway	of	extracellular	adenosine.	Yet,	
when	 excessively	 boosting	 the	 immune	 system,	 one	 has	 to	 be	well	 aware	 of	 the	 risk	 to	 cause	 an	
overshooting	immune	response,	which	may	cause	severe	adverse	effects.	Therefore,	vitamin	C	might	
bring	 the	 advantage	 of	 indirectly	 enhancing	 RIG-I	 therapy	 by	 primarily	 acting	 on	 ROS.	 Altogether,	
these	 findings	 cover	 a	 fundamental	 part	 in	 the	 development	 of	 RIG-I	 ligands	 into	 successful	
immunotherapeutics	to	improve	prognosis	of	melanoma	patients.		
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8 Appendix	
8.1 Abbreviations	
	
3pRNA	 5’-triphosphate	RNA	
ACT	 adoptive	cell	transfer	
AKT	 RAC-alpha	serine/threonine	protein	kinase	
AP-1	 activator	protein	1	
APC	 allophycocyanin	
ATG	 autophagy	protein	
ATP	 adenosine	triphosphate	
BiKE	 bispecific	killer	cell	engager	
BiTE	 bispecific	T	cell	engager	
BPB	 bromphenolblue	
BRAF	 serine/threonine-protein	kinase	B-raf	
BSA	 bovine	serum	albumin	
CAR	 chimeric	antigen	receptor	
CARD	 caspase	activation	and	recruitment	domain	
CCL22	 C-C	motif	chemokine	22	
CD	 cluster	of	differentiation	
cDNA	 complementary	DNA	
cGAS	 cyclic	GMP-AMP	synthase	
CLR	 C-type	lectin	receptor	
CpG	 cytosine-guanine	oligodeoxynucleotide	
CTD	 C-terminal	domain	
CTL	 cytotoxic	T-lymphocyte	
CTLA-4	 cytotoxic	T-lymphocyte-associated	protein	4	
CTP	 cytidine	triphosphate	
CXCL10	 interferon-dependent	lymphocyte-attracting	chemokine	10	
Cy	 cyanines	
DC	 dentritic	cell	
DMEM	 dulbecco’s	modified	eagle	medium	
DMSO	 dimethylsulfoxide	
DTT	 dithiotreitol	
EDTA	 ethylenediaminetetraacetic	acid	
eIF2α	 eukaryotic	translation	initiation	factor	2	alpha	
ELISA	 enzyme-linked	immunosorbent	assay	
EMT	 epithelial-mesenchymal-transition	
FACS	 fluorescence-activated	cell	sorting	
Fam	 fluorescein	amidite	
FCS	 fetal	calve	serum	
FDA	 U.S.	food	and	drug	administration	
FITC	 fluorescein	isothiocyanate	
GFP	 green	fluorescent	protein	
GLUT1	 glucose	transporter	1	
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GM-CSF	 granulocyte	macrophage	colony-stimulating	factor	
Gr-1	 glutathione	reductase	1	
GTP	 guanosine	triphosphate	
H&E	 hematoxylin	and	eosin		
HER2	 human	epidermal	growth	factor	receptor	2	
HIF	 hyopoxia	inducible	factor	
HMGB1	 high	mobility	group	protein	B1	
HRP	 horseradish	peroxidase		
HSP90	 heat	shock	protein	90	
i.p.	 intraperitoneal	
i.t.	 intratumoral	
i.v.	 intravenous	
IFIT1	 interferon-induced	protein	with	tetratricopeptide	repeats	1	
IFN	 interferon	
IFNαR	 IFNα	receptor	
IHC	 immunohistochemistry	
IKK	 IκB	kinase	
IL	 interleukin	
IRF	 interferon-regulatory	factor	
ISG	 IFN-stimulated	gene	
IVT4	 in	vitro	transcript	4	
IκB	 inhibitor	of	NFκB		
Jak	 janus	kinase	
JNK	 c-Jun	NH2-terminal	kinase	
LGP2	 laboratory	of	genetics	and	physiology	2	
LPS	 lipopolysaccharide	
MACS	 magnetic	cell	separation	
MAPK	 mitogen-activated	protein	kinase	
MAVS	 mitochondrial	antiviral	signaling	protein	
MBL	 mannose-binding	lectin	
MDA5	 melanoma	differentiation	associated	factor	5	
MDSC	 myeloid-derived	suppressor	cells	
MEK	 MAPK	kinase	
MHC	 major	histocompatibility	complex	
MIC	 MHC	class-I	chain-related	molecule	
miRNA	 microRNA	
mRNA	 messenger	RNA	
mTOR	 mammalian	target	of	rapamycin	
NEAA	 non-essential	amino	acids	
NEMO	 NFκB	essential	modulator	
NFκB	 nuclear	factor-κB	
NK	 natural	killer	
NLR	 NOD-like	receptor	
NLRP3	 NACHT,	LRR	and	PYD	domains-containing	protein	3	
NOD	 nucleotide-binding	domain	
NOX2	 NADPH	oxidase	2	
Nrf2	 nuclear	factor	erythroid	2-related	factor	2	
ODN	 oligodeoxynucleotide	
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PAMP	 pathogen	associated	molecular	pattern	
PBS	 phosphate-buffered	saline	
PD-1	 programmed	cell	death	protein	1	
PDL-1	 programmed	cell	death	ligand	1	
PE	 phycoerythrin	
PEI	 polyethylenimine	
PerCP	 peridinin	chlorophyll	protein	complex	
PERK	 PRKP-like	endoplasmic	rediculum	kinase	
PMA	 phorbol	12-myristate	13-acetate	
PMP70	 peroxisomal	membrane	protein	70	
pO2	 partial	oxygen	pressure	
polyI:C	 polyinosinic:polycytidylic	acid	
PRR	 pattern	recognition	receptor	
qPCR	 quantitative	polymerase	chain	reaction	
RAE-1	 retinoic	acid	early-inducible	protein	1	
RIG-I	 retinoic	acid-inducible	gene	I	
RLR	 RIG-I-like	receptor	
RNAi	 RNA	interference	
RNF	 ring-finger	protein	
ROS		 reactive	oxygen	species	
RPMI	 roswell	park	memorial	institute	medium	
RT	 room	temperature	
SDS	 sodiumdodecylsulfate	
SEM	 standard	error	of	mean	
SLP	 synthetic	long	peptide	
STAT	 signal	transducer	activator	of	transcription	
SUMO	 small	ubiquitin-like	modifier-1	
SVCT	 sodium	vitamin	C	co-transporter	
TAA	 tumor-associated	antigen	
TBK1	 TANK-binding	kinase	1	
TBP	 TATA-box	binding	protein	
TBS	 tris-buffered	saline	
TCR	 T-cell	receptor	
TGFβ	 transforming	growth	factor	beta	
TLR	 Toll-like	receptor	
TNFα	 tumor	necrosis	factor	alpha	
TOM	 translocase	of	outer	membrane	
Treg	 regulatory	T-cells	
TriKE	 trispecific	killer	cell	engager	
TRIM	 tripartite	motif	protein	
TRP2	 tyrosinase-related	protein	2	
Ub	 ubiquitin	
UTP	 uridine	triphosphate	
VEGF	 vascular	endothelial	growth	factor	
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